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To Ángel and Juana,  
the ones who taught me the most valuable and unforgettable lessons.
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Las tierras, las tierras, las tierras de España, 
las grandes, las solas, desiertas llanuras. 
Galopa, caballo cuatralbo, 
jinete del pueblo, 
al sol y a la luna. 
 
¡A galopar, 
a galopar, 
hasta enterrarlos en el mar! 
 
A corazón suenan, resuenan, resuenan 
las tierras de España, en las herraduras. 
Galopa, jinete del pueblo, 
caballo cuatralbo, 
caballo de espuma. 
 
¡A galopar, 
a galopar, 
hasta enterrarlos en el mar! 
 
Nadie, nadie, nadie, que enfrente no hay 
nadie; 
que es nadie la muerte si va en tu montura. 
Galopa, caballo cuatralbo, 
jinete del pueblo, 
que la tierra es tuya. 
 
¡A galopar, 
a galopar, 
hasta enterrarlos en el mar! 
 
Capital de la Gloria - Rafael Alberti
 
The lands, the lands, the lands of Spain 
the great, lonely, deserted plains. 
Gallop, white horse, 
people's jockey, 
to the sun and to the moon. 
 
Let's gallop, 
let's gallop, 
until they're buried in the sea! 
 
The lands of Spain sound and resound like 
hearts on the horseshoes. 
Gallop, people's jockey, 
white horse, 
foam horse. 
 
Let's gallop, 
let's gallop, 
until they're buried in the sea! 
 
No one, no one, no one, there's no one to 
face; 'cause death is no one if she goes on 
your saddle. 
Gallop, white horse, 
people's jockey, 
'cause the land is yours. 
 
Let's gallop, 
let's gallop, 
until they're buried in the sea! 
 
Capital of Glory - Rafael Alberti 
 
 
 
 
 
Ever tried. Ever failed. No matter. Try again. 
Fail again. Fail better. 
 
Worstward Ho – Samuel Beckett
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Abstract 
 
Tail-anchored (TA) proteins are distinguished from other membrane proteins due to 
their particular topology. The best-characterized pathway for the targeting of TA-proteins is the 
GET pathway in yeast or the TRC pathway in mammals. Recently, several studies have 
reported that more than one post-translational pathway operate during targeting of TA-proteins 
to the ER-membrane such as the EMC pathway, Hsp40/Hsc70, the SND pathway and the PEX 
pathway.  
 
TRC40 is the cytoplasmic effector of the TRC pathway. This study aims to investigate the 
reliance of TA-proteins on the TRC pathway at the steady-state in vivo in mammalian cells. 
Moreover, the role of several functional domains of TRC40 during TA-proteins targeting to ER-
membrane and chaperoning in vivo is addressed in this study. Furthermore, this study wants 
to explore the potential alternative role of TRC40 as redox-regulated chaperone. 
 
A panel of cmyc-tagged TRC40 mutants was created and screened by immunofluorescence. 
The screen identified TRC40D74E, an ATPase-impaired mutant, as a trapping mutant that leads 
to an accumulation of TA-protein in the cytoplasm. This makes TRC40D74E a good tool for the 
study of TA-protein biogenesis and for determining the interactome of TRC40 in vivo.  
 
Eleven TA-proteins showed in vivo TRC-dependence by knocking-down TRC-pathway 
components such as WRB and TRC40. In contrast, another six TA-proteins did not show any 
evidence of in vivo TRC-dependence in this study, neither affected by down-regulation of TRC 
components nor by the presence of TRC40D74E. Many of the TA-proteins (e.g. USE1, UBE2J1, 
Vti1a) tested in this study were not reported to be TRC-dependent in literature. TMD 
hydrophobicity may be a major contributor in the TRC-dependence of the TA-proteins. 
However, the cytoplasmic domain may also contribute. The loss BAG6, essential for the TA-
targeting according to the proposed model in literature, strikingly showed no effect on the level 
of the TA-proteins in membranes at the steady-state; suggesting that BAG6 might not be 
essential for TA-protein targeting in vivo. 
 
Finally, the TRC pathway is kept in balance by a mechanism that tightly regulates the steady-
state levels of its components. Upon the loss of some of the components others get severely 
reduced in their steady-state levels. This TRC-pathway balance is not symmetrical and shows 
a hierarchical organization within the pathway. 
 
1.Introduction 
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1. Introduction 
1.1. Integral membrane proteins 
 
Membrane proteins constitute around 20-30% of the proteins encoded by the 
genome (Wallin and von Heijne 1998; Stevens and Arkin 2000; Krogh et al. 2001; 
Almén et al. 2009; Bill et al. 2011). These proteins are involved in many processes 
such as active transport, communication between contact sites, anchorage, cell marker 
recognition and signaling. Membrane proteins can be classified as peripheral 
membrane proteins or integral membrane proteins (IMPs). Peripheral membrane 
proteins do not fully penetrate the membrane but associate externally with the 
membrane. This membrane association is mediated by different physicochemical 
mechanisms for instance by non-specific hydrophobic associations, covalently-bound 
lipid anchors, such as palmitoylation, glycosylphosphatidylinositol (GPI), 
myristoylation, etc. (Silvius 2002). IMPs have at least one hydrophobic transmembrane 
segment. The transmembrane domain (TMD) of the IMPs enables the protein to be 
anchored in the membrane. Membrane proteins are further classified based on their 
topology (Fig. 1). 
 
 
1.2. Tail-anchored proteins 
 
Tail-anchored (TA) proteins are distinguished from other membrane proteins 
due to their particular topology (Borgese, Colombo, and Pedrazzini 2003; Kutay, 
Hartmann, and Rapoport 1993). This topology consists of a single transmembrane 
segment that lies at the very C-terminus of the protein with the N-terminus oriented to 
the cytoplasm. The TMD is found in the region of the last 50 amino acids and there is 
a short C-terminal tail oriented to the lumen no longer than 40 amino acids. TA-proteins 
lack of signal sequence and they are post-translationally inserted (Borgese, Colombo, 
and Pedrazzini 2003; Kutay, Hartmann, and Rapoport 1993) (Fig. 2). Single-pass type  
1.Introduction 
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Figure 1. Membrane proteins. Scheme depicting the different membrane proteins according to UniProt 
(The UniProt Consortium 2017). Single-pass type I (PDB ID: 2JO1) are those spanning the membrane 
just once whose N-terminus is on the extracellular side of the membrane and gets its signal sequence 
removed. Single-pass type II (PDB ID: 4CMH) are those single-span membrane proteins N-terminus is 
on the cytoplasmic side of the membrane. The transmembrane domain is close to the N-terminus 
serving as an anchor. Single-pass type III (PDB ID: 2LAT) are membrane proteins that span once the 
membrane and the N-terminus is on the extracellular side of the membrane but lack of signal sequence 
(in contrast to type I). Single-pass type IV (PDB ID: 2LPF) are those single-span membrane proteins N-
terminal is on the cytoplasmic side of the membrane. The transmembrane domain is close to the C-
terminus serving as an anchor (in contrast to type II). They are the so-called tail-anchored proteins (TA-
proteins). Multi-pass membrane protein (PDB ID: 5SYT) are those proteins that span the membrane 
more than once. GPI-anchored protein (PDB ID: 1LG4) are those whose C-terminus is bound to the 
membrane through a GPI-anchor (glycosylphosphatidylinositol-anchor). 
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IV membrane proteins are TA-proteins (Fig. 1). TA-proteins account for around 3-5% 
of the proteome (Beilharz et al. 2003; Kalbfleisch, Cambon, and Wattenberg 2007; 
Kriechbaumer et al. 2009). TA-proteins mediate several cell functions that include 
apoptosis (i.e. Bcl-2, Bcl-XL), vesicular transport (most SNAREs are TA-proteins, i.e. 
Stx5 and Stx6), protein translocation (i.e. Sec61b and Sec61g), lipid homeostasis (i.e. 
VAPA and VAPB) and protein quality control (i.e. UBE2J1 and UBE2J2) among others.  
 
 
Figure 2. Tail-anchored proteins characteristics. Scheme illustrating the TA-protein features. They 
are single-pass type IV membrane proteins. They are transmembrane polypeptides with a particular 
topology: one single transmembrane domain (TMD) at the very C-terminus, N-terminus oriented to the 
cytoplasm and a short tail after the TMD that is oriented towards the organelle lumen. 
 
The transmembrane segment of the TA-proteins contains a targeting signal for 
membrane insertion and the proper delivery of the TA-protein to its final organelle 
destination (endoplasmic reticulum, mitochondrial outer membrane, plasma 
membrane and peroxisomes)  (Borgese, Brambillasca, and Colombo 2007; Rabu et 
Single-pass 
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C
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Protein function
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al. 2009; Borgese and Fasana 2011; Hegde and Keenan 2011). Additionally, it has 
also been a long-standing assumption that a TA-protein of the secretory pathway, that 
includes plasma membrane and Golgi, are inserted into the endoplasmic reticulum 
(ER) membrane (Borgese et al. 2001; Bulbarelli et al. 2002; Borgese, Colombo, and 
Pedrazzini 2003; Borgese, Brambillasca, and Colombo 2007). The secretory pathway 
sorts cargo via transport vesicles to the Golgi apparatus and from Golgi they can be 
transported to other organelles or can be secreted (reviewed in C. K. Barlowe and 
Miller 2013; C. Barlowe and Helenius 2016; Kim and Gadila 2016; Arakel and 
Schwappach 2018). 
 
 
1.3. Protein biogenesis. Targeting and insertion 
of ER-membrane proteins 
 
Newly synthesized membrane proteins present a variable number of 
hydrophobic domains compared to cytoplasmic proteins that are synthesized in a 
hydrophilic cytosol. Many pathways have evolved to prevent the aggregation of the 
nascent membrane proteins in the cytoplasm and ensure the correct targeting and 
membrane insertion of the protein. The nascent integral membrane protein has to be 
recognized once exiting the ribosome. Next, it has to be targeted to the right organelle 
and inserted with the right topological orientation of the protein (Cross et al. 2009; 
Akopian et al. 2013). The most well-characterized pathway that targets IMPs involves 
the signal recognition particle (SRP) pathway (Blobel and Dobberstein 1975a; Blobel 
and Dobberstein 1975b). 
 
 
1.3.1. SRP pathway 
 
The SRP pathway mediates the translocation of single- or multi-spanning 
proteins into the ER membrane (Fig. 3). It can also translocate soluble polypeptides 
from the cytoplasm. SRP recognizes a hydrophobic N-terminal sequence from the 
nascent protein while translation is taking place on the ribosome. This N-terminal 
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sequence is cleavable and is known as a signal sequence (SS) (Rapoport 2007; 
Grudnik, Bange, and Sinning 2009) (Fig. 3, step 1). The interaction between the SRP 
and the ribosome nascent chain complex (RNC) slows down elongation and stalls 
translation (Halic et al. 2004). After binding the RNC, the SRP targets it to the SRP 
receptor that resides in the ER-membrane. The SRP receptor is formed by two 
subunits: SRa and SRb (Gilmore, Blobel, and Walter 1982; Gilmore, Walter, and Blobel 
1982). Once recruited by the SRP receptor, the RNC interacts with the Sec61 
translocon channel in the membrane and the SRP-SRP receptor dissociates. This 
process is GTP-mediated due to the GTPase activity of the SRP receptor subunits 
(Connolly and Gilmore 1986). The RNC aligns with the Sec61 translocon channel, then 
translation is resumed and the elongating polypeptide is subsequently targeted into the 
channel (Fig. 3, step 2). This process is known as co-translational protein targeting, 
given that it occurs while translation is taking place (Rapoport 2007; Grudnik, Bange, 
and Sinning 2009). The SRP pathway is conserved in all three domains of life (Pool 
2005). Recently, it has been reported that SRP is important for targeting membrane 
proteins independent of the relative position of the transmembrane segment(s), except 
TA-proteins (Costa et al. 2018). Nevertheless, many proteins that contained a N-
terminal SS were co-translationally targeted regardless of the absence of SRP (Costa 
et al. 2018). 
 
Many IMPs are targeted to the ER membrane by the SRP pathway. However, the 
absence of a SS in TA-proteins precludes co-translational, SRP-dependent targeting. 
TA-proteins remain in the ribosome until translation ends making it impossible for the 
SRP to bind the TMD at the very C-terminus. Therefore, it was proposed that TA-
proteins are inserted post-translationally (Kutay, Hartmann, and Rapoport 1993; Kutay 
et al. 1995). The best-characterized pathway for the targeting of TA-proteins is the 
GET pathway in yeast or the TRC pathway in mammals (Stefanovic and Hegde 2007; 
Favaloro et al. 2008; Schuldiner et al. 2008). Recently, several studies have reported 
that more than one post-translational pathway targets TA-proteins to the ER 
membrane such as the EMC pathway (Guna et al. 2018), Hsp40/Hsc70 (Rabu et al. 
2008; Rabu et al. 2009), the SND pathway (Aviram et al. 2016; Haßdenteufel et al. 
2017) or the PEX pathway (Jones, Morrell, and Gould 2004; Fujiki et al. 2014; Buentzel 
et al. 2015).  
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Figure 3. SRP pathway. (1) SRP (PDB ID: 5GAF) recognizes the signal sequence (SS) from the 
nascent protein on the ribosome. The interaction slows down the translation and stalls it. (2) SRP is 
recruited by the heterodimer SRP-receptor (SR) via SRα (PDB ID: 2FH5, 5L3Q). The ribosome nascent 
chain complex interacts with the Sec61 translocon channel (PDB ID: 3J7Q). The RNC aligns with the 
Sec61 translocon and then the translation is resumed. The elongating polypeptide is then funneled into 
the Sec61 translocon channel. 
 
 
1.3.2. Yeast GET pathway 
 
Get3 is a homodimeric P-loop ATPase that is localized in the cytoplasm (Shen 
et al. 2003; Leipe et al. 2002; Bange and Sinning 2013). Get3 was shown to be 
genetically linked to Get1 and Get2 in yeast (Schuldiner et al. 2005). Get1 and Get2 
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Figure 3. SRP pathway. (1) SRP (PDB ID: 5GAF) recognizes the signal sequence (SS) from the 
nascent protein on the ribosome. The interaction slows down the translation and stalls it. (2) SRP is 
recruited by the heterodimer SRP-receptor (SR) via SRα (PDB ID: 2FH5, 5L3Q). The ribosome 
nascent chain complex interacts with the Sec61 translocon channel (PDB ID: 3J7Q). The RNC 
aligns with the Sec61 translocon and then the transl tion is resumed. The elongating polypeptide is 
then funneled into the Sec61 translocon channel.
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were revealed to be the receptor for Get3. These proteins were reported to be involved 
in TA-protein insertion into ER-membranes in yeast (Schuldiner et al. 2008). Sgt2 is a 
cochaperone that can interact with heat-shock proteins (Hsps) (F. H. Liu et al. 1999; 
Scheufler et al. 2000; Liou, Cheng, and Wang 2007). It has been reported to identify 
and capture the TA-protein while exiting from the ribosome (Chang et al. 2010; Leznicki 
et al. 2010; Simpson et al. 2010; F. Wang et al. 2010; Rao et al. 2016) (Fig. 4, step 
1). Sgt2 interacts with Get5 and Get4 to form the so-called pre-targeting complex 
(Jonikas et al. 2009; Battle et al. 2010; Chang et al. 2010; Simpson et al. 2010) (Fig. 
4, step 2). The pre-targeting complex interacts with Get3 via Get4 (Jonikas et al. 2009; 
Gristick et al. 2014; Gristick et al. 2015) facilitating the handover of the TA-protein from 
Sgt2 to Get3 (F. Wang et al. 2010) (Fig. 4, step 3). The Get1/2 receptor assembles 
into an ER-membrane resident complex (Schuldiner et al. 2008; Mariappan et al. 2011; 
F. Wang et al. 2014). Get3 delivers the TA-protein to the Get1/2 receptor in a process 
dependent on ATP-hydrolysis (Mariappan et al. 2011; Stefer et al. 2011; F. Wang et 
al. 2011; F. Wang et al. 2014) (Fig. 4, step 4). The Get1/2 receptor acts as an insertase 
inserting the TA-protein into the ER-membrane (F. Wang et al. 2011; F. Wang et al. 
2014) (Fig. 4, steps 5 and 6). As noted before, the proteins of the secretory pathway 
will be sorted to their final destination (Borgese et al. 2001; Bulbarelli et al. 2002; 
Borgese, Colombo, and Pedrazzini 2003; Borgese, Brambillasca, and Colombo 2007). 
The impairment of the GET pathway can cause mislocalization of TA-proteins to 
mitochondria (Schuldiner et al. 2008). The AAA+ ATPase Msp1 was reported to be 
part of the quality control mechanism of the mitochondrial outer membrane (MOM). 
Msp1 was found to function in the clearance of mislocalized TA-proteins in the MOM 
in yeast (Okreglak and Walter 2014; Weir et al. 2017; Wohlever et al. 2017). ATAD1 is 
the mammalian homolog of Msp1 and in a similar fashion it was found to be required 
in mammals for the clearance of mislocalized TA-proteins into MOM (Y.-C. Chen et al. 
2014). 
 
TA-protein targeting of the GET pathway is driven by the ATPase cycle of Get3 along 
with its many conformational changes within this ATPase cycle (Hegde and Keenan 
2011; Wereszczynski and McCammon 2012; Chio et al. 2017). 
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Figure 4. Yeast GET pathway. (1) Sgt2 (PDB ID: 3ZDM, 5LYP) captures the newly synthesized TA-
protein (PDB ID: 2LPF) from the ribosome (PDB ID: 6EK0). Sgt2 can interact with Get4/Get5 (PDB ID: 
4PWX) via Get5. (2) The pre-targeting complex, through Get4, has preferentially a higher affinity for 
Get3 in a close state conformation (PDB ID: 4PWX). The binding of Get4/Get5 inhibits the ATPase 
activity of Get3. (3) The TA-protein is subsequently loaded into Get3 (PDB ID: 4XTR) from Sgt2. This 
interaction makes Get3 lose its affinity for Get4/Get5 and they dissociate. Get3 is loaded with the TA-
protein and ATP in this state. (4) Get3, after its dissociation from Get4/Get5, hydrolyzes ATP and 
interacts with the cytoplasmic domain of Get2 (PDB ID: 3ZS9). Get2 tethers Get3 loaded with the TA-
protein to the ER membrane. (5) Get3 then interacts with the cytoplasmic coiled-coil domain of Get1 
(PDB ID: 3SJB) which provokes more conformational changes in Get3 and makes the TA-protein to be 
loose. (6) The TA-protein is handed off to the receptor that has insertase activity and inserts it into the 
membrane. Get3 subunits are depicted in orange and deep purple. CD stands for cytoplasmic domain. 
Sgt2
ATP
ADP
TA-protein
Get4/Get5/Sgt2
Ribosome
TA-protein
Get1/Get2
Cytoplasm
ER lumen
TA-protein
Get1/Get2
Get5
Get4/Get5/Sgt2
Pi
Get4
Get2 CD
Get1 CD
1
2
3
4
5
6
1.Introduction 
 
 
 
 
9 
1.3.2.1. Get3 ATPase cycle 
 
Once dissociated from Get1/2, Get3 is believed to be in an apo-Get3 
conformation. This refers to an open Get3 conformation with no nucleotides bound (Hu 
et al. 2009). However, it remains unclear whether this conformation exists in vivo (Chio, 
Cho, and Shan 2017). The binding of ATP to the Walker A or P-loop of Get3 triggers 
a conformational change towards a so-called close state (Bozkurt et al. 2009; Mateja 
et al. 2009; Suloway et al. 2009; Mateja et al. 2015) (Fig. 5, step 1). The pre-targeting 
complex, via Get4, has preference for Get3 in a close state (Chartron et al. 2010; Rome 
et al. 2013; Rome et al. 2014; Gristick et al. 2014) and the binding of Get4/Get5 inhibits 
the ATPase activity of Get3 (Rome et al. 2013) (Fig. 5, step 2). Next, Sgt2 hands off 
the TA-protein to Get3 (F. Wang et al. 2010; Rome et al. 2013; Rao et al. 2016). This 
interaction weakens the affinity between Get3 and Get4/Get5 and allow them to 
dissociate (Rome et al. 2014). At that point of the cycle, Get3 is loaded with the TA-
protein and ATP (Fig. 5, step 3). After dissociation of Get4/Get5, Get3 subsequently 
hydrolyzes ATP. Get2 has a high affinity for Get3 loaded with the TA-protein and ADP 
and tethers it to the ER membrane (Mariappan et al. 2011; Stefer et al. 2011; Zalisko 
et al. 2017). The interaction with Get2 destabilizes the ADP within Get3 and ADP is 
released (Fig. 5, step 4). Additional conformational changes in Get3 upon the release 
of Get2 allows for an interaction with Get1. which provokes more conformational 
changes in Get3 and renders the TA-protein free to dissociate from Get3 (Mariappan 
et al. 2011; F. Wang et al. 2011). The TA-protein is handed off to the receptor that has 
insertase activity and inserts it into the ER-membrane (F. Wang et al. 2011; F. Wang 
et al. 2014) (Fig. 5, step 5). Get1 loses its affinity for Get3 after the handover of the 
TA-protein. Get3 is believed to be released from the ER membrane in a nucleotide-
free state (Mariappan et al. 2011; Stefer et al. 2011; Kubota et al. 2012; Rome et al. 
2014; Zalisko et al. 2017) (Fig. 5, step 6). 
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Figure 5. The Get3 ATPase cycle model. (1) Get3 is in an apo-Get3 conformation (PDB ID: 3H84). 
This is an open Get3 conformation with no nucleotides bound. The binding of ATP triggers a 
conformational change towards a so called close state (PDB ID: 2WOJ). (2) The pre-targeting complex, 
through Get4, has a higher affinity for this close state preferentially (PDB ID: 4PWX). The binding of 
Get4/Get5 (additionally Sgt2, not shown in the figure) inhibits the ATPase activity of Get3. (3) The TA-
protein (PDB ID: 2LPF) is thus loaded into Get3 (PDB ID: 4XTR) from Sgt2. This interaction makes Get3 
lose its affinity for Get4/Get5 and they dissociate. Get3 is loaded with the TA-protein and ATP. (4) Get3, 
after dissociation of Get4/Get5, hydrolyzes ATP. Get2 has affinity for Get3 loaded with the TA-protein 
and ADP and tethers it to the ER membrane (PDB ID: 3ZS9). This ADP is released after the interaction 
with Get2. (5) Additional conformational changes in Get3 upon the release of Get2 allow the interaction 
with Get1 (PDB ID: 3SJB) which provokes more conformational changes in Get3 and makes the TA-
protein to be loose. The TA-protein is handed off to the receptor that has insertase activity and inserts 
it into the membrane. (6) Get1 loses affinity for Get3 after handing off the TA-protein. Get3 subunits are 
depicted in orange and deep purple. CD stands for cytoplasmic domain. 
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Figure 6. The Get3 ATPase cycle model. (1) Get3 is in an apo-Get3 conformation (PDB ID: 
3H84). This is  open Get3 conformation with no nucleotides bound. The binding of ATP trig ers a 
conformational change towards a so called close state (PDB ID: 2WOJ). (2) The pretargeting 
complex, through Get4, has a higher affinity for this close state preferentially (PDB ID: 4PWX). The 
binding of Get4/Get5 (additionally Sgt2, not shown in the figure) inhibits the ATPase activity of 
Get3. (3) The TA-protein (PDB ID: 2LPF) is thus loaded into Get3 (PDB ID: 4XTR) from Sgt2. This 
interaction makes Get3 lose its affinity for Get4/Get5 and they dissociate. Get3 is loaded with the 
TA-prot and ATP. ( ) Get3, after dissociation of Get4/Get5, hydrolyzes ATP. Get2 has affinity for 
Get3 loaded with the TA-prot and ADP and tethers it to the ER membrane (PDB ID: 3ZS9). This 
ADP is released after the interaction with Get2. (5) Additional conformational changes in Get3 upon 
the release of Get2 allow the interaction with Get1 (PDB ID: 3SJB) which provokes more conforma-
tional changes in Get3 and makes the TA-prot to be loose. The TA-prot is handed off to the recep-
tor that has insertase activity and inserts it into the membrane. (6) Get1 loses affinity for Get3 after 
handing off the TA-prot. Get3 subunits are depicted in orange nd deep purple. CD stands for 
cytoplasmic domain.
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1.3.2.2. Get3 functional domains 
 
Get3 is a homolog of the archaeal ATPase ArsA (C. M. Chen et al. 1986; T Zhou 
and Rosen 1997; Shen et al. 2003). Get3 is a cytoplasmic P-loop ATPase that belongs 
to the signal recognition particle (SRP), MinD, and BioD (SIMIBI) ATPase class (Leipe 
et al. 2002; Bange and Sinning 2013; Shan 2016). Get3 has three very well conserved 
domains from ArsA and all of them are involved in the ATPase activity of the protein: 
(i) a Walker A or P-loop motif where the nucleotide binds (Walker et al. 1982; Saraste, 
Sibbald, and Wittinghofer 1990), (ii) an ATPase switch I domain and (iii) a DTAP switch 
II domain (Mateja et al. 2009; Stefer et al. 2011) (Fig. 6). These regions are named 
after the Switch I and Switch II domains of ArsA (Tongqing Zhou et al. 2001) that due 
to similarity were named after the correspondent GTPase domains (Sprang 1997; 
Tongqing Zhou et al. 2001). Get3 is a homodimer that is stabilized by a zinc ion 
coordinated by two CXXC motifs (C285 and C288), one per monomer (Bozkurt et al. 
2009; Mateja et al. 2009; Suloway et al. 2009; Hu et al. 2009; Yamagata et al. 2010). 
Mutations involving those cysteines were unable to rescue a get3 deletion strain under 
different stress conditions (Metz et al. 2006). 
 
As previously mentioned, Get3 undergoes many conformational changes during its 
ATPase cycle (Hegde and Keenan 2011; Wereszczynski and McCammon 2012; Chio 
et al. 2017). These conformational changes make regions of Get3 accessible, enabling 
the interaction with different partners. The N-terminal domain of Get4 interacts with 
Get3, preferentially in an ATP-bound state (Gristick et al. 2014). There are additional 
interactions in the interface of Get4-Get3 that inhibit the ATPase activity of Get3 
(Gristick et al. 2014). The region of Get3 where Get4 interacts overlaps with the 
interaction surface of Get1 and Get2 (Mariappan et al. 2011; Stefer et al. 2011; F. 
Wang et al. 2011) (Fig. 6A). Get3 binding with Get1 and Get2 is mediated by 
electrostatic interactions involving acidic residues in the helix 11 of Get3, the so called 
DELYED motif (Mariappan et al. 2011; Stefer et al. 2011) (Fig. 6A). There is a second 
interaction interface between Get1 and Get3. Get1 is believed, through this second 
interface, to reconfigure Switch I and Switch II into a conformation similar to the open 
state (Stefer et al. 2011) (Fig. 6A). Binding of ATP promotes a close conformation of 
that brings together helical domains with hydrophobic residues that will form a 
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hydrophobic groove (Mateja et al. 2015). This is the so-called TA-protein binding 
groove where the TA-proteins bind to Get3 (Mateja et al. 2009; Mateja et al. 2015) 
(Fig. 6A). 
 
 
Figure 6. Get3 functional domains. (A) Scheme illustrating the functional domains described for Get3. 
Get3 structure highlighting these functional domains. Binding sites for Get1/2 and Get4 close to the C-
terminal are overlapping. Due to this overlapping, the binding site of Get1/2 (blue) is shown on the left 
and Get4 binding site (light green) on the right. (B) TRC40 scheme depicting the functional domains 
based on the conserved residues after alignment of Get3 and TRC40. 
 
 
1.3.2.3. Alternative roles of Get3 
 
Apart from TA-protein targeting, other roles have been described for Get3. 
Yeast cells have been shown to survive in the absence of Get3 (Shen et al. 2003; Metz 
et al. 2006). However, Dget3 yeast cells present different phenotypes such as heat 
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Figure 6. Get3 functional domains. (A) Scheme illustrating the functional domains described for 
Get3. Get3 structure highlighting these functional domains. Binding sites for Get1/2 and Get4 close 
to the C-terminal are overlapping. The binding site of Get1/2 (blue) is shown on the left and Get4 
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sensitivity, copper sensitivity or hygromycin sensitivity (Shen et al. 2003; Metz et al. 
2006; Schuldiner et al. 2008; Kohl et al. 2011; Kiktev et al. 2012; Voth et al. 2014). 
Connected to heat sensitivity, Get3 was predicted to have a heat shock transcription 
element in its native promoter (Yunkai Liu, Ye, and Erkine 2009).  
 
Get3 has also been reported to be potentially involved in the targeting of GPI-anchored 
proteins, along with other chaperones, in an SRP-independent way (Ast, Cohen, and 
Schuldiner 2013). In addition, it has been reported to be a guanine-nucleotide 
exchange factor (GEF) for the Ga subunit Gpa1p (Lee and Dohlman 2008).  
 
Get3 was found in foci in glucose-depleted cells colocalizing with unfolding proteins 
and chaperones such as Hsp104, Hsp42, Ssa1 or Sis1 (Powis et al. 2013). 
Furthermore, Get3 foci were found in Dget1/Dget2 cells in normal glucose conditions 
(Powis et al. 2013). Recently, Get3 was reported to be a redox-regulated chaperone 
under oxidative stress conditions (Voth et al. 2014). Hsp33, a bacterial redox-regulated 
chaperone, shares some features with Get3 (Jakob et al. 1999; Kumsta and Jakob 
2009), such as a CXC-Xn-CXXC motif that is the key of the redox switch of Hsp33 
(Jakob et al. 1999; Voth et al. 2014). Upon oxidation in vitro, Get3 undergoes drastic 
structural rearrangements that result in the release the Zn2+ ion coordinated by the 
dimer interface, bury the TA-protein binding hydrophobic groove and turn Get3 into an 
ATP-independent holdase (Voth et al. 2014) (Fig. 7). This conformational 
rearrangement is reversible upon restoration of reducing conditions and Zn2+ is present 
in the medium. Interestingly, Get3 can form tetramers and high-order oligomers under 
oxidative conditions. Moreover, Get3 ATPase activity is severely reduced upon 
oxidation stress conditions (Fig. 7) (Voth et al. 2014).  
 
 
1.3.3. Mammalian TRC pathway 
 
Most of the proteins of the yeast GET pathway are conserved in mammals 
(except Get2 that has a functional ortholog in CAML). Therefore, the pathway is 
conserved and is known as the TRC pathway. Interestingly, the TRC pathway includes  
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Figure 7. Get3 can act as a redox-regulated chaperone. Get3 has been reported to be a redox-
regulated chaperone in vitro (Voth et al. 2014). Upon stress like oxidation or ATP depletion, Get3 
releases the Zn2+ ion coordinated by the dimer and the loaded ATP and undergoes conformational 
changes. This structural reorganization involves the burying of the ATPase pocket and the TA-binding 
groove. Get3 forms higher oligomer species, being tetramers the most abundant ones. This switch is 
reversible, upon non-oxidative conditions and in presence of Zn2+ and ATP Get3 recovers its ATPase 
activity and its conformation. According to the model, under stress conditions Get3 chaperone could not 
target TA-proteins to the Get1/2 receptor due to the inaccessibility of the TA-binding groove. 
 
BAG6, that is a protein not present in yeast (Leznicki et al. 2010; Mariappan et al. 
2010) but later in evolution (Mock et al. 2017). Homologs or functional orthologs 
between the yeast GET pathway and the mammalian TRC pathway are enlisted in the 
following Table 1. 
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Table 1. Components of the GET/TRC pathways. 
 Yeast Mammals 
Pre-targeting complex 
- BAG6 
Sgt2 SGTA 
Get5 UBL4A 
Get4 TRC35 
Cytoplasmic ATPase 
effector 
Get3 TRC40 
Receptor 
Get2 CAML 
Get1 WRB 
 
The pathway is conserved as little difference exist between the GET pathway and the 
TRC pathway. First, BAG6 is thought to interact with the ribosome, along with TRC35 
and UBL4A, and bind nascent substrates after their release from the ribosome 
(Mariappan et al. 2010). Second, TRC35 and UBL4A do not directly interact, in contrast 
to yeast where Get4 and Get5 directly interact (Mock et al. 2015). This is due to the 
fact that the Get4 b-loop that was involved in the Get4-Get5 interaction interface is 
missing in TRC35 (Chartron et al. 2010). The Get4 b-loop is only present in yeast but 
not in other Opisthokonta (Mock et al. 2017). Additionally, the N-terminal domain of 
Get5 is not present in UBL4A, so the interaction between Get4 and Get5 cannot 
happen in either way (Chartron et al. 2010; Mock et al. 2015). Instead, UBL4A and 
TRC35 bind to BAG6, which serves as a scaffolding protein. TRC35 interacts with the 
region of BAG6 containing the nuclear localization sequence (NLS) masking it and 
UBL4A docks on the BAG domain of BAG6 (Mock et al. 2015; Kuwabara et al. 2015; 
Mock et al. 2017) (Fig. 8A). Subsequently, SGTA is recruited, via the UBL domain, to 
either BAG6 or UBL4A (preferentially this last one) (Xu et al. 2012; Leznicki et al. 2013; 
Darby et al. 2014) (Fig. 8A). Therefore, BAG6 is the pre-targeting-complex 
cornerstone protein. In fact, a truncated version of BAG6 containing just the C-terminal 
domain (comprising the BAG6 and NLS domains) is sufficient for the in vitro handover 
of a TA-protein to TRC40 (Mock et al. 2015; Shao et al. 2017). A more detailed 
description of the components of the TRC pathway is described in the following lines. 
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Figure 8. Pre-targeting complex of the TRC pathway. (A) Scheme illustrating the BAG6 
heterotrimeric complex and its interactions with SGTA and TRC40. The PDB IDs are the following: Get3 
(4XTR), TA-protein (2LPF), SGTA (4CPG, 5LYP), TRC35 (6AU8), UBL4A (4X86). TRC40 is 
represented with the Get3 protein structure and BAG6 is depicted as a silhouette due to the lack of 
reported structure for both. 
 
 
1.3.3.1. TRC40 
 
TRC40 is the human homolog of yeast Get3 and is also known as ASNA1. 
TRC40 shares 46% identity to Get3 (Bhattacharjee, Ho, and Rosen 2001; Shen et al. 
2003). TRC40 heterozygous mice (Asna1+/-) presented a similar phenotype as the wild-
type (wt) whereas the TRC40 homozygous mice (Asna1-/-) showed early embryonic 
lethality between E3.5 and E8.5 (E stands for embryonic day) (Mukhopadhyay et al. 
2006). In contrast, two TRC40-knockout pancreatic b-cells and pancreatic epithelial 
cells showed impaired retrograde transport (plasma membrane-to-trans-Golgi network 
and Golgi-to-ER), hypoinsulinemia, impaired insulin secretion and pancreatic agenesis 
due to perturbation of pancreatic progenitor differentiation (Norlin et al. 2016; Norlin, 
Parekh, and Edlund 2018). Likewise, it was reported that TRC40 favorably regulated 
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Figure 7. Pretargeting complex of the TRC pathway. Graphical scheme of the BAG6 heterotri-
metic complex and its interactions with SGTA and TRC40. The PDB IDs are the following: TRC40 
(4XTR), TA-protein (2LPF), SGTA (4CPG, 5LYP), TRC35 (6AU8), UBL4A (4X86). TRC40 is repre-
sented with the Get3 protein structure and BAG6 is depicted as a silhouette due to the lack of 
structure for both.
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insulin secretion in Caenorhabditis elegans and mammalian cells (Kao et al. 2007). 
The knockdown of TRC40 increases the sensitivity to arsenite and chemotherapy 
platinating agents (such as cisplatin, carboplatin or oxaliplatin) in C.elegans, ovarian 
cancer and melanoma cells (Hemmingsson, Zhang, et al. 2009; Hemmingsson, Nöjd, 
et al. 2009; Hemmingsson et al. 2010).  
 
TRC40 was found to be the cytoplasmic factor involved in TA-protein targeting in 
mammalian cells (Stefanovic and Hegde 2007; Favaloro et al. 2008). Additionally, 
TRC40 was also found to be involved in the delivery of short secretory proteins, such 
as apelin and statherin, to the Sec61 translocon (Johnson et al. 2012). Interestingly, 
the knockdown of either BAG6 or TRC40 lead to an accumulation of ubiquitinated 
proteins (Q. Wang et al. 2011; Akahane et al. 2013) and to defects in the core 
proteasome assembly (Akahane et al. 2013; Sahara et al. 2014). Interestingly, TRC40 
has been found necessary for the efficient release of herpes simplex virus 1 virions 
(Ott et al. 2016).  
 
 
1.3.3.2. WRB 
 
WRB was identified while mapping the chromosome region connected to 
congenital heart disease of Down syndrome patients (Egeo et al. 1998). The down-
regulation of WRB has been reported to cause severe heart disorder and eye and heart 
abnormalities in medaka fish (Murata et al. 2009). Likewise, WRB has been found to 
associate to CASZ1, a transcription factor, during cardiac morphogenesis and they are 
essential to maintain tissue integrity (Sojka et al. 2014). WRB was reported to be the 
ER-membrane receptor for the TRC pathway (Vilardi, Lorenz, and Dobberstein 2011). 
It has been suggested that WRB and Get1 belong to the Oxa1 superfamily. This 
superfamily would contain the evolutionary conserved members Oxa1/Alb3/YidC that 
mediate membrane protein biogenesis in different organelles (Anghel et al. 2017). 
WRB and CAML are suggested to act as an insertase for inserting TA-proteins into 
ER-membrane (F. Wang et al. 2011; Y. Yamamoto and Sakisaka 2012; reviewed in Y. 
Yamamoto and Sakisaka 2015). The first two Get1/WRB helices form a coiled-coil, 
localized in the cytoplasmic domain of Get1/WRB (Stefer et al. 2011). This coiled-coil 
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domain of WRB is the one interacting with the DELYED motif on Get3/TRC40 
(Mariappan et al. 2011; Stefer et al. 2011; F. Wang et al. 2011). Several WRB-knockout 
animals were generated and caused synaptic hearing impairment, demonstrating how 
WRB is essential in inner-ear hair cells in zebrafish (Lin et al. 2016; Vogl et al. 2016) 
and in mice (Vogl et al. 2016). Furthermore, WRB loss caused impairment of the 
synaptic transmission in photoreceptors in zebrafish (Daniele et al. 2016; Lin et al. 
2016). TA-protein biogenesis was affected in a cardiomyocyte-specific and a 
hepatocyte-specific WRB-knockouts (Rivera-Monroy et al. 2016). 
 
 
1.3.3.3. CAML 
 
CAML was firstly identified as a cyclophilin B interactor in calcium signaling after 
a yeast two-hybrid screen (Bram and Crabtree 1994). WRB and CAML were reported 
to act as an insertase for inserting TA-proteins into ER-membrane (F. Wang et al. 2011; 
Y. Yamamoto and Sakisaka 2012) and to be sufficient to mediate the insertion of TA-
proteins (Vilardi et al. 2014). A RERR motif present in the first helix of the cytoplasmic 
domain of Get2 is responsible of the interaction with the DELYED motif of Get3 
(Mariappan et al. 2011; Stefer et al. 2011; F. Wang et al. 2011). The RERR motif is not 
present in CAML, instead a RRRK motif at the N-terminus is responsible for binding 
TRC40 (Y. Yamamoto and Sakisaka 2012; Y. Yamamoto and Sakisaka 2015). CAML 
was shown to be involved in epidermal growth factor (EGFR) and p56 Lck signaling 
and has been reported to be necessary for the survival of specialized immune cells 
(Tran et al. 2005; Zane et al. 2012; Chan et al. 2015). CAML-knockout mouse 
embryonic fibroblasts present chromosome instability and anaphase failure (Yu Liu et 
al. 2009). In contrast, CAML-knockout mouse presented early embryonic lethality (Tran 
et al. 2003). Interestingly, an inner-ear hair cells specific CAML-knockout resulted in 
deafness in mice (Bryda et al. 2012) in a similar line as reported for WRB-knockout 
animals (Lin et al. 2016; Vogl et al. 2016). 
 
 
1.3.3.4. BAG6 
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BAG6, also known as BAT3 or Scythe, is a nucleo-cytoplasmic protein that was 
mapped in chromosome 6 (Spies et al. 1989). It belongs to the BAG-family of 
antiapoptotic proteins that share a BAG domain (reviewed in Behl 2016). BAG6 
contains a UBL domain at the N-terminus (Banerji et al. 1990). This UBL domain can 
interact with other proteins such as SGTA (Leznicki et al. 2013; Darby et al. 2014), 
gp78 (Q. Wang et al. 2011), RNF126 (Rodrigo-Brenni, Gutierrez, and Hegde 2014), 
etc.  Also in the N-terminus of BAG6, is the BUILD domain where short hydrophobic 
segments can be recognized (H. Tanaka et al. 2016). BAG6 has a DEQD canonical 
cleavage site that can be cleaved by caspase-3 and subsequently triggering apoptosis 
(Y.-H. Wu, Shih, and Lin 2004; Preta and Fadeel 2012). BAG6 carries a NLS that 
enables it to translocate into the nucleus (Manchen and Hubberstey 2001). TRC35 
interacts with this NLS region (Mock et al. 2015; Mock et al. 2017). Finally, the BAG 
domain that characterizes the BAG-family can be found at the C-terminus (Thress et 
al. 2001). The BAG domain has been reported to modulate the activity of molecular 
chaperones Hsp70 (reviewed in Kabbage and Dickman 2008). However, unlike the 
other members of the BAG-family, the BAG domain of BAG6 cannot interact with the 
nucleotide binding domain of Hsp70 (Mock et al. 2015). UBL4A interacts with the BAG 
domain of BAG6 (Mock et al. 2015; Kuwabara et al. 2015). The UBL domain is 
conserved from invertebrates whereas the BAG domain is only present in vertebrates 
but not in invertebrates (Kawahara, Minami, and Yokota 2013). 
 
Different than TA-protein targeting, BAG6 has been reported to have a relevant role in 
protein quality control of mislocalized secretory and membrane proteins (MLPs) 
(Minami et al. 2010; Hessa et al. 2011; Leznicki and High 2012; Leznicki et al. 2013; 
Wunderley et al. 2014; Rodrigo-Brenni, Gutierrez, and Hegde 2014). BAG6 has been 
extensively linked to the ubiquitin-proteasome system. SGTA-BAG6 interplay with 
hydrophobic substrates to determine the fate of these substrates. BAG6 has been 
shown to recruit RNF126, a cytoplasmic E3 ubiquitin ligase, that can ubiquitylate MLP 
substrates (Zhi et al. 2013; Rodrigo-Brenni, Gutierrez, and Hegde 2014; Krysztofinska 
et al. 2016). Thus, BAG6 is thought to promote protein degradation (Leznicki and High 
2012). BAG6 downregulation leads to accumulation of ubiquitinated proteins (Q. Wang 
et al. 2011; Akahane et al. 2013) and to defects in the assembly of the proteasome 
(Akahane et al. 2013; Sahara et al. 2014). It has been reported that BAG6 can interact 
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with the proteasome receptor subunit PSMD4 or Rpn10 (Kikukawa et al. 2005; Minami 
et al. 2010; Hessa et al. 2011). 
 
Nevertheless, BAG6 is connected to more protein quality control processes. It was 
reported that BAG6 can also play a role in regulating the degradation of polytopic 
ERAD substrates (Payapilly and High 2014). BAG6 was found to chaperone 
translocated ERAD-substrates (Q. Wang et al. 2011). Likewise, BAG6 was reported to 
collaborate in the dislocation of misfolded glycopeptides (Claessen and Ploegh 2011). 
Furthermore, Ubiquilin-4 (UBQLN4) and BAG6 interact and cooperate in the 
recognition of defective newly synthesized polypeptides (Suzuki and Kawahara 2016). 
Additionally, BAG6 has been reported to mediate substrate-degradation in preemptive 
quality control (pQC) required for the maintenance of ER homeostasis (Kadowaki et 
al. 2015).  
 
BAG6 heterotrimeric complex was found to translocate into the nucleus upon DNA 
damage. It is believed to be part of the DNA damage response (DDR) pathway 
(Krenciute et al. 2013). Constitutive BAG6 knockout in mice is embryonically lethal and 
causes developmental defects in several organs (Desmots et al. 2005; Sebti et al. 
2014). BAG6 can interact and form a complex with the acetyl-transferase p300 (Sasaki 
et al. 2007). The interaction between BAG6-p300 enhances the acetylation of p53 and 
thus p53 transcriptional activity (Sasaki et al. 2007). BAG6 modulates the nucleo-
cytoplasmic localization of p300 (Sebti et al. 2014) and regulates autophagy via p300-
mediated acetylation of p53 upon starvation. In contrast, BAG6 inhibits the p300-
mediated acetylation of ATG7 (Sebti et al. 2014). 
 
 
1.3.3.5. SGTA 
 
SGTA is a tetratricopeptide repeat (TPR)-containing protein which contains 
three TPRs (Lamb, Tugendreich, and Hieter 1995; Kordes et al. 1998; Blatch and 
Lässle 1999). TRP-containing proteins have been shown to interact with the EEVD 
motif of molecular chaperones like Hsp70 and Hsp90 (S. Chen et al. 1998; Scheufler 
et al. 2000). Additional to TA-protein targeting, SGTA has been described to have an 
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important role in protein quality control of MLPs (Hessa et al. 2011; Leznicki et al. 2013; 
Rodrigo-Brenni, Gutierrez, and Hegde 2014; Wunderley et al. 2014). Opposite to 
BAG6, SGTA was reported to promote deubiquitylation (Leznicki and High 2012; 
Wunderley et al. 2014). In fact, SGTA interacts with the proteasomal ubiquitin receptor 
Rpn13 modulating quality control (Leznicki et al. 2015; Thapaliya et al. 2016). Rpn13 
has been reported to bind the deubiquitinase UCH37 (UCHL5) and it has been 
speculated that this could revert the fate of ubiquitylated-proteins chaperoned by SGTA 
(Sahtoe et al. 2015; Vander Linden et al. 2015). SGTA was reported to help BAG6 
chaperoning ERAD-translocated substrates (Xu et al. 2012). Additionally, SGTA was 
found to interact with Hsp70 and DNAJC5 in neurons and to have a role in synaptic 
transmission. Over-expression of SGTA in hippocampal neurons results in impaired 
synaptic transmission (Tobaben et al. 2001) and SGTA-knockout mouse showed 
reduced body size and decrease the offspring viability (Philp et al. 2016). 
 
 
1.3.3.6. TRC35 
 
TRC35, also known as GET4, CEE or C7orf20, was identified as a conserved 
gene during evolution (Fernandes et al. 2008). TRC35, apart from TA-protein targeting, 
was reported to shuttle as a part of a complex with UBL4A and BAG6 into the nucleus 
upon DNA damage where they are believed to be part of the DDR pathway (Krenciute 
et al. 2013). TRC35 has been reported to regulate the nuclear-cytoplasmic distribution 
of BAG6 (Q. Wang et al. 2011; Mock et al. 2017) by binding the NLS of BAG6 and 
therefore masking it (Mock et al. 2015; Mock et al. 2017). BAG6 prevents the RNF126-
mediated ubiquitylation and subsequent degradation of TRC35 (Mock et al. 2017). 
 
 
1.3.3.7. UBL4A 
 
UBL4A, also known as GdX, was identified in the 1980s (Toniolo, Persico, and 
Alcalay 1988; Yang, Skaletsky, and Wang 2007). Apart from TA-protein targeting, 
UBL4A has been reported to be involved in Akt signaling by promoting Arp2/3-
dependent actin branching (Yu Zhao et al. 2015). Moreover, UBL4A was also involved 
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with STAT3 signaling (Y. Wang et al. 2014). UBL4A was found to translocate into the 
nucleus, along with TRC35 and BAG6, upon DNA damage and are also believed to be 
part of the DDR pathway (Krenciute et al. 2013). UBL4A-knockout mice were 
generated (Y. Wang et al. 2012; Y. Wang et al. 2014; Yu Zhao et al. 2015; Liang et al. 
2018) and show that UBL4A null mice presented (i) increased neonatal mortality and 
defects in the liver synthesis of glycogen (Yu Zhao et al. 2015); (ii) perturbed genes 
related to osteogenesis and chondrogenesis leading to dysregulation of these 
processes (Liang et al. 2018).  
 
 
1.3.4. Redundancy in the insertion pathways 
 
Several studies have suggested the existence of other post-translational 
pathways operating in the ER-targeting of TA-proteins (Fig. 9, Fig. 10). Some of these 
pathways overlap in their substrate spectra and may compensate in the targeting of 
certain TA-proteins. The following pathways are described in the literature: 
 
 
1.3.4.1. EMC pathway 
 
In a recent study, calmodulin (CaM) was identified to interact with the TA-protein 
squalene synthase (SQS) (Guna et al. 2018). SQS is a TA-protein that presents a TMD 
with moderate hydrophobicity. CaM was found to shield TA-proteins with low-
hydrophobic TMDs (Guna et al. 2018) (Fig. 10E). Likewise, CaM was reported to 
interact with TA-proteins in another study (Haßdenteufel et al. 2011). In addition, CaM 
was also shown to bind hydrophobic regions (Shao and Hegde 2011). CaM was 
proposed to deliver the TA-protein to the ER membrane protein complex (EMC). 
Interestingly, EMC was found to be an ER-insertase for moderately hydrophobic TMDs 
(Guna et al. 2018) (Fig. 10E). In contrast, CaM was shown to inhibit the ER-insertion 
of certain TA-proteins in an insertion assay using rabbit reticulocyte lysate (RRL) and 
rough microsomes (RMs) (Haßdenteufel et al. 2011). Some TA-proteins were shown 
to have partial dependence on the EMC pathway and in the TRC pathway (Guna et al. 
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2018). Based on those results, the authors proposed an approximate point where both 
pathways might overlap around the Sec61b TMD hydrophobicity (Guna et al. 2018). 
 
 
1.3.4.2. PEX pathway 
 
This pathway is responsible of peroxisomal membrane proteins (PMPs) 
targeting to the ER-membrane or to preexisting peroxisomes (Jones, Morrell, and 
Gould 2004; reviewed in Mayerhofer 2016). Peroxin-19 (PEX19) is the cytoplasmic 
factor that recognizes a peroxisomal targeting sequence (PTS) (Gould et al. 1989; 
Swinkels et al. 1991) in the PMPs and targets them to the receptor PEX3 (Muntau et 
al. 2003; Fang et al. 2004; Jones, Morrell, and Gould 2004; Yuqiong Liu, Yagita, and 
Fujiki 2016) (Fig. 9A, Fig. 10D). PEX3 is a membrane protein localized in the ER and 
peroxisomes (Toro et al. 2007; Aranovich et al. 2014; Mayerhofer et al. 2016; Schrul 
and Kopito 2016). The pathway is conserved in yeast and mammals. There are seven 
PMPs that are TA-proteins (Table 17). The PMPs TA-proteins are targeted to 
peroxisomes using this pathway. However, Pex15p is targeted using the GET pathway 
in yeast (van der Zand, Braakman, and Tabak 2010). In contrast, the insertion of the 
functional homolog of Pex15p in mammals, PEX26, is TRC-independent (Halbach et 
al. 2006; Yagita, Hiromasa, and Fujiki 2013; Buentzel et al. 2015). The presence of 
PTS and basic residues following the TMD are responsible for the PEX19-targeting of 
the PMP TA-proteins (Yagita, Hiromasa, and Fujiki 2013). 
 
 
1.3.4.3. SND pathway 
 
The SRP-independent targeting (SND) pathway was recently described in yeast 
(Aviram et al. 2016). SND components described were the cytoplasmic Snd1 and the 
ER-resident proteins Snd2 and Snd3 (Fig. 9B). Snd1 was predicted to bind the RNC 
(Fleischer et al. 2006) whereas Snd2 and Snd3 are found in a complex with the 
translocon (Aviram et al. 2016). The SND pathway predominantly targets membrane 
proteins whose transmembrane segments are in the middle of the protein. The SND 
pathway has been shown to compensate for the loss of the SRP pathway and the GET 
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pathway (Aviram et al. 2016), acting as a rescue pathway. In mammals, Snd2 (also 
known as TMEM208), homolog of the homonym yeast protein, is the only conserved 
protein from the yeast SND pathway. So far, there are no reported pathway-partners 
for Snd2 (Fig. 10F) (Yuanbo Zhao et al. 2013; Haßdenteufel et al. 2017).  
 
 
1.3.4.4. Ubiquilins 
 
Ubiquilins (UBQLN1-4) were reported to be able to chaperone mitochondrial 
membrane proteins in cytoplasm (Itakura et al. 2016). Mitochondrial TA-proteins are 
suitable to be UBQLN-substrates (Fig. 10A). In addition, they can also triage these 
membrane proteins and target them for degradation (Itakura et al. 2016).  
 
 
1.3.4.5. Hsp40/Hsc70 
 
In a reconstituted system, Hsp40/Hsc70 are able to promote the membrane-
insertion of TA-proteins (B. M. Abell et al. 2007; Rabu et al. 2008). However, when 
tested in HeLa cells in the presence of selective inhibitors of Hsp40/Hsc70 only a small 
subset of TA-proteins, characterized by low hydrophobicity in their TMDs, was affected 
(Rabu et al. 2008) (Fig. 9D, Fig. 10B).  
 
 
1.3.4.6. SRP pathway 
 
VAMP2 and Sec61b in vitro insertion was reported to be SRP-dependent in a 
post-translational manner (Benjamin M. Abell et al. 2004; B. M. Abell et al. 2007). 
Likewise, SRa-downregulated HeLa M cells showed a decrease of SERP1 and 
Sec61b steady-state levels (Casson et al. 2017). This would suggest that some TA-
protein might require the SRP pathway to be targeted to the ER (Casson et al. 2017) 
(Fig. 10G). Interestingly, Get4-Get5 have been shown to compete for co-
translationally-inserted substrates with SRP in a Sgt2-independent way (Zhang et al. 
2016). 
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Figure 9. Tail-anchored protein insertion pathways in yeast. (A) Pex19 targets PMPs that are TA-
proteins with basic residues in its C-terminal tail to its receptor Pex3. Pex3 can be localized in ER or 
peroxisomes. (B) In the SND pathway, Snd1 can take TA-proteins to its receptor Snd2/Snd3 that forms 
a complex Sec66, Sec62, Sec72, Sec63 and Sec61. (C) The GET pathway begins when Sgt2 grabs the 
TA once exits the ribosome, it binds the pre-targeting complex composed of Get4 and Get5 and it hands 
the TA off to Get3. Get3 is the cytoplasmic factor that carries the protein to the Get1/Get2 ER-receptor 
and it releases it in an ATP-dependent manner. The receptor is an insertase that inserts the protein into 
the ER. (D) Hsp70/Hsp40 have been proposed as alternative cytoplasmic factors that can hold TA-
proteins. TA-protein model is PLN (PDB ID: 2LPF). 
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Figure 10. Tail-anchored protein insertion pathways in mammals. (A) Ubiquilins are believed to 
target mitochondrial TA-proteins. (B) Hsp70/Hsp40, in a similar fashion to yeast, have hypothetically 
been proposed as alternative cytoplasmic factors that can hold TA-proteins. (C) The TRC pathway is 
analog to the Get pathway in yeast but with the addition of the mammalian protein BAG6. SGTA grabs 
the TA once exits the ribosome, it binds the pre-targeting complex composed of BAG6, UBL4A and 
TRC35 and it hands the TA off to TRC40. TRC40 is the cytoplasmic factor that carries the protein to the 
WRB/CAML ER-receptor and it releases it in an ATP-dependent manner. The receptor is an insertase 
that inserts the protein into the ER. (D) The PEX19 pathway is analog to the one in yeast. PEX19 targets 
PMPs that are TA-proteins with basic residues in its C-terminal tail to its receptor PEX3 such as PEX26. 
PEX3 can be localized in ER or peroxisomes. (E) Calmodulin can target TA-proteins that contain a TMD 
with low hydrophobicity to the ER membrane protein complex (EMC) that is formed by 10 subunits. (F) 
Snd2, homolog of the homonym yeast protein, is the only conserved protein in mammals of the yeast 
SND pathway. There are no reported pathway-partners for Snd2. (G) Some TA-protein might require 
the SRP pathway to be post-translationally targeted to the ER. TA-protein model is PLN (PDB ID: 2LPF). 
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1.3.4.7. Unassisted insertion of TA-proteins 
 
Cytochrome b5 (Cytb5) is a TA-protein that is localized at the ER-membrane. It 
was the first TA-protein studied (Anderson, Mostov, and Blobel 1983). Cytb5 has a 
low-hydrophobicity TMD. It has been reported that can be inserted into protein-free 
liposomes in an unassisted-manner (Yabal et al. 2003; Brambillasca et al. 2005; 
Brambillasca et al. 2006; Sara F. Colombo, Longhi, and Borgese 2009). In addition, it 
might require Hsp40/Hsc70 chaperoning (Rabu et al. 2008). In a similar line, Cytb5 
has been reported not to require the TRC pathway for ER-targeting (Stefanovic and 
Hegde 2007; Favaloro et al. 2008). Cytb5 localized in MOM in cytosol-free 
semipermeabilized cells (Figueiredo Costa et al. 2018). Therefore, it was proposed 
that MOM might be the default destination of TA-proteins able to be inserted in an 
unassisted-manner (Figueiredo Costa et al. 2018). 
 
 
1.4. Glucocorticoid receptor signaling 
 
Glucocorticoids are a class of steroid hormones that are produced by the 
adrenal cortex under a strong regulation of the hypothalamic-pituitary-adrenal gland 
axis (reviewed in Vandevyver, Dejager, and Libert 2014). They are involved in a broad 
variety of processes such as inflammatory and immune responses, development, 
reproduction, metabolic homeostasis, etc. Glucocorticoids interact with their 
intracellular receptor called glucocorticoid receptor (GR) (Fig. 11). GR belongs to the 
steroid-hormone receptor (SR) family (reviewed in Whitfield et al. 1999). GR 
predominantly localizes in cytoplasm in the absence of ligand but it is continuously 
shuttling between the cytoplasm and the nucleus (Madan and DeFranco 1993; 
Guiochon-Mantel et al. 1994). In the cytoplasm, the GR is part of a multimeric complex 
composed of heat-shock proteins (e.g. Hsp40, Hsp70 and Hsp90) and TPR-containing 
proteins (e.g. Hop, SGTA, Chip, FKBP52, FKBP51, Hip among others) (S. Chen et al. 
1998; S. Chen and Smith 1998; Hernández, Chadli, and Toft 2002; Paul et al. 2014; 
reviewed in Cheung and Smith 2000; reviewed in Smith 2004). The stimulation of the 
GR with a glucocorticoid receptor agonist results in a conformational rearrangement 
that exposes two nuclear localization signals (NLS) (Picard and Yamamoto 1987). This 
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conformational change remodels the chaperone complex and leads to the association 
of FKBP52 that interacts with dynein to drive the GR along microtubules to the nucleus 
(Davies, Ning, and Sánchez 2002; Harrell et al. 2004). GR is translocated to the 
nucleus after interaction with importins (Guiochon-Mantel et al. 1991; Haché et al. 
1999; M. Tanaka et al. 2003; Freedman and Yamamoto 2004). GR homodimerizes 
and binds to specific DNA regions called glucocorticoid response elements (GREs). 
These GREs are located in the promoter region of glucocorticoid-regulated genes 
(Beato 1989; Del Monaco et al. 1997; Meijsing et al. 2009; Surjit et al. 2011). Then, 
GR can interact with other coactivators/corepressors and regulate the expression of 
glucocorticoid-responsive genes (Phuc Le et al. 2005; Surjit et al. 2011).  
 
GR presents different domains in its structure. At the N-terminus sits the N-terminal 
domain (NTD). The NTD contains AF1 that is required for maximal transcription 
activation (Dieken and Miesfeld 1992). In the central portion of the protein is located 
the so-called DNA-binding domain (DBD). The DBD contains two zinc fingers that 
recognize the GREs and also contains the homodimerization motif (Härd et al. 1990; 
Luisi et al. 1991; Watson et al. 2013). Glucocorticoids interact with the ligand-binding 
domain (LBD) that is located towards the C-terminus of the protein (reviewed in 
Vandevyver, Dejager, and Libert 2014). A hinge region links the DBD with the LBD. 
Hsp90 was reported to bind the LBD due to its elevated hydrophobicity (Bresnick et al. 
1989; Picard et al. 1990; Ricketson et al. 2007).  
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Figure 11. Glucocorticoid receptor signaling pathway. The GR is kept soluble in cytoplasm by a 
chaperone machinery composed by several proteins from the heat shock proteins (Hsps) as Hsp40, 
Hsp70, Hsp90 and TPR-containing proteins like p23, SGTA and Hop. Once the protein is mature it gets 
rid of Hsp70, Hsp40 and Hop and FKBP51 binds, this form is ready to bind the ligand and get activated. 
The ligands can diffuse through the plasma membrane and get into the cytoplasm. In the presence of 
the ligand, FKBP52 interacts with the GR and FKBP51 exits the complex. Once bound to FKBP52, the 
GR can shuttle into the nucleus, it dimerizes and binds to the glucocorticoid response elements (GREs) 
in the DNA through which the GR mediates the transactivation or transrepression of several genes. 
Adapted from (Cato et al. 2014). 
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1.5. Aims 
 
 
o The first aim of this study is to explore the role of several functional domains of 
TRC40 in targeting TA-proteins targeting to ER-membrane and chaperoning in vivo 
in mammalian cells.  
 
o The second aim of this study is to investigate the dependence of TA-proteins on 
the TRC pathway at the steady-state in vivo in mammalian cells. Recently, several 
post-translational pathways for TA-protein targeting have been described, but little 
is known about TRC-dependence in mammalian cells in vivo. 
 
o Yeast Get3, TRC40 homolog, was characterized by Voth et al. to have an 
alternative role as a redox-regulated chaperone. Almost nothing is known about the 
redox behavior of TRC40, which shares homology with yeast Get3. My aim was to 
investigate the redox behavior of TRC40 in vitro to elucidate whether it can act as 
a redox-regulated chaperone as well as to explore the behavior of TRC40 under 
oxidative conditions in vivo in human cell lines. This study is interested in the 
identification of putative substrates of this potential TRC40 chaperone. 
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2. Material and Methods 
2.1. Material 
 
2.1.1. Bacterial strains 
 
Table 2. Bacterial strains used in this study. 
Strain Genotype Reference 
Escherichia coli 
BL21 (DE3) 
F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3 
[lacI lacUV5- 7 gene 1 ind1 sam7 nin5] 
Novagen. 
Catalog #: 
69450 
E. coli ElectroTen 
blue 
Δ(mcrA)183 
Δ(mcrCBhsdSMRmrr)173 endA1 supE44 thi1 r
ecA1 gyrA96 relA1 lac Kanr [F' proAB lacIqZΔM
15 Tn10 (Tetr)] 
 
Agilent. 
Catalog #: 
200159 
 
 
2.1.2. Yeast (S. cerevisiae) strains 
 
Table 3. Yeast strains used in this study. 
Strain Genotype Background Reference 
BY4741 MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 
S288C (Brachmann et 
al. 1998) 
BY4741 
Dget3 
MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 ydl100c::KanR 
BY4741 (Schuldiner et 
al. 2008; 
Jonikas et al. 
2009) 
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BY4741 
Dget1/2 
MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 get1::KanR 
get2::NatR 
BY4741 (Schuldiner et 
al. 2008) 
BY4741 
Dsgt2 
MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 yor007c::KanR 
BY4741 This study 
BY4742 MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 
S288C (Brachmann et 
al. 1998) 
BY4742 
Dget3 
MATa his3∆1 leu2∆0 met15∆0 
ura3∆0 
ydl100c::KanR 
BY4742 This study 
K700a MATa ade2-1 trp1-1 can1-100 
leu2-3,112 his3-11,15 ura3 GAL+ 
psi+ ssd1-d2 
W303 Nasmyth, K. 
K700a Dget3 MATa ade2-1 trp1-1 can1-100 
leu2-3,112 his3-11,15 ura3 GAL+ 
psi+ ssd1-d2 ydl100c::KanR 
K700a This study 
 
 
2.1.3. Cell lines 
 
Table 4. Cell lines used in this study. 
Strain Organism Derived from Reference 
HeLa P4 Human Epithelial cells 
from cervix 
(Scherer, Syverton, and Gey 
1953; Charneau et al. 1994) 
Flp-In T-REx 293 
Stx5-opsin 
Human Embryonic 
kidney cells 
Invitrogen. Catalog#: R78007 
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2.1.4. Mouse lines 
 
All the procedures involving animals were reviewed and approved by the 
Institutional Animal Care and Use Committee of the University Medical Center 
Göttingen, in compliance with the human care and use of laboratory animals.  
 
Wrbfl/fl line was previously described (Vogl et al. 2016). This mouse line was bred with 
a Myh6-MerCreMer (B6.FVB(129)-A1cfTg(Myh6-cre/Esr1*)1JmK/J) that was acquired from the 
Jackson Laboratory (Stock# 005657). The MerCreMer is an engineered Cre 
recombinase version composed by the fusion of this protein with two mutant estrogen-
receptor (Mer) ligand binding domains (LBD). This engineered Cre recombinase is able 
to recombine regions flanked with recombinase recognition sequences (loxP sites or 
fl). The MerCreMer expression is under the control of the a-myosin heavy chain 
promoter (Myh6), what confines its expression to cardiac tissue (Sohal et al. 2001). 
Wrbfl/fl  presents exons two and four flanked by loxP sites (Vogl et al. 2016; Rivera-
Monroy et al. 2016). The fusion of the Cre recombinase to the Mer makes Cre a tightly-
controlled cytoplasmic protein that only can translocate into the nucleus upon the 
addition of tamoxifen, that is an agonist/antagonist of the estrogen receptor (Metzger 
et al. 1995; Schwenk et al. 1998; Sohal et al. 2001). Upon the MerCreMer translocation 
to the nucleus, Wrb exons 2 to 4 will be excised leaving a truncated non-functional 
version of Wrb. Hence, the result was a cardio-specific WRB conditional knockout 
where the WRB is controlled spatial-temporally.  
 
MerCreMer-dependent recombination was induced in six-week old animals by injection 
of 40 mg/kg of tamoxifen (diluted in ethanol-soybean oil) as previously described 
(Lexow et al. 2013).
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2.1.5. Plasmids 
 
Table 5. Plasmids used in this study. 
Internal 
database 
ID 
Short name Description Bacterial marker 
Yeast 
marker Reference 
Z1257 Get3 pQE80-10xHis-2xZZ-TEV-Get3 Amp - (Metz et al. 2006) 
 His-MBP-TRC40 pQE80-10xHis-MBP-TRC40 Amp - Vilardi, F. 
AI1730 3GRE-LacZ pUCΔSS-26X-3GRE-LacZ Amp URA3 (Schena and 
Yamamoto 1988) 
AI1729 ratGR pDS-063-ratGR Amp LEU2 (Schena and 
Yamamoto 1988; 
Picard et al. 1990) 
X1153 p413 p413RS Amp HIS3 (Sikorski and Hieter 
1989) 
AM1926 p413_Get3 pRS413Met25_Get3 Amp HIS3  
AM1927 p413_Get3_D57E pRS413Met25_Get3_D57E Amp HIS3  
AM1928 p413_Get3_CCCC240,242,285,2
88TTTT 
pRS413Met25_Get3_CCCC240,242
,285,288TTTT 
Amp HIS3  
AM1929 p413_Get3_C317T pRS413Met25_Get3_ C317T Amp HIS3  
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AM1930 p413_Get3_ CCC36,85,317TTT pRS413Met25_Get3_ 
CCC36,85,317TTT 
Amp HIS3  
AM1931 p413_Get3_ 
CCCCC36,85,285,288,317TTTTT 
pRS413Met25_Get3_ 
CCCCC36,85,285,288,317TTTTT 
Amp HIS3  
AM1932 p413_Get3_ 
CCCC36,85,240,242TTTT 
pRS413Met25_Get3_ 
CCCC36,85,240,242TTTT 
Amp HIS3  
AM1933 p413_Get3_ 
CCCCC36,85,240,242,317TTTTT 
pRS413Met25_Get3_ 
CCCCC36,85,240,242,317TTTTT 
Amp HIS3  
AM1934 p413_Get3_I193D pRS413Met25_Get3_ I193D Amp HIS3  
AP2064 mVenus pVenus-C1 Kan -  
AP2065 mVenus-TRC40 pVenus-TRC40 Kan - Vilardi, F. 
AP2089 mVenus-ratGR pVenus-ratGR Kan -  
AJ1798 MBP-TEV-TRC40/ZZ-EMD-op pQE80_MBP-TEV-TRC40_10xHis-
ZZ-EMD-opsin 
Amp - (Favaloro et al. 
2010; Pfaff et al. 
2016) 
AO2049 pcDNA3.1(-) pcDNA3.1(-) Amp - Invitrogen 
AO2050 pcDNA3.1_cmyc-TRC40 pcDNA3.1(-)_cmyc-siTRC40ins wt Amp -  
AP2052 pcDNA3.1_cmyc-TRC40_G46R pcDNA3.1(-)_cmyc-
siTRC40ins_G46R 
Amp -  
AP2054 pcDNA3.1_cmyc-TRC40_D74E pcDNA3.1(-)_cmyc-
siTRC40ins_D74E 
Amp -  
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AP2056 pcDNA3.1_cmyc-TRC40_I193D pcDNA3.1(-)_cmyc-
siTRC40ins_I193D 
Amp -  
AP2058 pcDNA3.1_cmyc-
TRC40_CC246,248SS 
pcDNA3.1(-)_cmyc-
siTRC40ins_CC246,248SS 
Amp -  
AP2051 pcDNA3.1_cmyc-TRC40_F15A pcDNA3.1(-)_cmyc-siTRC40ins_ 
F15A 
Amp -  
AP2057 pcDNA3.1_cmyc-TRC40_Y256F pcDNA3.1(-)_cmyc-siTRC40ins_ 
Y256F 
Amp -  
AP2061 pcDNA3.1_cmyc-TRC40_L303V pcDNA3.1(-)_cmyc-siTRC40ins_ 
L303V 
Amp -  
AP2060 pcDNA3.1_cmyc-
TRC40_CCCC246,248,289,292S
SSS 
pcDNA3.1(-)_cmyc-siTRC40ins_ 
CCCC246,248,289,292SSSS 
Amp -  
AP2062 pcDNA3.1_cmyc-TRC40_Y310C pcDNA3.1(-)_cmyc-siTRC40ins_ 
Y310C 
Amp -  
AQ2106 pcDNA3.1_cmyc-TRC40_E259R pcDNA3.1(-)_cmyc-siTRC40ins_ 
E259R 
Amp -  
AP2063 pcDNA3.1_cmyc-TRC40_P344S pcDNA3.1(-)_cmyc-siTRC40ins_ 
P344S 
Amp -  
AQ2108 pcDNA3.1_cmyc-TRC40_P75R pcDNA3.1(-)_cmyc-siTRC40ins_ 
P75R 
Amp -  
AQ2110 pcDNA3.1_cmyc-TRC40_R189W pcDNA3.1(-)_cmyc-siTRC40ins_ 
R189W 
Amp -  
AQ2107 pcDNA3.1_cmyc-
TRC40_E307R/D308R 
pcDNA3.1(-)_cmyc-siTRC40ins_ 
E307R/D308R 
Amp -  
AP2053 pcDNA3.1_cmyc-
TRC40_CC53,55SS 
pcDNA3.1(-)_cmyc-siTRC40ins_ 
CC53,55SS 
Amp -  
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AS2236 pcDNA3.1_cmyc-
TRC40_D74E/I193D 
pcDNA3.1(-)_cmyc-siTRC40ins_ 
D74E/I193D 
Amp -  
AS2239 pcDNA3.1_cmyc-TRC40_ 
D74E/L190D/I193D 
pcDNA3.1(-)_cmyc-siTRC40ins_ 
D74E/L190D/I193D 
Amp -  
AL1886 pOG44 pOG44 Amp - Invitrogen Catalog#: 
V600520 
 pcDNA5_Stx5-opsin pcDNA5/FRT/TO_Stx5-opsin Amp - Rivera-Monroy, J. 
AG1603 p413_mCherry-Sbh2 pRS413Met25_mCherry-Sbh2 Amp HIS3 Vilardi, F. 
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2.1.6. Primers 
 
The DNA oligos were ordered from Sigma with desalted purification and in dry 
format. The oligos were HPLC-purified in case they were bigger than 50 bp. 
 
Table 6. DNA oligos used in this study. 
Internal 
database ID 
Name Sequence (5’-3’) 
JavPR98 XhoI-ratGR-For ATACTACTCGAGGAATGGACTCCAAA
GAATCCTTAGC 
JavPR99 ratGR-BamHI-Rev ATACTAGGATCCTCATTTTTGATGAAA
CAGAAGCTTTTTG 
JhonPR59 EcoRI-TRC40-For ATACTAGAATTCATGGCGGCAGGGGT
GGCCGG 
JhonPR60 TRC40-BamHI-Rev ATACTAGGATCCCTACTGGGCACTGG
GGGGCT 
JhonPR61 siTRC40ins-For TCCCCCTTTATTTCCCAAATGTGCAAC
ATGCTGGGCCTGG 
JhonPR62 siTRC40ins-Rev TTGGGAAATAAAGGGGGAGATCTGGT
TCTTGATCTGCAT 
JhonPR63 XhoI-cMyc-TRC40-For ATACTACTCGAGATGGAGCAGAAACT
CATCTCTGAAGAGGATCTGATGGCGG
CAGGGGTGGCC 
JavPR70 TRC40_D74E-For GTGTTCTGATCATCTCCACAGAGCCA
GCACACAACATCTCAG 
JavPR71 TRC40_D74E-Rev CTGAGATGTTGTGTGCTGGCTCTGTG
GAGATGATCAGAACAC 
JavPR72 TRC40_G46R-For GGATCTTCGTCGGGGGCAAGCGGGG
TGTGGGCAAGACCACC 
JavPR73 TRC40_G46R-Rev GGTGGTCTTGCCCACACCCCGCTTGC
CCCCGACGAAGATCC 
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JavPR74 siTRC40ins_I193D-For CCTGGGCCGGCTTATGCAGGACAAGA
ACCAGATCTCC 
JavPR75 siTRC40ins_I193D-
Rev 
GGAGATCTGGTTCTTGTCCTGCATAA
GCCGGCCCAGG 
JavPR86 TRC40_CC246,248SS
-For 
GCAGACAACTTTCATCAGCGTAAGCA
TTGCTGAGTTCCTGTCC 
JavPR87 TRC40_CC246,248SS
-Rev 
GGACAGGAACTCAGCAATGCTTACGC
TGATGAAAGTTGTCTGC 
JavPR138 TRC40_L190D/I193D-
For 
GGAGCGGGGCCTGGGCCGGGACATG
CAGGACAAGAACCAG 
JavPR139 TRC40_L190D/I193D-
Rev 
CTGGTTCTTGTCCTGCATGTCCCGGC
CCAGGCCCCGCTCC 
JavPR76 TRC40_F15A-For 
 
GGTTGAGGCAGAGGAGGCCGAAGAT
GCTCCTGATGTGG 
JavPR77 TRC40_F15A-Rev CCACATCAGGAGCATCTTCGGCCTCC
TCTGCCTCAACC 
JavPR78 TRC40_P75R-For GTTCTGATCATCTCCACAGACCGAGC
ACACAACATCTCAGATGC 
JavPR79 TRC40_P75R-Rev GCATCTGAGATGTTGTGTGCTCGGTC
TGTGGAGATGATCAGAAC 
JavPR80 TRC40_Y256F-For GCATTGCTGAGTTCCTGTCCCTGTTT
GAGACAGAGAGGCTGATCC 
JavPR81 TRC40_Y256F-Rev GGATCAGCCTCTCTGTCTCAAACAGG
GACAGGAACTCAGCAATGC 
JavPR82 TRC40_Y310C-For 
 
GGACCAGATGGAGGACCTGTGTGAA
GACTTCCACATCG 
JavPR83 TRC40_Y310C-Rev CGATGTGGAAGTCTTCACACAGGTCC
TCCATCTGGTCC 
JavPR84 TRC40_P344S-For CCTCCTGGAGCCCTACAAGTCCCCCA
GTGCCCAGTAGG 
JavPR85 TRC40_P344S-Rev CCTACTGGGCACTGGGGGACTTGTAG
GGCTCCAGGAGG 
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JavPR88 TRC40_CC289,292SS
-For 
CGACCCCGAGAAGCCCAGCAAGATGT
CTGAGGCCCGTCAC 
JavPR89 TRC40_ 
CC289,292SS -Rev 
GTGACGGGCCTCAGACATCTTGCTGG
GCTTCTCGGGGTCG 
JavPR96 TRC40_L303V-For 
 
CAAGATCCAGGCCAAGTATGTGGACC
AGATGGAGGACCTG 
JavPR97 TRC40_L303V-Rev CAGGTCCTCCATCTGGTCCACATACT
TGGCCTGGATCTTG 
JavPR103 TRC40_CC53,55SS-
For 
GGCAAGACCACCAGCAGCAGCAGCC
TGGCAGTCCAGCTCTC 
JavPR104 TRC40_ CC53,55SS -
Rev 
GAGAGCTGGACTGCCAGGCTGCTGC
TGCTGGTGGTCTTGCC 
JavPR109 TRC40_R189W-For CGTGGAGCGGGGCCTGGGCTGGCTT
ATGCAGATCAAGAACC 
JavPR110 TRC40_R189W-Rev GGTTCTTGATCTGCATAAGCCAGCCC
AGGCCCCGCTCCACG 
JavPR134 TRC40_E259R-For 
 
CCTGTCCCTGTATGAGACAAGGAGGC
TGATCCAGGAGCTGG 
JavPR135 TRC40_E259R-Rev CCAGCTCCTGGATCAGCCTCCTTGTC
TCATACAGGGACAGG 
JavPR136 TRC40_E307R/D308R
-For 
CCAAGTATCTGGACCAGATGAGGAGG
CTGTATGAAGACTTCCACATCG 
JavPR137 TRC40_ 
E307R/D308R -Rev 
CGATGTGGAAGTCTTCATACAGCCTC
CTCATCTGGTCCAGATACTTGG 
2.Material and Methods 
 
 
41 
 
2.1.7. Small interfering RNA 
 
Table 7. Small interfering RNA (siRNA) used in this study. 
Internal 
database 
ID 
Target Sense (5'-3') Antisense (5'-3') Overhang Provider Source 
si2 BAG6 #1 UUUCUCCAAGAGCAG
UUUA 
UAAACUGCUCUUGGAG
AAA 
[dT][dT] Sigma (Minami et al. 2010) 
si3 BAG6 #2 AUGAUGCACAUGAACA
UUC 
GAAUGUUCAUGUGCAU
CAU 
[dT][dT] Sigma (Minami et al. 2010) 
si4 Luciferase CGUACGCGGAAUACU
UCGA 
UCGAAGUAUUCCGCGU
ACG 
[dT][dT] Sigma Dharmacon. Catalog#: 
D-001100-01 
si5 TRC40 GCCCUUUCAUCUCACA
GAU 
AUCUGUGAGAUGAAAG
GGC 
[dT][dT] Sigma Ambion. Catalog’: 
s1675. (Pfaff et al. 
2016; Rivera-Monroy et 
al. 2016) 
si7 WRB AAAUCCAACAGGUAAU
UCCAACACC 
GGUGUUGGAAUUACCU
GUUGGAUUU 
[dT][dT] Sigma (Y. Yamamoto and 
Sakisaka 2012; Rivera-
Monroy et al. 2016) 
si15 NT    Ambion. 
Catalog#: 
AM4635 
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2.1.8. Antibodies 
 
2.1.8.1. Primary antibodies 
 
The antibodies used for different techniques such as Western-blot (WB), indirect immunofluorescence (IF) or immunoprecipitation 
(IP) are listed in the following tables (Tables 8-10). They contain the information about the commercial antibodies and the working 
dilution used in this study. 
 
 
Table 8. Primary antibodies used in this study. 
Unique ID Name Raised in Company Catalog no. Lot # Dilution (WB) 
Dilution 
(IF) 
Ab0021 β-Actin mouse Santa Cruz sc-47778 A2315 1:10000  
Ab0076 BAG6 mouse Abnova H00007917-B01P FC071 1:2000  
Ab0072 BAG6 #5 AP rabbit Custom made    1:300 
Ab0073 BAG6 #5 Ser rabbit Custom made   1:2000  
Ab0071 BAG6 #7 rabbit Custom made   1:2000  
Ab0074 BAG6 CT rabbit Custom made   1:2000 1:300 
Ab0436 Calnexin mouse BD Transduction Laboratories 610524   1:200 
Ab0069 CAML guinea pig Synaptic Systems 359004 359004/1 1:1000  
Ab0144 EEA1 mouse BD Transduction Laboratories 610456 03689  1:200 
Ab0133 Emerin rabbit Santa Cruz sc-15378 H1115 1:1000 1:150 
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Ab0442 FDFT1 mouse Santa Cruz sc-271602  1:1000  
Ab0159 GAPDH mouse NeoBiotech NB-29-00852 16/06-G4-C5 1:40000  
Ab0163 Get3 #1 guinea pig Custom made   1:2000  
Ab0172 GFP rabbit Torrey Pines biolabs TP401 081211 1:5000  
Ab0188 GM130 mouse BD Transduction Laboratories 610823 24277 1:1000 1:300 
Ab0660 GOSR2 rabbit Synaptic Systems 170003 170003/4 1:1000 1:200 
Ab0192 GR rabbit Santa Cruz sc-8992 G1614 1:1000 1:250 
Ab0193 GR mouse Santa Cruz sc-393232 C1115 1:1000  
Ab0679 HIF-1α mouse BD Transduction Laboratories 610959  1:1000  
Ab0203 Hsc70 mouse StressMarq Biosciences SMC-151 0904  1:200 
Ab0204 Hsc70 rat Enzo Life Sciences ADI-SPA-815-F 12051444 1:1000  
Ab0205 Hsp40 rabbit abcam ab69402 6R195077-8 1:1000  
Ab0206 Hsp90α/β mouse Santa Cruz sc-13119 B2316 1:1000 1:200 
Ab0214 JNK1 mouse Cell Signaling 3708 1 1:1000  
Ab0280 P-JNK (Thr183/Tyr185) rabbit Cell Signaling 4668 12 1:1000  
Ab0642 Lamin-A/C mouse abcam ab40567   1:200 
Ab0236 myc mouse Santa Cruz sc-40 B0116 1:1000 1:200 
Ab0615 myc chicken abcam ab172 GR221409-9  1:150 
Ab0239 Na+/K+-ATPase α1 mouse Santa Cruz sc-21712 B1516 1:1000  
Ab0555 Opsin mouse From Bernhard Dobberstein   1:1000  
Ab0270 PGK1 mouse Thermo Fisher Scientific 459250 459250/K8914 1:3000  
Ab0630 PTP1B rabbit Sigma-Aldrich HPA012542  1:1000 1:100 
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Ab0657 Sec22b rabbit Synaptic Systems 186003 186003/1-8 1:1000 1:200 
Ab0346 Sec61β rabbit From Bernhard Dobberstein   1:1000 1:300 
Ab0350 SGTA #5143 chicken From Steve High   1:2000  
Ab0353 Syntaxin 1 mouse Synaptic Systems 110011 110011/13 1:1000  
Ab0354 Syntaxin 5 rabbit Synaptic Systems 110053 110053/16 1:2000 1:250 
Ab0355 Syntaxin 6 rabbit Synaptic Systems 110062 110062/9 1:1000 1:300 
Ab0358 Syntaxin 8 rabbit Synaptic Systems 110083 110083/1-11 1:1000 1:300 
Ab0452 Syntaxin 18 rabbit Synaptic Systems 110183   1:1000 
Ab0400 TRC40 mouse Sigma-Aldrich WH0000439M3 D3011-2H3 1:1000 1:100 
Ab0401 TRC40 rabbit Proteintech 15450-1-AP 00021130 1:1000  
Ab0405 TRC40 #4 rabbit From Bernhard Dobberstein   1:1000  
Ab0676 UBE2J1 mouse Santa Cruz sc-377002 H2917 1:1000  
Ab0391 Ubiquitin mouse Enzo Life Sciences BML-PW8810 5021240 1:1000  
Ab0668 USE1 rabbit Proteintech 25218-1-AP 00022214 1:1000  
Ab0650 VAPA rabbit Proteintech 15275-1-AP  1:1000  
Ab0629 VAPB rabbit Proteintech 14477-1-AP  1:1000 1:200 
Ab0407 Vti1a mouse BD Transduction Laboratories 611220 0000073424-K 1:1000  
Ab0408 Vti1b mouse BD Transduction Laboratories 611404 0000073424-L 1:1000  
Ab0659 Vti1b rabbit Synaptic Systems 164002 164002/7  1:200 
Ab0417 WRB serum 7676 rabbit Synaptic Systems 324002 324002/1-2 1:1000  
Ab0210 IgG (normal mouse) mouse Santa Cruz sc-2025 E3117   
Ab0655 IgG (normal rabbit) rabbit Cell Signaling 2729 8   
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The opsin monoclonal antibody (R2-15) comes from the laboratory of Bernhard Dobberstein from the University of Heidelberg 
and it was a kind gift from Paul A. Hargrave from the University of Florida that was described long time ago (Adamus et al. 1991). 
 
The mouse anti-GR, rabbit anti-TRC40 #4 and rabbit anti-Stx5 were also used for immunoprecipitation. 5µg of these antibodies 
were used for each IP. As a control 5µg of IgG (normal mouse) or IgG (normal rabbit) were used respectively.  
 
 
2.1.8.2. Secondary antibodies 
 
 
Table 9. WB secondary antibodies used in this study. 
Short Name Raised in Against Conjugated to Company Catalog no. Lot # Dilution 
α-mouse HRP   mouse IgGκ HRP Santa Cruz sc-516102 F2017 1:10000 
α-rabbit 800 donkey rabbit IRDye 800CW LI-COR 926-32213   1:5000 
α-rabbit 680 donkey rabbit IRDye 680LT LI-COR 926-68023   1:5000 
α-mouse 800 donkey mouse IRDye 800CW LI-COR 926-32212   1:5000 
α-mouse 680 goat mouse IgG1 IRDye 680LT LI-COR 926-68050   1:5000 
α-guinea pig 680 donkey guinea pig IRDye 680LT LI-COR 926-32421   1:5000 
α-rat 800 donkey rat IRDye 800CW LI-COR 926-32219   1:5000 
α-chicken 800 donkey chicken IRDye 800CW LI-COR 926-32218   1:5000 
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Table 10. IF secondary antibodies used in this study. 
Short Name Raised in Against Conjugated to Company Catalog no. Lot # Dilution 
α-rabbit 488 goat rabbit Alexa Fluor 488 Invitrogen A11034 1616933 1:1000 
α-rabbit 488 goat rabbit Alexa Fluor Plus 488 Invitrogen A32731 SE250296 1:1000 
α-mouse 546 goat mouse Alexa Fluor 546 Invitrogen A11030 1829584 1:1000 
α-mouse 647 goat mouse Alexa Fluor 647 Invitrogen A21235 1511346 1:1000 
α-mouse 647 goat mouse Alexa Fluor Plus 647 Invitrogen A32728 SE250294 1:1000 
α-chicken 647 goat chicken Alexa Fluor 647 Invitrogen A21449 1806124 1:1000 
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2.1.9. Media and buffers 
 
       Table 11. List of media and buffer used in this study and their composition. 
Name Composition 
ATP buffer 4 mM ATP 
ATPase activity assay buffer 100 mM HEPES 
10 mM MgCl2 
20% Glycerol 
5 U/µL Pyruvate kinase in 3,2M NH4(SO4)2 pH 6 
75 U/µL Lactate dehydrogenase in 3,2M 
NH4(SO4)2 pH 7 
100 mM ATP 
100 mM Phosphoenol pyruvate 
50 mM NADH 
Ampicillin stock solution 
(1000x) 
100 mg/mL 
Coomassie destaining 
solution 
20% (v/v) Ethanol 
10% (v/v) Acetic acid 
Coomassie staining solution 45% (v/v) Ethanol 
10% (v/v) Acetic acid 
0,1% (w/v) Coomassie brilliant blue G250 
DMEM++ medium 500 mL Dulbecco’s Modified Eagle Medium 
10% (v/v) Fetal bovine serum 
2 mM L-Glutamine 
DNA loading buffer (6x) 30% (v/v) Ficoll 400 
0,04% Orange G 
Elution buffer (maltose) 50 mM HEPES-HCl pH 7 
150 mM KOAc 
10 mM MgAc 
20 mM Maltose 
Elution buffer (imidazole) 50 mM HEPES-HCl pH 7 
150 mM KOAc 
10 mM MgAc 
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20 mM Imidazole 
Extraction buffer 50 mM HEPES-HCl pH 7 
150 mM KOAc 
10 mM MgAc 
High-salt buffer 500 mM KOAc 
Homogenization buffer 320 mM Sucrose 
20 mM HEPES pH 7,4 
2 mM EDTA 
50 mM NaCl 
1x Protease inhibitors (cOmplete, Roche) 
Kanamycin stock solution 
(1000x) 
50 mg/mL 
Kpi buffer 40 mM KH2PO4 pH 7,5  
LB medium 10 g/L Tryptone 
5 g/L Yeast extract 
5 g/L NaCl 
Adjust to pH 7 
Lithium acetate stock (10x) 1 M Lithium acetate dihydrate 
Lysis stock buffer 50 mM HEPES-NaOH pH 7,5 
150 mM NaCl 
1,5 mM MgCl2 
1 mM Na-EGTA 
1x Protease inhibitors (cOmplete, Roche) 
Lysis buffer for hypoxia 400 mM NaCl 
10 mM Tris-HCl pH 8 
1 mM EDTA 
1% (v/v) Triton X-100 
1x Protease inhibitors (cOmplete, Roche) 
PBS 137 mM NaCl 
2,7 mM KCl 
8 mM Na2HPO4 
1,5 mM KH2PO4 
PEG stock solution 50% (v/v) Polyethylene glycol  
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4% PFA in PBS pH 7,4 4% (w/v) Paraformaldehyde in PBS pH 7,4 
SDS loading buffer 250 mM Tris-HCl pH 6,8 
50% (v/v) Glycerol 
10% (v/v) SDS 
0,5% (w/v) Bromophenol blue 
SDS running buffer 25 mM Tris-HCl pH 8,3 
250 mM Glycine 
0,1% (v/v) SDS 
SOC medium 20 g/L Trypton 
5 g/L Yeast extract 
10 mM NaCl 
2,5 mM KCl 
10 mM MgCl2 
20 mM Glucose 
Adjust pH to 7,4 
Solubilization buffer 
based on (Kline et al. 2009) 
1,5% (v/v) Triton X-100 
0,1% (v/v) SDS 
50 mM Tris pH 7,4 
10 mM NaCl 
5 mM EDTA 
2,5 mM Na-EGTA 
0,75% (w/v) Sodium deoxycholate 
1x Protease inhibitors (cOmplete, Roche) 
T4 ligase buffer (10x) 50 mM Tris-HCl pH 7,4 
10 mM MgCl2 
1 mM DTT 
1 mM ATP 
50 g/L Polyethylene glycol 
TAE buffer 40 mM Tris-acetate 
20 mM Glacial acetic acid 
1 mM EDTA 
Adjust pH to 8 
TE buffer stock (10x) 100 mM Tris-HCl pH=7,5 
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10 mM EDTA pH=8 
Tetracycline stock solution 
(1000x) 
10 mg/mL 
TEV cleavage buffer 50 mM HEPES-HCl pH=7 
150 mM KOAc 
10 mM MgAc 
0,5 mM DTT 
0,5 mM EDTA 
Transfer buffer 192 mM Glycine 
250 mM Tris pH=8,3 
Transport buffer 20 mM HEPES 
110 mM KOAc 
2 mM Mg(OAc)2 
1 mM EGTA, pH 7,3 
2 mM DTT 
0,1 mM PMSF 
1 µg/mL Leupeptin 
1 µg/mL Pepstatin 
1 µg/mL Aprotinin 
Yeast synthetic complete 
(SC) medium/selective 
medium 
6,7 g Yeast nitrogen base 
X g Dropout mix (according to manufacturer’s 
instructions) 
20 g/L Glucose 
According to what is needed: 
40 mg/L Adenine 
20 mg/L L-Histidine 
100 mg/L L-Leucine 
20 mg/L Uracil 
20 mg/L L-Methionine 
50 mg/L L-Tryptophan 
Yeast agar 15 g/L Bactoagar for yeast 
Yeast agar plates 50% (v/v) Yeast agar 
50% (v/v) Yeast medium 
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2.1.10. Kits and other reagents 
Table 12. Kits and other reagents used in this study. 
Name Company Catalog No. Lot No. 
Agar Invitrogen 30391-023  
Amylose agarose New England 
Biolabs 
E8021L 0161403 
ATP Roth K054.4 101.288 
b-AP15 Millipore 662140 2881385 
Coomassie Plus Protein 
Assay Reagent 
Thermo-Fisher 
Scientific 
1856210 SA245727 
cOmplete EDTA-free 
inhibitor cocktail 
Roche 04693132001 
 
 
CSM dropout mix (-Ade, 
-His, -Leu, -Met, -Trp, -
Ura) 
MP Biomedicals 4560-222 47264 
CSM dropout mix (-Ade, 
-His, -Leu, -Trp) 
Formedium DCS1229 FM1A215/006441 
Deoxycorticosterone or 
21-
Hydroxyprogesterone 
(DOC) 
Sigma D6875 SLBG9391V 
Dexamethasone (DEX) Sigma D4902  
4′,6-Diamidino-2-
phenylindole 
dihydrochloride (DAPI) 
Sigma D9542 096M4014V 
Digitonin Fluka 37008 7D011626 
5-5’-Dithiobis(2-
nitrobenzoic acid) 
(DTNB) 
Sigma D8130 SHBF2531V 
DMEM (Dulbecco's 
Modified Eagle Medium) 
Gibco 41966-029  
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DMSO Thermo-Fisher 
Scientific 
F515  
Expand High Fidelity 
PCR System 
Roche 11759167001  
Fast alkaline 
phosphatase 
Thermo-Fisher 
Scientific 
EF0654  
FBS Superior Biochrom S0615  
Fluorescein di-β-D-
galactopyranoside 
(FDG) 
Life Technologies F1179 1445261 
GFP-trap M ChromoTek GmbH gtm-20  
L-Glutamine Gibco 25030-024  
Guanidine hydrochloride 
(GdnCl) 
PanReac 
AppliChem 
144229.1211 6L010646 
High Pure PCR Product 
Purification Kit 
Roche 11732676001  
Immobilon Western 
Chemiluminescent HRP 
Substrate 
Millipore WBKLS0500 16066902 
Nitrocellulose 
Amersham Protran 
Premium 0,45  
GE Healthcare 10600003 A10074169 
Lactate dehydrogenase 
(LDH) from rabbit 
muscle 
Roche 10127230001 14908627 
Laminin 1mg mouse Corning 354232  
Lipofectamine 2000 
transfection reagent 
Thermo-Fisher 
Scientific 
11668-019  
Lipofectamine 
RNAiMAX transfection 
reagent 
Thermo-Fisher 
Scientific 
13778-150  
Methanol Roth 4627.5  
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β-Nicotinamide adenine 
dinucleotide, reduced 
disodium salt hydrate 
(NADH) 
Sigma N8129 SLBJ2605V 
Ni-NTA agarose Qiagen 30230 127147847 
dNTP Set Thermo-Fisher 
Scientific 
R0181  
NucleoBond Xtra Midi Macherey-Nagel 740410 
 
 
NucleoSpin Plasmid 
EasyPure 
Macherey-Nagel 740727 
 
 
Opti-MEM Reduced 
serum medium 
Gibco 31985-070  
PageRuler Prestained 
Protein Ladder 
Thermo-Fisher 
Scientific 
26616  
Paraformaldehyde 
BioChemica 
PanReac 
AppliChem 
A3813,0250  
Phosphoenol pyruvate 
(PEP) 
Sigma P7002 088K3783 
Phos-STOP Roche 04906837001  
Phusion polymerase Homemade   
PMSF BioChemica PanReac 
AppliChem 
A0999  
PNGase F New England 
Biolabs 
P0704  
Protein A Sepharose 4 
Fast flow 
GE Healthcare 17-5280-01 10241063 
Protein G Sepharose 4 
Fast flow 
GE Healthcare 17-0618-01 10244349 
Pyruvate kinase (PK) Sigma P1506-5KU SLBH1134 
SafeView NBS-Biologicals NBS-SV1  
T4 DNA ligase Thermo-Fisher 
Scientific 
EL0011 00546681 
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0,25% Trypsin-EDTA Gibco 25200-056  
Tween-20 Millipore 822184  
Yeast nitrogen base w/o 
amino acids 
Melford Y2004  
 
 
2.2. Methods 
 
2.2.1. Plasmid construction 
For pRS413met25_Get3 and the different mutants they were obtained by digesting 
previous p416met25 vectors containing these mutants with XbaI and XhoI and ligating 
them into pRS413me25.  
 
For mVenus-C1-ratGR it was obtained after subcloning it from pDS-063-ratGR. ratGR 
was amplified by PCR with primers JavPR98 and JavPR99. These amplified DNA 
fragments were digested with XhoI and BamHI, along with an empty vector mVenus-
C1, and ligated them later. 
 
For pcDNA3.1(-)_cmyc-siTRC40ins it was obtained after subcloning it from MBP-TEV-
TRC40/ZZ-EMD-op into a pcDNA3.1(-) using overlap extension PCR. Primers for 
mutagenesis of the TRC40 for making it insensitive to the siRNA were included. On 
the one hand, one PCR using a forward primer containing an N-terminal cmyc-tag for 
TRC40 and a restriction site for XhoI (JhonPR63) and the reverse primer (JhonPR62) 
was containing the sequence to be mutagenized. On the other hand, a second PCR 
using a forward primer (JhonPR61) overlapping the sequence on JhonPR62 and a 
reverse primer targeting the C-terminus of TRC40 and containing a restriction site for 
BamHI (JhonPR60). A third PCR using as template 2 µL of the PCR products coming 
from the two previous PCRs was performed. The primers used for this PCR were 
JhonPR63 and JhonPR60. The DNA fragments obtained and an empty pcDNA3.1(-) 
vector were digested with XhoI and BamHI first, incubated the backbone for 10 min at 
37°C with 1 U of fast alkaline phosphatase and later ligated. 
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For the pcDNA3.1(-)_cmyc-siTRC40ins mutants they were obtained by using site-
directed mutagenesis with two primers, forward and reverse, with overlapping 
sequences containing the mutation in the middle of the primer. The primers used can 
be found in Table 6. The PCR products were later digested with DpnI. 
 
All sequences were submitted for Sanger sequencing (GATC Biotech, Konstanz, 
Germany) and the obtained sequences were carefully aligned and checked with the 
expected one. 
 
2.2.2. Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) (Saiki et al. 1985) was employed for the amplification 
of DNA fragments. 50 ng of DNA template were mixed with 16 µM of a mixture of 
deoxynucleotides (dNTPs) (Thermo-Fisher Scientific), 250 nM of the correspondent 
oligonucleotide primers, 5% DMSO, 2 U of a thermo-stable proofreading DNA 
polymerase (homemade Phusion polymerase) and 1-fold expand high-fidelity buffer 
(Roche, Basel, Switzerland). The reaction mixture was then subjected to multiple 
cycles in a thermocycler as it follows: 
 
 
 
*Adjust the annealing temperature according to the lowest melting temperature of the 
oligonucleotide primers. 
 
Initial denaturation step 95°C 2 min
DNA-melting step 95°C 1 min
10x Annealing step 50°C* 45 sec
Extension step 72°C X min = (1 min per Kb of DNA) + 30 sec 
DNA-melting step 95°C 1 min
20x Annealing step 52°C* 45 sec
Extension step 72°C X min = (1 min per Kb of DNA) + 30 sec 
Final extension step 72°C 1,5X min
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Primers were designed with a length of 18-30 annealing bp for regular PCR and 44-60 
bp for site-directed mutagenesis. All primers used can be found in Table 6. 
 
PCR products were loaded and run in agarose gels. Next, the correspondent bands 
were excised from the gel and purified using a DNA purification kit (High Pure PCR 
Product Purification; Roche) according to manufacturer’s instructions. 
 
2.2.3. Site-directed mutagenesis 
PCR was performed for site-directed mutagenesis. The PCR mix was as described 
before. The reaction mixture was then subjected to multiple cycles in a thermocycler 
as it follows: 
 
 
 
PCR products were loaded and run in agarose gels. Next, the correspondent bands 
were cut off from the gel and purified using a DNA purification kit (Roche) according to 
manufacturer’s instructions. The PCR products were then subjected to DpnI 
(Fermentas, Waltham, USA) digestion with 1 U of DpnI for 4 h at 37°C. Later, the 
digested PCR products were transformed into electro-competent ElectroTen blue cells.  
 
2.2.4. Agarose gel electrophoresis 
Agarose gels were used for the separation of the DNA fragments based on their size 
for later excision and purification. The DNA samples were mixed with 6x DNA loading 
buffer and loaded into the correspondent agarose gel. SafeView (NBS-Biological, 
Huntingdon, UK) was used as a nucleic acid stain for casting the agarose gels. The 
gels were subjected to electrophoresis at 180 V (constant V). A DNA ladder 
(Fermentas) was also loaded and run with the DNA samples. The gel was analyzed 
Initial denaturation step 95°C 2 min
DNA-melting step 95°C 30 sec
18x Annealing step 52°C 1 min
Extension step 72°C X min = (1 min per Kb of DNA) + 30 sec 
Final extension step 72°C 1,5X min
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under ultra violet (UV) light at 365 nm and the correspondent bands containing the 
DNA fragments were excised from the gel for later DNA purification. 
 
2.2.5. DNA ligation 
Linearized vector and DNA fragments suitable for insertion were mixed with 1 U of T4 
DNA-ligase (Thermo-Fisher Scientific) and 1-fold of T4 DNA-ligase buffer. They were 
incubated for 2 h or O/N at 18°C. Then, T4 DNA-ligase was heat-inactivated at 70°C 
for 10 min. 
 
2.2.6. DNA-transformation in bacterial-cells by 
electroporation 
2 µL of the heat-inactivated ligation products or 1,5 µL of the DpnI digested product 
were transformed into electro-competent ElectroTen blue cells. They were mixed with 
50 µL of bacterial cells and later transferred into pre-cooled electroporation-cuvettes. 
The electroporation unit (Gene Pulse; BioRad, Hercules, USA) was set to 25 µF and 
2,5 kV. The pulse controller was set to 400 W. They were resuspended in 1 mL of SOC 
medium and incubated for 30 min at 37°C with medium shaking. Cells were spinned-
down and resuspended in 50 µL that were plated in to LB plates with the correspondent 
selective antibiotic. 
 
2.2.7. Yeast culture 
Yeast strains used for this study are listed above (Table 3). Yeast cultures were grown 
O/N in yeast SC or selective media at 30°C incubator at 150 rpm shaking. For having 
the yeast culture in mid-log phase, yeast cultures were spinned-down and washed with 
sterile water and diluted 1:10 and incubate it at 30°C in a new tube for 4 h. 
 
2.2.8. Yeast transformations 
Yeast plasmids used for this study are listed above (Table 5). For yeast 
transformations a modified version of the lithium acetate-PEG method was used (Ito 
et al. 1983). Yeast were grown O/N in SC or selective media as described before. Cells 
were pelleted and washed twice with sterile water. Then cells were resuspended in 1,4 
mL of a solution of lithium acetate/PEG in TE buffer. Next 0,5 µg of the plasmid along 
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with 18 µg of carrier DNA were added. The mixture was vortexed intensely until full 
homogenization and incubated for 1 h at 37°C and later 20 min at 42°C. Cells were 
centrifuged at 10.000 rpm for 5 min and the supernatant was discarded. Cells were 
resuspended in water and plated in SC selective agar plates. The selectivity was given 
by the absence of the amino acid for the selection of the transformed cells. The plates 
were grown for 48 h in the yeast incubator at 30°C until colonies were grown enough. 
 
2.2.9. Yeast  b-galactosidase assay 
Yeast strains were grown in the correspondent selective media O/N at 30°C and 150 
rpm shaking. The OD600 of the cultures were measured and cultures were diluted to 
OD600=0,2 and grown for four more hours at 30°C for reaching mid-log phase. Cell 
were pelleted and washed with water and resuspended them in selective media. Each 
strain was split into two tubes: to one of the tubes I added deoxycorticosterone (DOC) 
to a final concentration of 100 nM and to the second one I added the same volume of 
absolute ethanol (DOC solvent). Incubate them for 2 h at 30°C shaking at 150 rpm. I 
prepared a FDG solution in situ containing: 500 µM of FDG, 0,25% Triton X-100 in 125 
mM PIPES. In a 96-well plate, I added 100 µL of each strain the cell cultures by 
triplicate followed by 20 µL of the FDG solution per well. The plates were shaken gently 
and briefly the plates. I covered them in aluminum foil and incubated them at 37°C for 
90 min. Once the incubation was over, I added 20 µL of 1 M Na2CO3 per well to stop 
the enzymatic reaction. The plates were shaken gently and briefly the plates. The 
plates were read with a plate reader (Synergy HT; BioTek, Winooski, USA) using an 
excitation wavelength of 485 nm and an emission wavelength of 530 nm. Read it by 
triplicate. Besides, read the absorbance, OD600, for normalize the fluorescence 
readings to the cell density. Read it by duplicate. For the analysis of the experiment 
the following step for calculations were made: first, the fluorescence readings were 
averaged and divided by the averaged OD600 for normalizing them to the cell density. 
Second, average the normalized fluorescence was averaged among the three 
technical replicates added into the 96-well plates. Third, the averaged 
autofluorescence coming from cells not transformed with the GR construct was 
subtracted from the fluorescence calculated in step two obtaining the absolute 
fluorescence signal. The GR activity was calculated by dividing the fluorescence 
2.Material and Methods 
 
 
59 
intensities (coming from the previous step) from stimulated cells by the non-stimulated 
ones. 
 
2.2.10. Yeast NaOH lysis for protein extraction 
I used 1 mL from the correspondent yeast cultures, pelleted by centrifuging at 2000 
rpm for 5min and discarded the supernatant. The cells were resuspended in a freshly 
prepared solution of 250 mM of NaOH + 12 µL/mL b-mercapethanol. Cells were briefly 
vortexed and incubated 10 min on ice. The OD600 was measured in a 
spectrophotometer for later adjusting the amount of SDS loading buffer added. OD600 
* 4= volume of loading buffer to add (in mL). TCA precipitation was performed with 
each sample after the incubation with NaOH was over. 
 
2.2.11. TRC40 protein purification 
BL21 (DE3) cells expressing a 10xHis-MBP-TEV-TRC40 construct. O/N cell cultures 
were diluted 1:100 in regular LB media. Cells were grown at 37°C until reaching OD600= 
0,6. Next, the cells were induced with 0,4 mM IPTG for 4 h at 30°C shaking at 160 rpm. 
After induction, cells were centrifuged at 6000 g for 20 min at 4°C. The supernatant 
was discarded and the pellet was resuspended in 40 mL of cold extraction buffer. Cells 
were centrifuged at 5300 g for 10 min at 4°C.  The supernatant was discarded. The 
pellet was resuspended in 30 mL of cold extraction buffer supplemented with 1 mM 
phenylmethanesulfonyl fluoride (PMSF), half a tablet of protease inhibitors (Roche), 3 
mM DTT and a tip of DNase I. Cells were lysed with an Emulsiflex-C3 high-pressure 
homogenizer (Avestin, Ottawa, Canada). The crude-cellular lysates were cleared by 
centrifuging at 25.000 rpm for 30 min at 4°C. In parallel, 5,5 mL of dry amylose resin 
(New England Biolabs, Ipswich, USA) were used and they were pre-equilibrated with 
cold extraction buffer. The lysate supernatant was subsequently put in contact with the 
pre-equilibrated amylose resin and incubated during 90 min slightly shaking at 4°C. 
The lysates-resin were loaded into purification columns and washed six times following 
the next scheme: 
o 2 times with 2 volumes of ATP buffer. 
o 2 times with 2 volumes of high-salt buffer. 
o 2 times with 2 volumes of extraction buffer. 
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The protein was eluted from the resin with maltose elution buffer and the flow-through 
was collected in fractions tubes. TRC40-containing fractions were pooled together. The 
purified protein was cleaved with a 1:100 6xHis-tagged TEV protease and dialyzed for 
24 h at 4°C against TEV cleavage buffer. The content of the dialysis tube was 
transferred into a new tube and centrifuged at 5.000 g for 15 min at 4°C for removing 
aggregates. In parallel, 3 mL of Ni-NTA resin (Qiagen, Hilden, Germany) were pre-
equilibrated with extraction buffer. The pre-washed Ni-NTA was loaded into a 
purification column. The pre-cleared dialyzed protein was run into the Ni-NTA columns 
for subsequently remove the uncleaved TRC40 and the 6xHis-TEV protease. The flow-
through was collected in fractions tubes. Cleaved TRC40-containing fractions were 
pooled together and the protein was concentrated with concentrator tubes (Spin-X UF 
20, #431489; Corning, Corning, USA) up to 100 µM. The Ni-NTA was eluted with 
imidazole elution buffer. The recombinant protein was stored at -80°C with 2 mM DTT. 
The efficiency of purification and cleavage were monitored by SDS-PAGE. 
 
2.2.12. TRC40 reduction and oxidation 
The recombinant TRC40 was diluted in 40 mM HEPES-KOH (pH 7,5). For the 
reduction of TRC40, I used 5 µM of the freshly purified protein and added 5 mM of 
DTT, 5 µM ZnCl2 and 0,5 mM of ATP. I incubated the mixture at 30°C at 450 rpm for 5 
h. I used desalting columns (Thermo Fisher Scientific, #89890), equilibrated with 40 
mM HEPES-KOH (pH 7,5) for getting rid of the reductants. For the oxidation of TRC40, 
I used freshly reduced TRC40 and I added 2 mM H2O2 and 50 µM CuCl2 at 37°C at 
450 rpm for 10 min. For removing the oxidants H2O2 and CuCl2 I used again desalting 
columns as described before. I measured the protein concentration by Bradford using 
a BSA standard curve.  
 
2.2.13. ATPase activity assay 
To monitor the ATP hydrolysis I performed a NADH-coupled ATPase assay (Kiianitsa, 
Solinger, and Heyer 2003) in a 96-well plate. The assay is based on an ATP 
regeneration system that turns out into the oxidation of NADH upon ATP hydrolysis by 
the ATPase protein. This regeneration system is formed by phosphoenol pyruvate 
(PEP), pyruvate kinase (PK), L-lactate dehydrogenase (LDH) and β-Nicotinamide 
adenine dinucleotide, reduced (NADH) that are part of the ATPase activity assay buffer 
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described above. The system works as it follows: PEP is converted to pyruvate by the 
PK upon the regeneration of ATP back from ADP. The pyruvate is subsequently 
processed by the LDH into lactate upon the oxidation of NADH into NAD+ (Nørby 
1988). The oxidation of NADH can be monitored by the decrease of absorbance at 340 
nm that is coupled to the steady-state rate of ATP hydrolysis. The assay was performed 
with recombinant TRC40 protein oxidized and reduced as described before in a 96-
well plate and measured in a plate reader (Synergy HT, BioTek) using an absorbance 
wavelength of 340 nm over time.  
 
2.2.14. Ellman’s assay 
To explore the redox state of TRC40, I performed an Ellman’s assay (Ellman 1958; 
Riddles, Blakeley, and Zerner 1983) that enables to monitor the free thiols present in 
the protein. The Ellman’s reagent or 5-5’-Dithiobis(2-nitrobenzoic acid) (DTNB) 
(Ellman 1958), via the aromatic disulfide, interacts with free thiols releasing a mole of 
2-nitro-5-benzoate per mole of thiol group in the protein. This 2-nitro-thiobenzoate 
(TNB) in a mild alkaline media (pH around 7-8) results in 2-nitro-5-thiobenzoate anion 
(TNB2-) that is a yellow compound that can be monitored in a spectrophotometer at 
412 nm. I used 1 µM of recombinant TRC40 protein oxidized and reduced, obtained 
as described before, in Kpi buffer plus 165 µg/mL DTNB and 6 M GndCl. The GndCl 
at high concentrations denatures proteins, in this case it served for exposing all the 
residues to the DTNB. Kpi buffer plus DTNB and GndCl without TRC40 was used as 
a blank. The mixtures were incubated in the darkness at RT for 15 min. The assay was 
performed in a 96-well plate and measured in a plate reader (Synergy HT, BioTek) 
using an absorbance wavelength of 412 nm. The following equation was applied in 
order to calculate the free thiols: 
 
 
 
M stands for the molarity of TRC40, d for the optical pathlength in cm2 and e for the 
molar extinction coefficient of TNB2- that is 13800 M-1 cm-1 in 6M GndCl.  
Free thiols =
A412 sample - A412 blank
İTNB * MTRC40 * d
İTNB = 13800 M-1 cm-1
MTRC40 = 0,000001 M
d = 0,6 cm
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2.2.15. Human cell lines culture 
HeLa P4 cells (Charneau et al. 1994) were obtained from the NIH AIDS Reagent 
Program and T-REx 293 Stx5-opsin cells were grown both in DMEM supplemented 
with 10% (v/v) FBS and 2 mM L-glutamine (DMEM++) under 5% CO2 at 37°C. No 
antibiotics were added. They were tested for contamination by mycoplasma on a 
regular basis. 
 
2.2.16. Cell passaging 
Cells were passaged when around 80% of confluence was reached. The DMEM++ 
medium was removed and they were washed with sterile PBS. One fifth of the original 
volume was added of a medium containing 0,25% Trypsin-EDTA, distributed over the 
plate and removed. The plate was kept on a hotplate at 37°C for 5 min. The cells were 
suspended in 10 mL of DMEM++ medium and the correspondent dilution was done in 
a new plate. The cell dilution was always higher than 2%. 
 
2.2.17. T-REx 293 Stx5-opsin cell line generation 
Flp-In T-REx 293 cells were obtained (Invitrogen, Carlsbad, USA). They were cultured 
with DMEM++ plus 10 µg/mL blasticidin. This cell line stably expresses the blasticidin 
gene for cell line selection. The following plasmids were co-transfected: pOG44 and 
pcDNA5/FRT/TO_Stx5-opsin. The Flp-In T-REx 293 has integrated a Flp 
Recombination Target (FRT) site. pOG44 plasmid expresses a Flp recombinase under 
the control of a CMV promoter. The construct of pcDNA5/FRT/TO_Stx5-opsin carries 
Stx5-opsin under the control of a CMV promoter, two tetracycline operators (TetO2) 
sites adjacent to the promoter, a FRT site and a hygromycin resistance gene. The 
expression of the Flp recombinase mediates the insertion of the 
pcDNA5/FRT/TO_Stx5-opsin construct integrated into FRT site in the genome 
(O’Gorman, Fox, and Wahl 1991).  The TetO2 sites repress the expression of the gene 
under their control in absence of tetracycline in the medium, upon the presence of 
tetracycline the gene expression is induced. 48 h after transfection, cells were 
incubated with DMEM++ supplemented with 200 µg/mL hygromycin B and 15 µg/mL 
blasticidin for two weeks. Cells were split every 5 days renewing the selective media. 
Control cells transfected with only the pOG44 construct (thus hygromycin-sensitive) 
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were subjected to the same protocol to determine the sensitivity to hygromycin of Stx5-
opsin non-transfected cells. The expression of Stx5-opsin from the stable transfectants 
selected with hygromycin and blasticidin was tested by Western blot. They were tested 
for contamination by mycoplasma before preparing freezing stocks and on a regular 
basis. 
 
2.2.18. Stx5-opsin induction in T-REx 293 Stx5-opsin cell 
line 
Tetracycline was added into DMEM++ medium up to a concentration of 10 µg/mL. The 
cell medium was removed and washed once with PBS. The DMEM+tetracycline was 
added and the cells were incubated at 37°C into the cell incubator for 6 h. 
 
2.2.19. Plasmid transient transfection in human cell lines 
HeLa P4 or T-REx 293 cells were seeded to be 60-80% the day of transfection. 
Lipofectamine 2000 (Invitrogen) was used for transfections. The lipofectamine 
transfection solution was prepared under the cell culture hood in two different tubes. 
Depending on the plate volume, the preparation of the solutions was as it follows: 
 
Table 13. Recipe of the transfection solutions used in this study according to plate size. 
 Tube 1 Tube 2 
Plate 
Plate 
volume 
(mL) 
OptiMEM 
volume 
(μL) 
Lipofectamine 
2000 volume 
(μL) 
Plate 
volume 
(mL) 
OptiMEM 
volume (μL) 
Amount of 
plasmid (μg) 
10 cm 10 1000 30 10 1000 14 
6-well 2 200 6 2 200 2,8 
12-
well 
0,85 85 2,55 0,85 85 1,2 
24-
well 
0,5 50 1,5 0,5 50,0 0,7 
 
Tube 1 and Tube 2 were incubated separately for 5 min at RT. Next, it was the content 
of both tubes by pipetting and incubated the mix for 15 min at RT under the hood. The 
cells were washed with PBS and added the correspondent volume of OptiMEM. 
Finally, it was added the Lipofectamine+plasmid solution and incubated for 6 h at 37°C 
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within the cell incubator. Once the Lipofectamine incubation was over, the cells were 
washed with PBS and split the cells to a new plate in a 1:5 dilution. Cell were harvested 
48 h after Lipofectamine 2000 transfection. 
 
2.2.20. siRNA-mediated gene silencing in human cell lines 
HeLa P4 or T-REx 293 cells were seeded to be 60-80% the day of siRNA transfection. 
Lipofectamine RNAiMAX (Invitrogen) was used for transfections. The RNAiMAX 
transfection solution was prepared under the cell culture hood in two different tubes. 
Depending on the plate volume, the preparation of the solutions was as it follows: 
 
Table 14. Recipe of the silencing solutions used in this study according to plate size. 
 Tube 1 Tube 2 
Plate 
Plate 
volume 
(mL) 
OptiMEM 
volume (μL) 
Lipofectamine 
RNAiMAX volume 
(μL) 
Plate 
volume 
(mL) 
OptiMEM 
volume 
(μL) 
Amount of 
10μM 
siRNA (μL) 
10 cm 10 500 30 10 500 40 
6-well 2 100 6 2 100 8 
12-
well 0,85 42,5 2,55 0,85 43 6,8 
24-
well 0,5 25 1,5 0,5 25 4 
 
Tube 1 and Tube 2 were incubated separately for 5 min at RT. Next, it was the content 
of both tubes by pipetting and incubated the mix for 15 min at RT under the hood. The 
cells were washed with PBS and added the correspondent volume of DMEM++. 
Finally, it was added the Lipofectamine RNAiMAX+siRNA solution and incubated for 
24 h at 37°C within the cell incubator. The next day once the Lipofectamine RNAiMAX 
incubation was over, the cells were washed with PBS and split the cells into a new 
plate in a 1:3 dilution.  
 
A second round of silencing was done (necessary for down-regulating TRC40, not 
necessary for WRB or BAG6) exactly as described. Cells were split into a new plate in 
a 1:5 dilution. Cell were harvested 48 h after this last round of Lipofectamine RNAiMAX 
silencing. 
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2.2.21. siRNA-mediated gene silencing plus plasmid 
transient transfection in human cell lines 
HeLa P4 or T-REx 293 cells were seeded to be 60-80% the day of siRNA transfection. 
Lipofectamine RNAiMAX (Invitrogen) was used for transfections. The RNAiMAX 
transfection solution was prepared under the cell culture hood in two different tubes. 
Depending on the plate volume, the preparation of the solutions was as it follows: 
 
Table 15. Recipe of the co-transfection (silencing + transfection) solutions used in this study according 
to plate size. Round 1. 
 Tube 1 Tube 2 
Plate 
Plate 
volume 
(mL) 
OptiMEM 
volume (μL) 
Lipofectamine 
RNAiMAX volume 
(μL) 
Plate 
volume 
(mL) 
OptiMEM 
volume 
(μL) 
Amount of 
10μM 
siRNA (μL) 
10 cm 10 500 30 10 500 40 
6-well 2 100 6 2 100 8 
12-
well 0,85 42,5 2,55 0,85 43 6,8 
24-
well 0,5 25 1,5 0,5 25 4 
 
Tube 1 and Tube 2 were incubated separately for 5 min at RT. Next, it was the content 
of both tubes by pipetting and incubated the mix for 15 min at RT under the hood. The 
cells were washed with PBS and added the correspondent volume of DMEM++. 
Finally, it was added the Lipofectamine RNAiMAX+siRNA solution and incubated for 
24 h at 37°C within the cell incubator. The next day once the Lipofectamine RNAiMAX 
incubation was over, the cells were washed with PBS and split the cells into a new 
plate in a 1:3 dilution.  
 
The second round of silencing was a co-transfection of siRNA and plasmid into the cell 
lines. In contrast with the first round, Lipofectamine 2000 (Invitrogen) was used for 
transfections. The Lipofectamine 2000 transfection solution was prepared under the 
cell culture hood in two different tubes. Depending on the plate volume, the preparation 
of the solutions was as it follows: 
 
 
Table 16. Recipe of the co-transfection (silencing + transfection) solutions used in this study according 
to plate size. Round 2. 
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 Tube 1 Tube 2 
Pla
te 
Plate 
volume 
(mL) 
OptiMEM 
volume 
(μL) 
Lipofectamine
2000 volume 
(μL) 
Plate 
volume 
(mL) 
OptiMEM 
volume 
(μL) 
Amount of 
plasmid 
(μg) 
Amount of 
10μM siRNA 
(μL) 
10 
cm 10 1000 30 10 1000 14 40 
6-
we
ll 
2 200 6 2 200 2,8 8 
12-
we
ll 
0,85 85 2,55 0,85 85 1,2 6,8 
24-
we
ll 
0,5 50 1,5 0,5 50,0 0,7 4 
 
Tube 1 and Tube 2 were incubated separately for 5 min at RT. Next, it was the content 
of both tubes by pipetting and incubated the mix for 15 min at RT under the hood. The 
cells were washed with PBS and added the correspondent volume of OptiMEM. 
Finally, it was added the Lipofectamine 2000+siRNA+plasmid solution and incubated 
for 6 h at 37°C within the cell incubator. Once the Lipofectamine 2000 incubation was 
over, the cells were washed with PBS and split the cells into a new plate in a 1:5 
dilution. Cell were harvested 48 h after Lipofectamine 2000 transfection. 
 
2.2.22. Hypoxic incubation 
HeLa P4 cells were cultured in an in vivo hypoxia workstation (Ruskinn Technologies, 
Bridgend, South Wales, UK) in defined hypoxic conditions (94% N2, 5% CO2, 1% O2) 
for 6 h or 24 h. The sample processing was done within the hypoxia workstation using 
a lysis buffer for hypoxia detailed previously (Table 11) for 1h and following with TCA-
precipitation. 
 
2.2.23. Glucocorticoid receptor stimulation in HeLa cells 
For the glucocorticoid receptor stimulation, HeLa P4 cells were treated with the 
corresponding volume of solvent (absolute ethanol) or a stock resulting in a final 
concentration of 100 nM of dexamethasone in DMEM for 60 min at 37°C within the cell 
incubator. 
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2.2.24. Deubiquitinases (DUBs) inhibition in HeLa cells 
For the inhibition of DUBs, HeLa P4 cells were treated with the corresponding volume 
of solvent (DMSO) or a stock resulting in a final concentration of 1 µM of b-AP15 in 
DMEM for 6 h at 37°C within the cell incubator. 
 
2.2.25. Cardiomyocyte primary cells isolation 
The primary cell isolation protocol was performed as described (Rivera-Monroy et al. 
2016). 
 
2.2.26. Homogenization and protein extraction of 
mammalian tissue 
After organ extraction, keep the tissue on ice or snap-freeze with liquid nitrogen. For 
processing, 1 mL of pre-cold homogenization buffer was added to a flat-bottom 
eppendorf tube containing the organ. The sample was processed with a homogenizer 
(MICCRA D-1; MICCRA GmbH, Müllheim, Germany) and followed by 15-20 strokes 
with a dounce homogenizer. Homogenate samples were centrifuged at 4°C at 100.000 
g for 30 min. 300 µL of solubilization buffer were added and it was incubated for 30 
min on ice, agitating smoothly with no air bubbles. The solubilized samples were again 
centrifuged for 30 min at 100.000 g at 4°C and the supernatant was transferred into a 
new tube. Protein concentration of the samples was determined after this step and the 
samples were subjected to TCA precipitation. 
 
2.2.27. Protein extraction from cell lines 
DMEM++ medium was removed and the cells were washed once with PBS. 600 µL of 
solubilization buffer were added to the plates and they were incubated for 1 h in the 
cold room at 4°C light shaking. The solubilized samples were collected into 
ultracentrifugation tubes and centrifuged for 35 min at 100.000 g at 4°C and the 
supernatant was transferred into a new tube. Protein concentration of the samples was 
determined after this step and the samples were subjected to TCA precipitation. 
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2.2.28. Protein extraction from isolated cardiomyocytes 
Cells were resuspended in 300 µL of solubilization buffer and incubated for 1 h on ice. 
The solubilized samples were collected into ultracentrifugation tubes and centrifuged 
for 35 min at 100.000 g at 4°C and the supernatant was transferred into a new tube. 
Protein concentration of the samples was determined after this step and the samples 
were subjected to TCA precipitation. 
 
2.2.29. Cell fractionation 
Cell medium was removed, washed once with PBS and they were harvested with 
750µL of PBS. Next, they were centrifuged at 200 g for 5 min. PBS was removed and 
the cells were resuspended in 700 µL of cold lysis stock buffer (for more details check 
Table 11, section 2.1.9). Cells were lysed with a dounce homogenizer and the lysate 
was centrifuged at 180.000 g for 1 h at 4°C in order to sediment the membranes. The 
supernatant, cytosol, was kept for later TCA-precipitation. The pellet, membranes, was 
resuspended with 700µL of cold lysis stock buffer and then centrifuged at 180.000 g 
for 20 min at 4°C for washing the membranes. After centrifugation the supernatant was 
removed and the pellet underwent to protein extraction with solubilization buffer (for 
more details check Table 11, section 2.1.9) for 30 min at 4°C. Cells were centrifuged 
at 15.000 rpm for 20 min and the supernatant was kept and the pellet was discarded. 
Protein from cytosol and membranes was measured by a Bradford assay. Finally, both 
fractions underwent TCA-precipitation. 
 
2.2.30. TCA precipitation 
TCA was added to the samples to a final concentration of 12,5% (w/v) (from a stock 
solution of 50% (w/v) TCA), gently vortexed the tubes and incubated on ice for 30 min. 
Then, the samples were centrifuged at 10.500 rpm for 7 min at 4°C and the supernatant 
was discarded. The pellet was then resuspended and washed with -20°C cold acetone. 
Samples were centrifuged at 10.500 rpm for 7 min at 4°C and the supernatant was 
discarded. The pellet was washed a second time with cold acetone and centrifuged. 
The supernatant was discarded and the pellet was dried at 37°C for 15 min until 
complete evaporation of acetone. SDS loading buffer was added according to protein 
concentration calculations and the samples in loading buffer were incubated at 1.200 
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rpm for 20 min at 30°C. Finally, samples were ready for loading them into SDS-PAGE 
gels. 
 
2.2.31. Bradford assay for protein quantification 
Protein in solution was measured using Coomassie Plus Protein Assay Reagent 
Thermo Scientific). 1 mL of the reagent was added into a plastic cuvette plus 2 µL of 
the sample to be measured. Samples were vortexed and incubated for 5 min with the 
reagent. Correspondent blank samples were incubated with 2µL of the correspondent 
buffers. Known protein concentration solutions of BSA were prepared in order to obtain 
a standard curve for absorbances. Absorbance at 595 nm was determined in a 
spectrophotometer for the samples. The protein quantification was calculated based 
on the OD595 obtained for the BSA standard curve. 
 
2.2.32. SDS-PAGE 
To separate proteins by SDS-PAGE (Laemmli 1970) gels were casted following these 
recipes (Sambrook and Russell 2006). Higher acrylamide percentage gels were casted 
when interested in low MW proteins and lower acrylamide percentage gels were casted 
when interested in big proteins. They were casted in gel casters (Hoefer, Hollister, 
USA) and the height of the stacking was around 1/3 of upper part of the gel whereas 
the resolving was 2/3 of the lower part of the gel. Gels were electrophoresed at 20 mA 
(constant amperage) per gel during 90 min in SDS running buffer in electrophoresis 
units (SE250 Mighty small II, Hoefer). 
 
2.2.33. Western blotting 
Proteins separated by SDS-PAGE were subsequently blotted into nitrocellulose 
membranes (GE Healthcare) using a wet blotting tank (TE22 Mighty small transfer 
tank, Hoefer) filled with transfer buffer. The gel was placed onto the nitrocellulose 
membrane and they were sandwiched by two blotting papers pre-equilibrated with 
transfer buffer. The membrane sandwich was then placed into a blotting cassette that 
was inserted into the blotting tank with the membrane directed towards the anode. 
They were electroblotted at 60 V (constant voltage) and the current limited at 0,5 A for 
70 min. Once blotted, the membranes were blocked in a solution of 5% Milk in PBS 
plus 0,1% Tween-20 (Millipore) and shaking for 1 h. Primary antibodies were prepared 
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in the same blocking solution consistent of 5% Milk in PBS plus 0,1% Tween-20 
(Millipore) and the incubation took place O/N at 4°C while shaking. The list of primary 
antibodies and the WB dilutions used can be found in Table 8. Membranes were 
washed thrice with enough volume of PBS plus 0,1% Tween-20 for 5 min each washing 
step. 1:5000-diluted fluorescent secondary antibodies (LI-COR Biosciences, Lincoln, 
USA) (Table 9) were added to the membranes in blocking solution and they were 
incubated for 90 min. Membranes were washed thrice with enough volume of PBS plus 
0,1% Tween-20 for 5 min each washing step. The detection of the fluorescent 
antibodies was carried out with an Odyssey Sa Imaging System (LI-COR) and the 
acquired images were analyzed and quantified with ImageStudio Lite 5.2.5 software 
(LI-COR). 
 
2.2.34. Coomassie staining 
In order to visualize the proteins in polyacrylamide gels, Coomassie staining is a 
method commonly used. For that the gel was soaked in fixation buffer (30% v/v, 15% 
v/v acetic acid) for around 15 min at RT while shaking. Next, the gels were stained by 
soaking the gel in Coomassie staining buffer (30% v/v ethanol, 10% v/v acetic acid and 
0,2% w/v Coomassie brilliant blue). This solution was quickly boiled in the microwave 
for 15-20 sec and incubated for 20 min at RT while shaking. For removing gel-
unspecific Coomassie staining, the gel was left O/N in destaining solution at RT while 
shaking. 
 
2.2.35. GFP-trap pulldown 
HeLa P4 cells were transfected with the correspondent plasmids for EV, Venus and 
Venus-TRC40wt or Venus-GR. Cells were washed with PBS and harvested. Cells were 
resuspended in 700 µL of IP binding buffer (150 mM KCl, 5 mM MgCl2, 20 mM Tris pH 
7,4). Cells were lysed with a dounce homogenizer and the lysate was centrifuged at 
100.000 g for 35 min at 4°C in order to pellet the membranes. I kept the supernatant 
and discarded the pellet. I took 10% of the supernatant volume was subjected to TCA 
precipitation and served as the input control of the pulldown. The rest of the 
supernatants were incubated with pre-washed GFP-trap M magnetic beads 
(ChromoTek, Martinsreid, Germany), using 20 µL per reaction, for 60 min at 4°C in a 
rotation wheel. Briefly, the beads were washed with IP binding buffer incubating them 
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in a rotation wheel at 4°C for 20 min and doing four more washes in the magnetic rack, 
the two first of which contained 0,1% Triton X-100 and the two latest with no detergent. 
After the incubation with the beads was over, I placed the tubes into the magnetic rack 
and discarded the supernatant and washed four times with IP binding buffer with no 
detergent. The beads were eluted with 50 µL of SDS loading buffer and incubated 
them for 10 min at 30°C 1000 rpm shaking, then samples were ready for Western blot. 
 
2.2.36. Co-immunoprecipitation of Stx5 and TRC40 
T-REx 293 Stx5-opsin stable cell line was transfected with the correspondent plasmids 
for EV, TRC40wt, TRC40D74E. Cells were treated for 6 h with tetracycline for the 
induction of the expression of Stx5-opsin. Cells were washed with PBS and harvested. 
Cells were subjected to cell fractionation as described above. I was just interested in 
the cytosolic fraction, I discarded the pellets. Protein concentration of the samples was 
quantified by Bradford. I took 10% of the volume of the cytosolic fractions and I 
performed TCA precipitation, they served as the input controls. The Protein G beads 
(GE Healthcare, Chicago, USA) were incubated with the correspondent antibody: IgG 
normal rabbit as IP control, anti-Stx5 or anti-TRC40 at 4°C for 1 h in a rotation wheel 
followed by four washes with lysis stock buffer. After the washes, the pre-loaded beads 
were incubated with a solution containing 3% of BSA for 20 min at 4°C in the rotation 
wheel. The cytosolic fractions were then incubated with Protein G beads pre-loaded 
with the correspondent antibody for 150 min at 4°C in a rotation wheel. Once the 
incubation was over, the supernatant was discarded and the beads were washed four 
times with lysis stock buffer. No detergents were added in any step. The beads were 
incubated for 15 min at RT with SDS loading buffer and then eluted. Samples were 
ready for Western blot. 
 
2.2.37. Co-immunoprecipitation of the GR and TRC40 
HeLa P4 cells were cultured up to 70% confluency. They were washed with PBS and 
harvested. Cells were subjected to cell fractionation as described above. I was just 
interested in the cytosolic fraction, I discarded the pellets. Protein concentration of the 
samples was quantified by Bradford. I took 10% of the volume of the cytosolic fractions 
and I performed TCA precipitation, they served as the input controls. The Protein A 
beads (GE Healthcare) were incubated with the mouse anti-GR antibody (serving IgG 
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normal mouse as control) at 4°C for 1 h in a rotation wheel followed by four washes 
with lysis stock buffer. The Protein G beads (GE Healthcare) were incubated with the 
rabbit anti-TRC40 antibody (serving IgG normal rabbit as control) at 4°C for 1 h in a 
rotation wheel followed by four washes with lysis stock buffer. After the washes, the 
pre-loaded beads were incubated with a solution containing 3% of BSA for 20 min at 
4°C in the rotation wheel. The cytosolic fractions were then incubated with the beads 
pre-loaded with the correspondent antibody for 150 min at 4°C in a rotation wheel. 
Once the incubation was over, the supernatant was discarded and the beads were 
washed four times with lysis stock buffer. No detergents were added in any step. The 
beads were incubated for 15 min at RT with SDS loading buffer and then eluted. 
Samples were ready for Western blot. 
 
2.2.38. PNGase F treatment 
T-REx 293 Stx5-opsin stable cell line was transfected with the correspondent plasmids 
for EV, TRC40wt, TRC40D74E. Cells were treated for 6 h with tetracycline for the 
induction of the expression of Stx5-opsin. Cells were washed with PBS and harvested. 
Cells were subjected to cell fractionation as described above with some modifications. 
Membranes were solubilized with solubilization buffer for 30 min on ice and centrifuged 
at 180.000 g for 30 min at 4°C, pellet was discarded afterwards. Protein concentration 
was quantified by Bradford. TCA precipitation to both membranes and cytosol fractions 
was carried out. TCA pellets were washed twice with cold acetone and dried 10 min at 
37°C. PNGase F buffer (consistent of 1-fold glycoprotein denaturing buffer, 1-fold G7 
buffer, 2,5% NP-40 in ddH2O) was added to the TCA precipitates and incubated at 
37°C for 30 min at 1400 rpm. Per 300 µg of total protein, 50 µL of PNGase F buffer 
was added. Once the incubation for denaturing glycoproteins was over, 1 µL of 
PNGase F (10 U/µL in the final volume) (New England Biolabs) was added and the 
samples were incubated at 37°C for 30 min. Samples were supplemented afterwards 
with 5x SDS loading buffer and DTT for Western blot analysis. 
 
2.2.39. Digitonin semipermeabilization 
Coverslips with HeLa P4 cells were transferred into a 12-well plate. They were washed 
once with PBS and placed the 12-well plate on ice. A cold solution of 0,007% of 
digitonin in transport buffer (for more details check Table 11, section 2.1.9) was added 
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and incubated for exactly 5 min. The digitonin solution was quickly removed and the 
coverslips were washed twice with cold transport buffer. The coverslips were then 
suitable for starting an indirect fluorescence protocol. 
 
2.2.40. Indirect immunofluorescence (IF) 
UV-sterilized 10 mm coverslips were added to the plates and HeLa P4 cells seeded 
on top. When it was due the harvesting, cells were washed twice with PBS and later 
they were fixed with 4% (w/v) PFA in PBS for 15 min. Secondly, they were 
permeabilized with 0,3% Triton X-100/0,05% SDS in PBS for 10 min at room 
temperature. Samples were blocked with 10% FBS in PBS for 30 min and incubated 
with primary antibodies diluted in blocking buffer overnight at 4°C. Incubation with 
Alexa Fluor secondary antibodies (Invitrogen) (Table 10) was performed for 60 min at 
room temperature. The samples were mounted with Mowiol-DAPI for the confocal 
microscope. 2x PBS washes were performed in between the different steps. 
 
In the case of digitonin-semipermeabilized cells, the PFA fixation was done right after 
and the Triton X-100/SDS permeabilization step was skipped. 
 
2.2.41. Imaging with a LSM 510-META confocal microscope 
Cells were analyzed using an Axiovert 200M fluorescence microscope with a 63× Plan-
Neofluar 1.3 NA water-corrected objective and appropriate filter settings. Images were 
taken using a LSM 510-META confocal laser scanning microscope (Zeiss, Jena, 
Germany). For confocal imaging a UV laser (405 nm) at 25 mW, a tunable Argon laser 
(488 nm) at 30 mW, HeNe laser line (543 nm) at 1 mW, HeNe laser lines (633 nm) at 
3 mW were used for excitation. Emission filters: 450/60 nm, 518/25 nm, 588/56 nm, 
long-pass (LP) 650 nm respectively. 
 
2.2.42. Imaging with an Imaging Machine 03-dual widefield 
screening microscope 
HeLa P4 cells were seeded in laminin-coated (Corning #354232) 384-well glass-
bottom plates (Matriplate, Brooks Life Science Systems #MGB101-1-2-LG-L; 
Manchester, United Kingdom) and there the immunostaining was performed as 
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described above. The plates were automatically imaged on an Imaging Machine 03-
dual widefield high-content screening microscope (Acquifer; Karlsruhe, Germany) 
equipped with a white light-emitting diode array for brightfield imaging, a light-emitting 
diode fluorescence excitation light source, a sCMOS (2,048 × 2,048 pixel) camera, and 
a stationary plate holder in combination with movable optics. Images were acquired 
with 405-nm, 470-nm and 625-nm filter cubes (excitation 390/40 nm, emission 452/45 
nm, and dichroic 405 nm; excitation 469/35 nm, emission 525/39 nm, and dichroic 497 
nm; and excitation 628/40 nm, emission 692/40 nm, and dichroic 660 nm; respectively) 
with a 40× CFI Super Plan Fluor ELWD NA 0.60 (Nikon; Tokyo, Japan). Integration 
times were fixed at 50ms for the 405-nm channel and 100 ms for the other two 
fluorescence channels. The focal plane was detected in the 405-nm channel using an 
autofocus algorithm. 
 
2.2.43. Indirect immunofluorescence image quantification 
The images acquired were loaded into the open-source image-analysis software 
CellProfiler (Version 2.1.1 (rev 6c2d896)) (Carpenter et al. 2006) that was used to 
analyze and measure intensities. ImageJ was used to convert the lsm format files 
generated by the confocal software into TIFF files recognized by CellProfiler. GR- or 
BAG6-background discrimination was done on Otsu threshold to the GR or BAG6-
channel images. A cell mask was created based on the area covered by the GR- or 
BAG6-channel image differentiated from the background. The nucleus discrimination 
relied on the DAPI-channel images, based as well on Otsu threshold. A nucleus mask 
was created based on the area covered by the DAPI staining, from the previous step, 
on the GR or BAG6-channel images. A cytosolic mask was creating by subtracting the 
nucleus mask to the cell mask. GR or BAG6 mean intensities within the nucleus mask 
and the cytosol mask were measured. The GR/BAG6 nucleus-mask intensities were 
divided by the cytosol-mask intensities giving the nucleo-cytoplasmic ratio. In the case 
of the BAG6 nucleo-cytoplasmic ratio in the presence of TRC40 variants, there was an 
extra mask. This mask was made from the cmyc-channel images for filtering and 
measure only those transfected cells. This mask was placed and applied before the 
others. All the measurements and calculations were automatically exported into a csv 
file. Further details from the algorithm can be found in the 7.5.1 and 7.5.2 in the 
Appendix section.  
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2.2.44. Statistics and software 
Statistical analyses were calculated with Graph Prism 6.0 for MacOS (GraphPad 
Software Inc., San Diego, USA) using a two-tail unpaired t test with equal SD. The dot-
plots and scatter-plots were also done in Graph Prism 6.0 for MacOS.  
 
Indirect immunofluorescence images analyses were performed with ImageJ 1.51w 
software (US National Institutes of Health, Bethesda, USA) (Schneider, Rasband, and 
Eliceiri 2012). Quantification of the images was done using CellProfiler (Version 2.1.1 
(rev 6c2d896)) (Carpenter et al. 2006). CellProfiler pipelines used for quantification 
can be found in sections 7.5.1 and 7.5.2 in Appendix. 
 
Blot quantification were done in ImageStudio Lite 5.2.5 software (LI-COR). For the blot 
figures scanned images were exported from ImageStudio, rotated and cropped in 
Adobe Photoshop CS6 (Adobe, San José, USA) and the composition was done in 
Adobe Illustrator CS6 (Adobe, San José, USA). 
 
Structure figures were generated using PyMOL (The PyMOL Molecular Graphics 
System, Version 2.0 Schrödinger, LLC.) and the Protein Data Bank files were obtained 
from RCSB PDB (www.rcsb.org) (Berman et al. 2000). The PDB IDs were provided in 
the correspondent figure legends. 
 
For plasmid edition, sequencing alignment and primer design were done using 
SnapGene 4.1.6 software (GSL Biotech, Chicago, USA). 
mRNA expression levels from human tissue was coming from the human Genotype-
Tissue Expression database v6, GTEx (GTEx Consortium 2015; Melé et al. 2015; 
Rivas et al. 2015). Data available here: https://www.gtexportal.org/home/. 
 
Protein sequences alignments were performed with Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) (Li et al. 2015). The FASTA sequences 
provided for the alignments and the UniProt accession numbers were obtained from 
UniProt (http://www.uniprot.org) (The UniProt Consortium 2017). NCBI protein 
accession numbers were obtained from NCBI Protein 
(https://www.ncbi.nlm.nih.gov/protein). 
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The transmembrane segment of the TA-proteins was predicted using the TMHMM 
algorithm (Krogh et al. 2001; Möller, Croning, and Apweiler 2001) using the website 
TMHMM Server 2.0 (http://www.cbs.dtu.dk/services/TMHMM/). 
 
The helical wheel analysis was performed using the application wheel.pl v1.4 
(Zidovetzki et al. 2003). Available here: http://rzlab.ucr.edu/scripts/wheel/wheel.cgi 
 
The sequence logo was generated using the web-based generator Seq2Logo 2.0 
(Thomsen and Nielsen 2012). Available here: 
http://www.cbs.dtu.dk/biotools/Seq2Logo/. Parameters used in the analysis are 
available in section 7.5.3 in Appendix. 
 
The phylogenetic tree was generated using the web tool Interactive Tree of Life (iTOL) 
v4.2 (Letunic and Bork 2016). Available here:  http://itol.embl.de  
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3. Results 
 
3.1. TRC40D74E, a mutant for the study of TA-
protein biogenesis in vivo 
 
Since the role of Get3 in the GET pathway was published (Schuldiner et al. 
2008), its structure and domains have been described in multiple papers (Mateja et al. 
2009; Suloway et al. 2009; Bozkurt et al. 2009; Hu et al. 2009; Yamagata et al. 2010; 
Stefer et al. 2011; Mariappan et al. 2011; Kubota et al. 2012; Gristick et al. 2014; 
Mateja et al. 2015; Gristick et al. 2015). The relevance of mutations within those 
domains, in particular mutations affecting the ATPase domain or the TA-binding groove 
of Get3, has been characterized. Nevertheless, little is known about TRC40 structure 
and domains apart from the assumption that similar, or conserved, domains execute 
the same functions. 
 
A well characterized mutant of Get3 is Get3I193D, which substitutes a side chain facing 
the TA-protein binding groove. This mutant, whose interaction with TA-proteins was 
shown to be impaired in vitro (Mateja et al. 2009), has also been proposed to represent 
a fully chaperone-active form (Voth et al. 2014). Another widely-used mutant is the 
Get3D57E, which targets the conserved Switch I ATPase domain. As expected, this 
mutation, or another exchange at the same position, i.e. Get3D57N, affects the ATPase-
activity of Get3 (Mateja et al. 2009; Powis et al. 2013; F. Wang et al. 2011; Stefer et 
al. 2011; Chio et al. 2017). There is also insight into the effects of changing D45 in the 
Switch I domain of the bacterial homolog ArsA (Tongqing Zhou and Rosen 1999). A 
third mutant, Get3G30R which targets the P-loop or Walker A motif, has been used as 
an ATPase-dead mutant of Get3 in several papers (Shen et al. 2003; Schuldiner et al. 
2005; Suloway et al. 2009; F. Wang et al. 2011; Johnson, Powis, and High 2013). This 
mutant has been shown to be deficient in nucleotide-binding (Saraste, Sibbald, and 
Wittinghofer 1990). 
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For the purpose of dissecting the chaperone function of TRC40 in vivo and its relation 
to the TRC-pathway components and substrates I created a panel of cmyc-tagged 
TRC40 mutants (Fig. 12B). This set is very useful for screening changes in subcellular 
localization of potential substrates by indirect immunofluorescence. These mutants 
were resistant (siTRC40ins) to the siRNAs established for TRC40 knock-down (Pfaff 
et al. 2016), thus one can down-regulate the endogenous TRC40 and monitor the 
transfected cmyc-tagged TRC40. 
 
 
 
Figure 12. Investigated TRC40 mutants in the context of TRC40 domains. (A) TRC40 scheme 
illustrating functional domains based on the residues between Get3 and TRC40. (B) Mutations 
generated for the different functional domains of TRC40. (C) The mutations generated in the TA-protein 
binding groove of TRC40 are highlighted (in yellow) in the conserved residues of Get3 crystal structure. 
Side view. (D) A 135º plane rotation. Frontal view. (E) A 90º plane rotation. Top view. Get3 subunits are 
depicted in orange and deep purple whereas TA-protein is depicted in red. PDB ID: 4XTR. 
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The SNARE protein syntaxin 5 (Stx5) is the best characterized TRC40 substrate 
(Rivera-Monroy et al. 2016; Norlin et al. 2016; Casson et al. 2017; Norlin, Parekh, and 
Edlund 2018). Similarly, yeast syntaxin 5 (Sed5) requires Get3 for proper targeting and 
localization (Schuldiner et al. 2008; Jonikas et al. 2009; Powis et al. 2013; Voth et al. 
2014). Therefore, I used Stx5 subcellular localization by IF as a reliable readout of the 
impairment of TRC40-dependent TA-targeting in the analysis of TRC40 mutants. First, 
I silenced the endogenous TRC40 and then transfected HeLa cells with the set of 
TRC40 mutants. I performed IF co-staining for Stx5 and cmyc-TRC40. Among the 
mutants analyzed there was one with a striking effect: upon transfection with the 
TRC40D74E mutant, Stx5 changed its subcellular localization showing an apparently 
cytoplasmic staining instead of the Golgi-staining reflecting proper targeting and 
sorting of Stx5 (Appendix Fig. 1A). 
 
 
3.1.1. In the presence of TRC40D74E, certain TA-proteins 
accumulate in cytoplasm 
 
I set out to dissect the effects of the TRC40D74E mutant on Stx5. First, I tested 
whether the TRC40D74E mutant had its striking effect only in the absence of 
endogenously expressed TRC40 and transfected the constructs without prior siRNA-
mediated silencing of TRC40. Indeed, it turned out that the effect on Stx5 distribution 
was indistinguishable from the previous result obtained after knockdown of 
endogenous TRC40 (data not shown). To test the contribution of the TA-protein 
binding groove on the effects of TRC40D74E expression, I generated a couple of D74E 
mutants that additionally carried mutations in the region encoding the TA-protein 
binding groove (Fig. 12C) such as TRC40D74E/I193D and TRC40D74E/L190D/I193D (Mateja et 
al. 2009; F. Wang et al. 2010; Shao et al. 2017). I transfected HeLa cells with these 
TRC40 constructs and performed an indirect immunofluorescence staining for the 
TRC40 variants, for Stx5, and for Emerin (EMD), a second TA-protein, which has been 
shown to be a substrate of the TRC pathway (Pfaff et al. 2016; Rivera-Monroy et al. 
2016). 
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In the presence of the TRC40D74E, both Stx5 and EMD showed cytoplasmic staining 
(Fig. 13A, Fig. 14A). Moreover, no Golgi staining was observed for Stx5 in TRC40D74E-
transfected cells. Whereas for Stx5 the over-expression of TRC40wt did show partial 
cytoplasmic staining, for EMD there were no major effects compared to transfection 
with the empty vector. Quantification of the results is shown in Fig. 19A, Fig. 19B. 
Regarding the D74E TA-protein binding mutants, the phenotype of both, Stx5 and 
EMD, was maintained in the presence of the mutant carrying one single mutation, 
compared to TRC40D74E, but the phenotype was milder and reduced in the presence 
of the mutant with two mutations changing side chains within the TA-protein binding 
groove. Interestingly, Stx5 subcellular localization in the presence of 
TRC40D74E/L190D/I193D was intermediate between the one observed in the case of the 
TRC40D74E transfection and the one observed after transfection of the empty vector. 
This indicates that the mutations investigated might not be sufficient to completely 
disrupt the interaction of Stx5 with the TA-protein binding groove or that the binding of 
Stx5 to TRC40 also involves a different region of TRC40. 
 
Stx5 plays an important role in the maintenance of Golgi apparatus structure (Suga et 
al. 2005; Amessou et al. 2007) and an impairment of the TRC pathway results in 
reduced steady-state levels of Stx5 and a fragmented Golgi structure (Rivera-Monroy 
et al. 2016; Norlin, Parekh, and Edlund 2018). In those cells transfected with the 
TRC40D74E, the protein GM130, which is a component of the cis-Golgi stack that helps 
to maintain the Golgi structure (Barr and Short 2003; Gillingham and Munro 2016), and 
hence serves as a marker for the Golgi apparatus, revealed a fragmented Golgi (Fig. 
13A). In conclusion, reduced targeting of Stx5 to the Golgi may result in an altered 
structure of this organelle. In contrast, mistargeting of EMD did not affect its target 
compartment, the inner nuclear membrane (INM). In fact, lamin A/C, a marker protein 
for the INM, was unaffected in the presence of TRC40D74E over-expression (Fig. 21A) 
indicating that the INM is not altered in these cells. 
 
Based on these results, which suggest that TRC40D74E can be used as a tool to 
uncover the interaction of TRC40 with substrates. I expanded the panel of TA-proteins 
tested with the TRC40D74E mutant. Upon the over-expression of this mutant, later 
experiments revealed that Stx8 also showed cytoplasmic staining in TRC40D74E-
transfected HeLa cells (Fig. 15A). Stx8 is a t-SNARE localized to endosomes. Similar  
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Figure 13. TRC40D74E alters the subcellular localization of the v-SNARE Stx5. (A) 
Immunofluorescence of Stx5 upon over-expression of different TRC40 variants in HeLa cells. Images 
of Stx5, the cis-Golgi marker GM130, and cmyc-TRC40 stained by indirect immunofluorescence are 
shown. Three to seven biological replicates were analyzed. Scale bars: 20 µm. 
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Figure 13. TRC40 D74E alters the subcellular localization of the v-SNARE Stx5. (A) 
Immunofluorescence of Stx5 upon over-expression of different TRC40 variants in HeLa 
cells. Images of Stx5, the cis-Golgi marker GM130, and cmyc-TRC40 stained by indirect 
immunoflu r scence are shown. Thre  to seven biological replicates were analysed. Scale 
bars: 20 µm.
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Figure 14. TRC40D74E alters the subcellular localization of the inner nuclear membrane protein 
EMD. (A) Immunofluorescence of EMD upon over-expression of different TRC40 variants in HeLa cells. 
Images of EMD and cmyc-TRC40 stained by indirect immunofluorescence are shown. Four to six 
biological replicates were analyzed. Scale bars: 20 µm. 
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Figure 14. TRC40_D74E alters the subcellular localization of the inner nuclear mem-
brane protein EMD. (A) Immunofluorescence of EMD upon over-expression of different 
TRC40 variants in HeLa cells. Images of EMD and cmyc-TRC40 stained by indirect immu-
nofluor cence are shown. Four to six biological replicates were analysed. Scale bars: 20 
µm.
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Figure 15. TRC40D74E does alter the subcellular localization of the endosomal t-SNARE protein 
Stx8. (A) Immunofluorescence of Stx8 upon transfection of different TRC40 variants in HeLa cells. 
Images of Stx8, the early endosomal marker EEA1, and cmyc-TRC40 stained by indirect 
immunofluorescence are shown. Three biological replicates were analyzed. Scale bars: 20 µm. 
E
V
Stx8 EEA1 cmyc
+c
m
yc
-s
iT
R
C
40
in
s
TR
C
40
w
t
TR
C
40
_D
74
E
Merge with DAPI
TR
C
40
_I
19
3D
TR
C
40
_D
74
E
/I1
93
D
TR
C
40
_D
74
E
/L
19
0D
/I1
93
D
A
Figure 15. TRC40 D74E does alter the subc llular localiza ion of the e dosomal 
t-SNARE protein Stx8. (A) Immunofluorescence of Stx8 upon transfection of different TRC40 
variants in HeLa cells. Images of Stx8, the early endosomal marker EEA1, and cmyc-TRC40 
stained by indirect immunofluorescence are shown. Three biological replicates were analysed. 
Scale bars: 20 µm.
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to the staining of EMD, Stx8 was not altered in the TRC40wt-over-expressing cells or 
the double TA-groove mutant but the phenotype of the D74E/I193D mutant still 
presented a cytoplasmic staining. Quantification of the results is shown in Fig. 19A 
and Appendix Fig. 6. 
 
In contrast, other TA-proteins like Sec61b, an ER-protein that forms part of the Sec61 
translocon and has been extensively used to probe TRC40-dependence in in vitro-
experiments (Stefanovic and Hegde 2007) remained unaffected regardless of the 
TRC40 variant over-expressed (Fig. 16A). No cytoplasmic population was observed, 
instead colocalization with the ER marker protein calnexin was complete. Sec61b 
phenotype was quantified in Fig. 19A. Like Sec61b, PTP1B and VAPB are both ER-
resident TA-proteins. They were unaffected by the presence of the TRC40wt or the 
mutants (Fig. 17A, Fig. 18A). D74E effect was quantified in Fig. 19A. 
 
The TRC40D74E mutant affects some TA-proteins altering their native subcellular 
localization to a cytoplasmic one but it has no effect on other TA-proteins. For two 
proteins affected by this mutant, Stx8 and EMD, one additional mutation in the TA-
protein binding groove, I193D, is not sufficient to revert the phenotype. Whereas the 
combination of the D74E, exchanged with two mutations in the TA-protein binding 
groove, L190D and I193D, is enough to abolish the sequestration in the cytoplasm. 
Surprisingly, the triple mutant still affected the subcellular localization of Stx5, albeit to 
a lesser degree. This suggests a potential additional binding region relevant to the 
interaction of TRC40 with Stx5. 
 
3.1.2. Stx5 and EMD cytoplasmic accumulation upon 
TRC40D74E is sensitive to semipermeabilization with 
digitonin 
 
In order to discriminate whether the cytoplasmic staining pattern seen for Stx5 
and EMD in TRC40D74E-transfected cells indeed reflects localization to the cytoplasm, 
I performed a semipermeabilization with digitonin before the IF. Digitonin, at low 
concentrations and short incubation times on ice, is able to permeabilize preferentially 
the plasma membrane leaving the rest of the cell membranes, including the nuclear  
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Figure 16. TRC40D74E does not alter the subcellular localization of the ER protein Sec61ß. (A) 
Immunofluorescence of Sec61ß upon over-expression of different TRC40 variants in HeLa cells. Images 
of Sec61ß, the ER marker calnexin, and cmyc-TRC40 stained by indirect immunofluorescence are 
shown. Three to four biological replicates were analyzed. Scale bars: 20 µm. 
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Figure 16. TRC40 D74E does not alter the subcellular localization of the ER protein 
Sec61ß. (A) Immunofluorescence of Sec61ß upon over-expression of different TRC40 
variants in HeLa cells. Images of Sec61ß, the ER marker calnexin, and cmyc-TRC40 
stained by indirect immunofluorescence are shown. Three to four biological replicates were 
analysed. Scale bars: 20 µm.
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Figure 17. TRC40D74E does not alter the subcellular localization of the ER protein PTP1B. (A) 
Immunofluorescence of PTP1B upon over-expression of different TRC40 variants in HeLa cells. Images 
of PTP1B and TRC40 stained by indirect immunofluorescence are shown. Three biological replicates 
were analyzed. Scale bars: 20 µm. 
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Figure 17. TRC40 D74E does not alter the subcellular localization of the ER protein 
PTP1B. (A) Immunofluorescence of PTP1B upon over-expression of different TRC40 vari-
ants in HeLa cells. Images of PTP1B and TRC40 stained by indirect immunofluorescence 
are shown. Three biological replicates were analysed. Scale bars: 20 µm.
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Figure 18. TRC40D74E does alter the subcellular localization of the ER protein VAPB.  (A) 
Immunofluorescence of VAPB upon over-expression of different TRC40 variants in HeLa cells. Images 
of VAPB and TRC40 stained by indirect immunofluorescence are shown. Three biological replicates 
were analyzed. Scale bars: 20 µm. 
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Figure 18. TRC40 D74E does alter the subcellular localization of the ER protein VAPB. 
(A) Immunofluorescence of VAPB upon over-expression of different TRC40 variants in 
HeLa cells. Images of VAPB and TRC40 stained by indirect immunofluorescence are 
shown. Three biological replicates were analyzed. Scale bars: 20 µm.
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Figure 19. Quantification of the subcellular localization phenotype of the TA-proteins in the 
presence of different TRC40 mutants. (A) TRC40D74E effect over the subcellular localization of the 
TA-proteins tested in Fig. 13-18 using TRC40wt as control. The mixed phenotype represents a Golgi-
localized Stx5 that also shows in cytoplasm. From each protein 27 to 151 cells are represented. Two to 
seven biological replicates. (B) Quantification of the subcellular localization phenotype of Stx5 in the 
presence of TRC40 mutants tested in Fig. 13. n= 60-311 cells are represented. Three to seven biological 
replicates. Extended quantification panel for EMD and Stx8 can be found in Appendix Fig. 6. 
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envelope, intact (Plutner et al. 1992; Wilson et al. 1995). To ensure that only the 
plasma membrane had been permeabilized, I assessed the integrity of the nuclear 
compartment. Lamin A/C, a INM protein marker, served as a control for the intact 
nuclear membrane, and demonstrated successful semi-permeabilization. 
 
Interestingly, Stx5 was washed out from the D74E-semipermeabilized cells compared 
to the control (where the cells were fixed in the first place and then permeabilized with 
Triton X-100). In contrast, semipermeabilization of the cells transfected with the empty 
vector revealed that Stx5 remains in the Golgi membrane (Fig. 20B). Taken together, 
this confirms that Stx5 was cytoplasmic, as suggested by indirect immunofluorescence 
staining. TRC40D74E therefore has the capacity to trap Stx5 in the cytoplasm. 
 
In the case of EMD, the putative cytoplasmic population present in the D74E-
transfected and semipermeabilized cells could be washed out. However, a fraction of 
the protein was still observed in the ER and at the nuclear rim (Fig. 21B). Hence, I was 
able to detect a cytoplasmic EMD population upon D74E transfection that was 
cytoplasmic, but unlike Stx5 EMD was also present in the membranes. 
 
 
3.1.3. Stx5 is not affected by the inhibition of 
deubiquitinases in TRC40D74E-transfected cells 
 
The lack of some components of the GET pathway in yeast provokes the 
accumulation of Sed5 in punctate foci (Schuldiner et al. 2008; Battle et al. 2010; Kohl 
et al. 2011; Vilardi et al. 2014; Voth et al. 2014; Powis et al. 2013). Get3 colocalizes 
with Sed5 in those puncta. Furthermore, Get3 accumulates in foci upon glucose 
deprivation (Powis et al. 2013). The addition of deubiquitinase (DUB) inhibitors, such 
as b-AP15, to glucose-starved yeast prevented the recruitment of Get3 into those foci 
(Powis 2012). Unlike Get3 in yeast, TRC40D74E does not appear in punctate structures 
but does colocalize with Stx5, and other substrates in the cytoplasm. DUBs have been 
implicated to play key roles in Endoplasmic reticulum-associated degradation (ERAD) 
(Q. Wang, Li, and Ye 2006; Ernst et al. 2009; Yanfen Liu et al. 2014). Moreover, SGTA 
interacts with the proteasomal ubiquitin receptor Rpn13 modulating quality control  
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Figure 20. Stx5 is washed out from TRC40 semi-permeabilized, D74E-transfected cells. (A) 
Immunofluorescence of Stx5 upon over-expression of different TRC40 variants in HeLa cells. Cells were 
semi-permeabilized with a solution containing 0,007 % digitonin in (B). One biological replicate was 
analyzed. Scale bars: 20 µm. 
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Figure 20. Stx5 is washed out from TRC40 semi-permeabilized, D74E-transfected cells. 
(A) Immunofluorescence of Stx5 upon over-expression of different TRC40 variants in HeLa 
cells. Cells were semi-permeabilized with a solution containing 0,007 % digitonin in (B). One 
biological replicate was analysed. Scale bars: 20 µm.
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Figure 21. EMD is washed out from semi-permeabilized, TRC40D74E-transfected cells. (A) 
Immunofluorescence of EMD upon over-expression of different TRC40 variants in HeLa cells. Cells 
were semi-permeabilized with a solution containing 0,007% digitonin in (B). The lamin A/C staining 
serves as a control demonstrating nuclear permeabilization in the presence of 0,3 % Triton-X 100 but 
not 0,007% digitonin. Three biological replicates were analyzed. Scale bars: 20 µm. 
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Figure 21. EMD is washed out from semi-permeabilized, TRC40 D74E-transfected 
cells. (A) Immunofluorescence of EMD upon over-expression of different TRC40 variants in 
HeLa cells. Cells were semi-permeabilized with a solution containing 0,007 % digitonin in 
(B). The laminA/C staining serves as a control demonstrating  nuclear permeabilization in 
the presence of 0,3 % Triton-X 100 but not 0,007 % digitonin. Three biological replicates 
were analysed. Scale bars: 20 µm.
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(Leznicki et al. 2015; Thapaliya et al. 2016). Rpn13 has been reported to bind the 
deubiquitinase UCH37 (UCHL5) and it has been speculated that this can revert the 
fate of ubiquitinated-proteins carried by SGTA (Sahtoe et al. 2015; Vander Linden et 
al. 2015). The DUB inhibitor b-AP15 is specific for the following DUBs: USP14 and 
UCHL5 (D’Arcy et al. 2011). Stx5 interaction with TRC40D74E might occur in the context 
of ERAD and the DUBs might be relevant to such an interaction. To explore this 
hypothesis, I tested the role of DUBs in this interaction and whether, as suggested by 
the experiments performed in yeast, blocking DUBs was able to prevent the interaction. 
I transfected HeLa cells with TRC40wt, TRC40D74E and used transfection with an empty 
vector as a control. For the purpose of inhibiting DUBs, I relied on the very-well 
described b-AP15 and performed an IF. 
 
Upon the addition of b-AP15, the staining of Stx5 changed slightly due to what seemed 
Golgi dispersion. Although its principal localization to the Golgi seemed unaffected. 
The inhibition of DUBs does not prevent the cytoplasmic localization of Stx5 in the 
TRC40D74E-transfected cells (Fig. 22A) pointing out that they are not required for the 
interaction to take place. There were also no changes in Stx5 steady-state levels (Fig. 
22B) as observed by Western blotting. 
 
 
3.1.4. Stx5 is strongly enriched in cytosol whereas the 
membrane-inserted population is decreased in TRC40D74E-
transfected cells 
 
The experiments performed by microscopy indicated that Stx5 accumulates in the 
cytoplasm upon over-expression of TRC40D74E. To further study this effect, we 
developed a stable cell line (Flp-In T-REx-293) with a Stx5 opsin-tagged at the C-
terminus under the control of a tetracycline-inducible promoter. The opsin tag is an N-
glycosylation tag, a 13-amino acid tag derived from bovine opsin that gets glycosylated 
on the luminal side once the protein is inserted into the ER. Thereby it monitors the 
ER-insertion of the protein (Pedrazzini et al. 2000; Borgese et al. 2001; B. M. Abell et 
al. 2007; Stefanovic and Hegde 2007; Schuldiner et al. 2008; Favaloro et al. 2010; 
Kutay et al. 1995; Masaki, Yamamoto, and Tashiro 1996; Honsho, Mitoma, and Ito 
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1998). In Western blots, membrane integration can be followed by the presence of an 
additional, slower-migrating, and deglycosidase-sensitive band (Fig. 23A). 
 
 
Figure 22. Stx5 is not affected by the inhibition of deubiquitinases in TRC40D74E-transfected cells. 
(A) Immunofluorescence of Stx5 upon over-expression of different TRC40 variants in HeLa cells. Cells 
were treated for 6 h with 1 µM of the deubiquitinating enzyme (DUB) inhibitor b-AP15. Images of Stx5 
and TRC40 stained by indirect immunofluorescence are shown. (B) Western blot was performed 
detecting the indicated proteins. phospho-JNK was used as a positive control for DUB inhibition (Brnjic 
et al. 2014). Two biological replicates were analyzed. Scale bars: 20 µm. 
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Figure 22. Stx5 is not affected by the inhibition of deubiquitinases in TRC40_D74E-trans-
fected cells. (A),PPXQRIOXRUHVFHQFHRI6W[XSRQRYHUH[SUHVVL QRIGLIIHUHQW75&YDUL-
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Figure 23. Stx5 is cytosolic and its insertion into the ER membrane is reduced in TRC40D74E-
transfected cells. (A) Scheme of glycosylation pattern for a TA-protein C-terminally tagged with opsin. 
(B) Cell lysate fractionation from a stable cell line expressing C-terminally opsin-epitope tagged Stx5 
(Flp-In T-REx-293 Stx5-opsin) from a tetracycline-inducible promoter. The cells were transfected with 
either cmyc-TRC40wt or cmyc-TRC40D74E. The cells were induced with 1 µg/mL of tetracycline (Tet) for 
6 hours. Western blot was performed detecting the indicated proteins. (C) Whole-cell lysate from a Flp-
In T-REx-293 Stx5-opsin stable cell line. The cells were transfected with either cmyc-TRC40wt or cmyc-
TRC40D74E. Western blot was performed detecting the indicated proteins. Two biological replicates were 
analyzed. TA-protein model (PDB ID: 2LPF). 
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In order to biochemically investigate whether Stx5 is accumulated in the cytosol, as 
predicted by its apparently cytoplasmic localization observed by IF, I transfected the 
Stx5-opsin (Stx5-op) stable cell line with TRC40wt and TRC40D74E, and an empty vector 
as a control, performed a subcellular fractionation and analyzed the individual fractions 
by Western blot. Stx5 steady-state levels are higher in the cytosolic fraction of the 
TRC40D74E-transfected cells than in the ones obtained from cells transfected with the 
empty vector, confirming the observations obtained by microscopy (Fig. 13A, Fig. 
20B), and migrated as one band (Fig. 23B). At the same time, the fraction of 
glycosylated-Stx5 (Stx5-G) in membranes was reduced with respect to the total of Stx5 
(Stx5+Stx5-G) (Fig. 23B). This decrease in glycosylation was also observed in whole 
cell lysate (Fig. 23C), consistent with the interpretation that less Stx5 was inserted into 
the membrane. Stx5 might be trapped in the cytoplasm by the D74E mutant thereby 
reducing the amount of Stx5-opsin that can reach the ER-membrane. 
 
 
3.1.5. Cytosolic Stx5 is minimally glycosylated 
 
Western blot analysis of Stx5-opsin in the fractions obtained by subcellular 
fractionation revealed a faint band migrating above the Stx5 band, raising the question 
whether this band reflected glycosylation. To test this hypothesis, I transfected 
TRC40wt and TRC40D74E in the T-REx-293 stable cell line, I separated cytosol from 
membranes and treated both fractions with and without PNGase F. This enzyme is an 
amidase that catalyzes the cleavage of asparagine-linked (N-linked) oligosaccharides 
from glycoproteins.  
 
Inspection of the membranes fraction revealed that the upper band (Stx5-G) 
disappeared upon treatment with PNGase and collapsed into the band of Stx5 proving 
the N-glycosylated nature of Stx5 in membranes (Fig. 24A). In the cytosol, the slower 
migrating form of Stx5 was less abundant but still responsive to PNGase treatment 
indicating the presence of a small population of glycosylated Stx5 in the control cytosol 
(Fig. 24A). Nevertheless, the proportion of Stx5-G in the cytosol obtained from the 
D74E-transfected cells is much lower than that observed for the wt or the empty vector. 
This points to the fact that most of the Stx5 protein present in the cytosol is 
unglycosylated. 
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Figure 24. Stx5-op deglycosylation with PNGase F after cellular fractionation. (A) PNGase F 
treatment (10 U/µL) of cytosol and membrane lysates after cellular fractionation from a stable cell line 
expressing C-terminally opsin-epitope tagged Stx5 (Flip-In T-REx-293 Stx5-opsin) from a tetracycline-
inducible promoter. The cells were transfected with either cmyc-TRC40wt or cmyc-TRC40D74E. The cells 
were induced with 1 µg/mL of tetracycline (Tet) for 6 hours. Western blot was performed and it was blot 
for the indicated proteins. Two biological replicates were analyzed. 
 
 
3.1.6. TRC40D74E and Stx5 interact in cytosol 
 
Stx5 was found to be enriched in the cytosol upon over-expression of the D74E mutant 
(Fig. 23B) and at the same time decreased in the membranes (Fig. 23B). The 
glycosylated fraction of Stx5 was reduced under those conditions (Fig. 24A). Taken 
together, these findings might indicate that TRC40D74E interacts with Stx5 in the cytosol 
and acts as a trap mutant keeping it there instead of allowing its handover to the TRC 
receptor followed by membrane insertion. Therefore, it was important to determine 
whether TRC40D74E and Stx5 interact in the cytosol. In order to test this, I transfected 
an empty vector, TRC40wt, TRC40D74E into the Stx5-opsin stable cell line and carried 
out a co-immunoprecipitation targeting both of the proteins: Stx5 and TRC40. Purified 
IgG from rabbit was used as a control for the specificity of the antibodies recognizing 
the target proteins. The experiment yielded the following results: 
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First, TRC40D74E was co-immunoprecipitated with Stx5 more than four-fold compared 
to TRC40wt (Fig. 25A) as determined by Western blot analysis of the 
immunoprecipitates. This is consistent and correlates with my previous IF analysis: 
overexpression of TRC40wt partially affects the subcellular localization of Stx5 (Fig. 
13A) whereas over-expression of TRC40D74E drastically affects Stx5 which is now 
observed in a completely cytoplasmic staining pattern (Fig. 13A) and can be washed 
out from semi-permeabilized cells (Fig. 20B). TRC40 was not the only protein co-
immunoprecipitated with Stx5. BAG6 was also enriched with Stx5, which suggests that 
is part of a complex formed between Stx5 and TRC40D74E in the cytosol. This would 
indicate that either the TRC pre-targeting complex or a chaperone scaffold might 
accumulate with TRC40D74E. In contrast, BAG6 was absent from the immunoprecipitate 
when Stx5 was immunoprecipitated from cells over-expressing TRC40wt.  
 
Second, Stx5 was co-immunoprecipitated with TRC40 in the reverse 
immunoprecipitation (anti-TRC40) (Fig. 25A). Western blot analysis using both, anti-
Stx5 and anti-Opsin, antibodies demonstrated the presence of Stx5-opsin in the 
immunoprecipitates. This confirms the presence of a complex containing Stx5 and 
TRC40 independently of the antibody used for immunoprecipitation. To create a 
biogenetic pulse of newly synthesized Stx5, cells were first transfected and Stx5-opsin 
expression was induced 6 h before harvesting the cells at a time point of 48 h after 
transfection. Thus, Stx5-opsin was induced in the presence of high levels of TRC40wt 
or TRC40D74E. Detection of Stx5-opsin via the anti-opsin antibody enables a 
comparison between endogenous Stx5 present before the transfection and Stx5-opsin 
expressed in the presence of high TRC40 levels. More Stx5-opsin was co-
immunoprecipitated with TRC40D74E than with TRC40wt (Fig. 25A). This finding 
supports the notion that Stx5 might be trapped by TRC40D74E just after the protein is 
synthesized. This trapping would then prevent the insertion into the ER-membrane and 
keep Stx5 soluble in the cytoplasm. 
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Figure 25. Co-immunoprecipitation shows Stx5, BAG6 and TRC40 in TRC40D74E-transfected cells 
together in cytosol. (A) Immunoprecipitation using a rabbit anti-Stx5 antibody and a rabbit anti-TRC40 
antibody from cytosol lysate after cellular fractionation from a stable cell line expressing C-terminally 
opsin-epitope tagged Stx5 (Flp-In T-REx-293 Stx5-opsin) from a tetracycline-inducible promoter. The 
cells were transfected with either cmyc-TRC40wt or cmyc-TRC40D74E. The cells were induced with 1 
µg/mL of tetracycline (Tet) for 6 hours. Western blot was performed and it was blot for the indicated 
proteins. Two biological replicates were analyzed. 
 
 
3.2. TA-protein dependence of the TRC pathway 
in vivo 
 
From an early characterization of the general requirements of TA-protein 
insertion (Kutay, Hartmann, and Rapoport 1993; Kutay et al. 1995; Masaki, Yamamoto, 
and Tashiro 1996; Honsho, Mitoma, and Ito 1998; Pedrazzini et al. 2000) it took a 
decade until the components of the GET pathway in yeast (Schuldiner et al. 2008) and 
the TRC pathway in mammals (Stefanovic and Hegde 2007; Mariappan et al. 2010; 
Leznicki et al. 2010; Vilardi, Lorenz, and Dobberstein 2011; Y. Yamamoto and 
Sakisaka 2012) were discovered. It was long assumed that TA-protein biogenesis 
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depended exclusively on the GET or TRC pathway (Mandon and Gilmore 2007; Mateja 
et al. 2009; Mariappan et al. 2010) although some studies indicated the possibility of 
other insertion pathways (Rabu et al. 2008; Rabu et al. 2009; Johnson, Powis, and 
High 2013). The GET pathway also entered cell biology textbooks (Alberts et al. 2014) 
as the pathway responsible for the insertion of TA-proteins. Recently, the point has 
been raised that the impairment of the TRC pathway and other insertion pathways, 
such the SND pathway (Aviram et al. 2016), differentially affects the spectra of TA-
proteins in vivo (Daniele et al. 2016; Lin et al. 2016; Norlin et al. 2016; Rivera-Monroy 
et al. 2016; Vogl et al. 2016; Casson et al. 2017; Haßdenteufel et al. 2017; Guna et al. 
2018). The same is true for the yeast GET pathway (Rivera-Monroy et al. 2016). 
Moreover, there are discrepancies between the in vitro and in vivo TRC-dependence 
reported results for some TA-proteins. Additionally, certain TA-proteins showed 
dependence on more than one insertion pathway. For instance Sec61b was shown to 
depend on the TRC pathway and the EMC pathway (Guna et al. 2018). Moreover, 
Pex15p, in contrast to the other peroxisomal TA-proteins in yeast, relies on the GET 
pathway for its insertion into a membrane (van der Zand, Braakman, and Tabak 2010). 
One differential parameter behind these observations could be the hydrophobicity of 
the transmembrane segment as pointed out in previous in vitro studies (Rao et al. 
2016; Guna et al. 2018; F. Wang et al. 2010; Costello, Castro, Camões, et al. 2017).  
 
First, the redundancy of TA-protein insertion pathways; second, the difficulty of 
correlating the in vitro results into in vivo; and finally, the fact that little is known about 
the fate of endogenous TA-proteins when the TRC pathway is impaired motivated me 
to study what happens to endogenous TA-proteins when knocking-down components 
of the pathway like TRC40, TRC40 in combination with the receptor or the scaffolding 
protein of the pre-targeting-complex BAG6. With this strategy I was able to assess the 
relevance of the TRC pathway in the stability of the TA-proteins integrated in an 
environment with other insertion and degradation mechanisms present. 
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3.2.1. TA-proteins show variable degrees of dependence on 
the TRC pathway impairment 
 
These experiments were performed in HeLa P4 cells and for the purpose of 
knocking-down the TRC pathway components small interference RNA (siRNA) was 
used with siRNA targeting luciferase as a control. I performed subcellular fractionations 
to separate cytosol and membranes. The purpose underlying this fractionation was to 
assess TA-protein steady-state levels that are actually inserted into the membranes. 
Small proportions of certain TA-proteins can be found in the cytosol adding noise to 
the analysis when using whole cell lysate (Larance et al. 2013). I performed a Western 
blot analysis on the fractions detecting different TA-proteins. This analysis revealed a 
diverse degree of dependence on the TRC pathway as several of the TA-proteins were 
affected by the combined knockdown of WRB and TRC40 (Fig. 26B). It was also 
striking that none of the TA-proteins analyzed were reduced upon BAG6 knockdown 
(Fig. 26B). Moreover, the components of the pathway seemed to be affected by the 
knockdown of other components of the same pathway (Fig. 26A). A more detailed 
analysis of these general conclusions will be presented in the following sections. 
  
 
3.2.2. WRB and CAML drop upon TRC40 knockdown 
 
The steady-state levels of the heterodimeric receptor of the TRC pathway, WRB 
and CAML, were decreased upon knockdown of TRC40 (Fig. 26B, Fig. 27B, Fig. 
27D). CAML was severely affected when WRB is down-regulated (Fig. 26B, Fig. 27D), 
which has already been described in the literature (Rivera-Monroy et al. 2016; Sara 
Francesca Colombo et al. 2016; Haßdenteufel et al. 2017). 
 
 
3.2.3. BAG6 is affected upon WRB/TRC40 knockdown 
 
Unexpectedly, BAG6 steady-state levels in the WRB and TRC40 knockdown-
cells were severely decreased (Fig. 26A, Fig. 27C) while they were unaffected upon 
the silencing of TRC40. 
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Figure 26. Tail-anchored proteins steady-state levels are altered upon knockdown of TRC40 or 
the TRC40 receptor. (A) Knock-down of TRC40, WRB/TRC40 or BAG6 performed in HeLa P4 cells. 
Cytosol and membrane fractions were analyzed for Western blot for the TRC-pathway components and 
GM130. (B) Knock-down of TRC40, WRB/TRC40 or BAG6 performed in HeLa P4 cells. Membrane 
fraction was analyzed for Western blot for different TA-proteins. Blot are representative of four 
independent knockdown experiments which are quantified in Fig. 27-32. 
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Figure 27. Quantification of the TRC-pathway components upon knockdown of TRC40, the 
TRC40 receptor or BAG6. (A) Quantification of TRC40 signal intensities from the blots performed in 
Fig. 26A. (B) Quantification of WRB signal intensities from the blots performed in Fig. 26B. (C) 
Quantification of BAG6 signal intensities from the blots performed in Fig. 26A. (D) Quantification of 
CAML signal intensities from the blots performed in Fig. 26B. Four biological replicates were analyzed. 
The graphs show the mean and the error bars represent standard error of the mean. * indicates a p-
value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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3.2.4. Steady-state levels of several TA-proteins decrease 
drastically upon WRB/TRC40 knockdown 
 
Interestingly, many TA-proteins showed a diverse degree of dependence on the 
TRC pathway. Several were altered upon the knockdown of WRB and TRC40 (Fig. 
26B). The simultaneous loss of the receptor (both WRB and CAML are drastically 
decreased, Fig. 27B and Fig. 27D) and TRC40 affected the steady-state levels of an 
overlapping yet distinct set of TA-proteins.  
 
Stx5 was the most affected TA-protein (Fig. 28A) along with USE1 (Fig. 29A), Stx6 
(Fig. 28B) and Sec22b (Fig. 30C). Stx5’s strong dependence on the TRC pathway has 
been previously described (Rivera-Monroy et al. 2016; Norlin et al. 2016; Casson et al. 
2017; Norlin, Parekh, and Edlund 2018). Therefore, it is known to be a bona fide 
substrate of the TRC pathway. Stx5 showed a reduction of 88% at the steady-state 
level in the membrane fraction (compared to 50% reduction in whole cell lysate, 
(Rivera-Monroy et al. 2016)) in the combined knockdown of WRB and TRC40. Upon 
TRC40 knockdown steady-state levels were reduced by 58% with no effects on the 
steady-state levels when BAG6 was down-regulated (Fig. 28A). The vesicle transport 
protein USE1 is a SNARE protein believed to be involved in the retrograde transport 
from the Golgi apparatus to the ER (Dilcher et al. 2003). Steady-state levels of USE1 
were severely decreased to 18% (Fig. 29A). Similarly, Stx6, a Golgi-resident protein 
involved in vesicular traffic, showed a 75% reduction at the steady-state level (Fig. 
28B). Sec22b, an ER-resident SNARE protein, reported to be involved in anterograde 
and retrograde transport (Yiting Liu and Barlowe 2002; Burri et al. 2003), showed a 
reduction at the steady-state level of around 73% (Fig. 30C). The Ubiquitin-conjugating 
enzyme E2 J1 (UBE2J1), an ER-resident TA-protein involved in ERAD, showed a 
decrease of 64% in comparison to the control cells (Fig. 29C). VAPB is an ER-resident 
protein involved in linking the ER to other organelles (Costello, Castro, Hacker, et al. 
2017; Hua et al. 2017; Gomez-Suaga et al. 2017; Dong et al. 2016) and in lipid 
trafficking, VAPB was found to be decreased to 59% at the steady-state level (Fig. 
29D).  
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Figure 28. Quantification of a panel of tail-anchored proteins tested upon knockdown of TRC40, 
the TRC40 receptor or BAG6. (A) Quantification of Stx5 signal intensities from the blots performed in 
Fig. 26B. (B) Quantification of Stx6 signal intensities from the blots performed in Fig. 26B. (C) 
Quantification of Stx1 signal intensities from the blots performed in Fig. 26B. (D) Quantification of Stx8 
signal intensities from the blots performed in Fig. 26B. Four biological replicates were analyzed. The 
graphs show the mean and the error bars represent standard error of the mean. * indicates a p-value < 
0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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Figure 28. Quantification of a panel of tail-anchored proteins tested upon knockdown of 
TRC40, the TRC40 receptor or BAG6. (A) Quantification of Stx5 signal intensities from the blots 
performed in Fig26B. (B) Quantification of Stx6 signal intensities from the blots performed in 
Fig26B. (C) Quantification of Stx1 signal intensities from the blots performed in Fig26B. (D) Quanti-
fication of Stx8 signal intensities from the blots performed in Fig26B. Four biological replicates were 
analysed. The graphs show the mean and the error bars represent standard error of the mean. * 
indicates a p-value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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Figure 29. Quantification of the tail-anchored proteins tested upon knockdown of TRC40, the 
TRC40 receptor or BAG6. (A) Quantification of USE1 signal intensities from the blots performed in Fig. 
26B. (B) Quantification of EMD signal intensities from the blots performed in Fig. 26B. (C) Quantification 
of UBE2J1 signal intensities from the blots performed in Fig. 26B. (D) Quantification of VAPB signal 
intensities from the blots performed in Fig. 26B. Four biological replicates were analyzed. The graphs 
show the mean and the error bars represent standard error of the mean. * indicates a p-value < 0.05; ** 
a p-value < 0.05; *** a p-value < 0.001. 
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Figure 29. Quantification of the tail-anchored proteins tested upon knockdown of TRC40, 
the TRC40 receptor or BAG6. (A) Quantification of USE1 signal intensities from the blots 
performed in Fig26B. (B) Quantification of EMD signal intensiti s from the blots performed in 
Fig26B. (C) Quantification of UBE2J1 signal intensities from the blots performed in Fig26B. (D) 
Quantification of VAPB signal intensities from the blots performed in Fig26B. Four biological repli-
cates were analysed. The graphs show the mean and the error bars represent standard error of the 
mean. * indicates a p-value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001.
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Figure 30. Quantification of a panel of tail-anchored proteins tested upon knockdown of TRC40, 
the TRC40 receptor or BAG6 plus GM130. (A) Quantification of Vti1a signal intensities from the blots 
performed in Fig. 26B. (B) Quantification of VAPA signal intensities from the blots performed in Fig. 
26B. (C) Quantification of Sec22b signal intensities from the blots performed in Fig. 26B. (D) 
Quantification of GM130 signal intensities from the blots performed in Fig. 26A. Four biological 
replicates were analyzed. The graphs show the mean and the error bars represent standard error of the 
mean. * indicates a p-value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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Figure 30. Quantification of a panel of tail-anchored proteins tested upon knockdown of 
TRC40, the TRC40 receptor or BAG6 plus GM130. (A) Quantification of Vti1a signal intensities 
from the blots performed in Fig26B. (B) Quantification of VAPA signal intensities from the blots 
performed in Fig26B. (C) Quantification of Sec22b signal intensities from the blots performed in 
Fig26B. (D) Quantification of GM130 signal intensities from the blot performed in Fig26A. Four 
biological replicates were analysed. The graphs show the mean and the error bars represent stand-
ard error of the mean. * indicates a p-value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001.
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EMD is a protein of the inner nuclear membrane and is also localized at the ER 
(Manilal, Nguyen, and Morris 1998; Pfaff et al. 2016). It showed a decrease of 56% 
(Fig. 29B). EMD was already reported to be a substrate of the TRC pathway (Pfaff et 
al. 2016) and is known to be affected by the lack of the TRC receptor (Rivera-Monroy 
et al. 2016). Stx8 is a SNARE protein preferentially located at early endosomes, but 
also in late endosomes (Prekeris et al. 1999; Subramaniam et al. 2000; Kazuo Kasai 
et al. 2008). Stx8 steady-state levels were reduced 62% in the combined WRB/TRC40-
knockdown cells compared to the siLuc control cells (Fig. 28D). Stx1 is a SNARE 
protein involved in the fusion between vesicles and the plasma membrane (Bennett, 
Calakos, and Scheller 1992; Söllner et al. 1993). Stx1 showed a reduction by 59% at 
the steady-state levels upon combined WRB/TRC40 knockdown compared to the 
control cells (Fig. 28C). Two other TA-proteins displayed a milder decrease in the 
amount of protein at the steady-state: VAPA and Vti1a. VAPA is an ER-resident protein 
that shares similarity with VAPB and is also involved in ER contact sites and sterol 
trafficking (Wyles, McMaster, and Ridgway 2002; Dong et al. 2016; Hua et al. 2017). 
VAPA showed a reduction of around 40% at steady-state level (Fig. 30B). Finally, 
Vti1a is a SNARE protein involved in the traffic between early/late endosomes and 
trans-Golgi network (TGN) (Mallard et al. 2002; Brandhorst et al. 2006; Ganley, 
Espinosa, and Pfeffer 2008) and upon the knockdown of WRB and TRC40 a 35% 
reduction at steady-state level was observed (Fig. 30A). 
 
The peripheral membrane component of the cis-Golgi, GM130, used as a control in 
the present study, was not altered upon the knockdown of the TRC pathway 
components tested in this study (Fig. 30D). 
 
 
3.2.5. Stx5, UBE2J1 and VAPB are also affected by TRC40 
knockdown 
 
In addition to the previous results, there were some TA-proteins also altered by 
the single knockdown of TRC40. Stx5 and UBE2J1 had showed a reduction by 60% 
at the steady-state level (Fig. 28A, Fig. 29C). Thus, the reduction of UBE2J1 was quite 
similar to the one observed upon combined WRB/TRC40 knockdown. Yet for Stx5 the 
3.Results 
 
 
 
108 
effect on its steady-state levels was less pronounced when comparing the TRC40 
single to the WRB/TRC40 double knockdown. VAPB, like Stx5, had a reduction of 
around 30% that was less than that observed for the WRB/TRC40 down-regulation 
(Fig. 29D). The rest of the analyzed TA-proteins remained unchanged upon the TRC40 
knockdown. 
 
Taken together, the majority of the TA-proteins (11 out of 17) tested in this study were 
affected by the knockdown of TRC40 plus the TRC receptor and a small subset of 
them (3 out of those 11) were also affected by the knockdown of just TRC40. 
 
 
3.2.6. Stx18, GOSR2 and UBE2J1 increase upon BAG6 
knockdown 
 
Most of the TA-proteins tested in this study did not show any change in their 
steady-state levels upon BAG6 knockdown. However, three TA-proteins showed a 
marked increase upon the loss of BAG6. UBE2J1, in contrast to the effect seen for the 
TRC40 and the WRB/TRC40 knockdown, showed a 2-fold increase upon BAG6 
knockdown at the steady-state level (Fig. 29C). A similar behavior was found for Stx18 
which had an increase higher than 2-fold at the steady-state level (Fig. 31A). Stx18 is 
a SNARE protein involved in Golgi-to-ER retrograde transport (Hatsuzawa et al. 2000; 
Hirose et al. 2004). GOSR2 was increased by 70% compared to the control cells (Fig. 
31B). GOSR2 is a SNARE protein involved in ER-to-Golgi anterograde transport 
(Jesse C. Hay et al. 1997; J C Hay et al. 1998) and in intra-Golgi transport (Lowe et al. 
1997). 
 
 
3.2.7. Several TA-proteins showed no variation at the 
steady-state level when TRC40 and WRB/TRC40 were 
impaired 
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There was a set of TA-proteins that remained unaltered upon the knockdown of 
TRC40 or TRC40 combined with WRB. Two of them, Stx18 and GOSR2, showed no 
reaction to these knockdowns but they had an increase at steady-state level upon 
BAG6 knockdown (Fig. 31A, Fig. 31B).  
 
PTP1B is an ER enzyme member of the protein tyrosine phosphatase family and it has 
been related to ER stress signaling (Gu et al. 2004; Krishnan et al. 2011). Vti1b is a 
SNARE protein that mediates the vesicle homotypic fusion of late endosomes and it is 
also involved in the heterotypic fusion of late endosomes with lysosomes (Antonin et 
al. 2000; Pryor et al. 2004; Itakura, Kishi-Itakura, and Mizushima 2012). Sec61b is a 
subunit of the ER-resident Sec61 translocon (Meyer, Krause, and Dobberstein 1982; 
Görlich et al. 1992). SQS is an enzyme localized at the ER that is involved in lanosterol 
biosynthesis, which is the first step in sterol biosynthesis (Ourisson and Nakatani 1994; 
Pandit et al. 2000). None of these six TA-proteins are affected upon TRC40 or 
WRB/TRC40 knockdown (Fig. 31, Fig. 32), contrasting to those eleven that were 
severely affected. 
 
 
Figure 31. Quantification of the tail-anchored proteins tested upon knockdown of TRC40, the 
TRC40 receptor or BAG6. (A) Quantification of Stx18 signal intensities from the blots performed in Fig. 
26B. (B) Quantification of GOSR2 signal intensities from the blots performed in Fig. 26B. Four biological 
replicates were analyzed. The graphs show the mean and the error bars represent standard error of the 
mean. * indicates a p-value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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Figure 31. Quantification of the tail-anchored proteins tested upon knockdown of TRC40, 
the TRC40 receptor or BAG6. (A) Quantification of Stx18 signal intensities from the blots 
performed in Fig26B. (B) Quantification of GOSR2 signal intensities from the blots performed in 
Fig26B. Four biological replicates were analysed. The graphs show the mean and the error bars 
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Figure 32. Quantification of a panel of tail-anchored proteins tested upon knockdown of TRC40, 
the TRC40 receptor or BAG6. (A) Quantification of PTP1B signal intensities from the blots performed 
in Fig. 26B. (B) Quantification of Vti1b signal intensities from the blots performed in Fig. 26B. (C) 
Quantification of Sec61β signal intensities from the blots performed in Fig. 26B. (D) Quantification of 
SQS signal intensities from the blots performed in Fig. 26B. Four biological replicates were analyzed. 
The graphs show the mean and the error bars represent standard error of the mean. * indicates a p-
value < 0.05; ** a p-value < 0.05; *** a p-value < 0.001. 
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TRC40, the TRC40 receptor or BAG6. (A) Quantification of PTP1B signal intensities from the 
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3.2.8. TRC pathway-dependence of the TA-proteins and the 
hydrophobicity of the transmembrane segments 
 
Since the first studies addressing the TA-proteins were conducted, one of the 
main questions has been how they are targeted to different organelles. There have 
been many factors taken into consideration: TMD length (Isenmann et al. 1998; 
Pedrazzini et al. 2000; Bulbarelli et al. 2002; Borgese, Brambillasca, and Colombo 
2007), C-terminal tail length and charge (Elgersma et al. 1997; Kuroda et al. 1998; 
Mullen and Trelease 2000; Horie et al. 2002; Borgese, Brambillasca, and Colombo 
2007; Yagita, Hiromasa, and Fujiki 2013; Costello, Castro, Camões, et al. 2017), 
membrane composition (Borgese, Brambillasca, and Colombo 2007), the cytoplasmic 
domain (Linstedt et al. 1995; Misumi et al. 2001; Joglekar et al. 2003) and 
hydrophobicity of the transmembrane segment (Borgese, Colombo, and Pedrazzini 
2003; Borgese, Brambillasca, and Colombo 2007). In fact, hydrophobicity has always 
been considered a key factor for organelle targeting of the TA-proteins. Other in vitro 
and in vivo studies have also studied this physicochemical property (Rao et al. 2016; 
Guna et al. 2018; F. Wang et al. 2010; Costello, Castro, Camões, et al. 2017). In fact, 
two different bioinformatic approaches were implemented in order to predict yeast and 
human TA-proteins (Beilharz et al. 2003; Kalbfleisch, Cambon, and Wattenberg 2007). 
In both analyses, hydrophobicity of the transmembrane segment has been taken into 
consideration. Multiple hydrophobicity scales have been used in order to establish the 
relative hydrophobicity of each amino acid residue.   
 
It has long been proposed that the hydrophobicity of mitochondria and the secretory 
pathway-targeted TA-proteins differ (Borgese et al. 2001; Bulbarelli et al. 2002; 
Borgese, Colombo, and Pedrazzini 2003; Borgese, Brambillasca, and Colombo 2007). 
It is also a long-standing assumption that a TA-protein of the secretory pathway, 
including Golgi and plasma membrane, are inserted into the ER membrane. It is an 
important hypothesis that Golgi proteins use TMD length as trafficking information 
(Munro 1995; Sharpe, Stevens, and Munro 2010). From this emerges the idea that 
secretory pathway TA-proteins will differ in their total hydrophobicity and therefore may 
need different targeting machinery. 
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In a recent study, mechanistic interpretations of the overlapping targeting activities of 
the TRC or the EMC pathway have been proposed (Guna et al. 2018). The authors 
claim that hydrophobicity plays a key role in the pathway-dependence. Sec61b has a 
moderate hydrophobicity and they suggest that, due to its dependence on both, the 
TRC and the EMC pathway, it marks the approximate point of substrate overlap 
between these pathways.  
 
I set out to test how the data obtained for 17 TA-proteins after TRC-pathway 
knockdown (Fig. 26-32) correlated with the most commonly used hydrophobicity 
scales: transmembrane tendency (G. Zhao and London 2006), Kyte & Doolittle (Kyte 
and Doolittle 1982), apparent free-energy (DGapp) (Hessa et al. 2007) and grand 
average of hydropathicity (GRAVY) (Kyte and Doolittle 1982). I was interested in the 
hydrophobicity behavior of all the known TA-proteins and how representative the 
subset of TA-proteins tested was. Based on a good correlation between hydrophobicity 
and TRC-dependence my results would help to implicate new TRC-pathway 
substrates. Therefore, I updated and systematically refined a list of predicted human 
TA-proteins previously published (Kalbfleisch, Cambon, and Wattenberg 2007) (Table 
17) and calculated the hydrophobicity scores for each TMD according to the different 
scales. Next, I plotted the result in dot-plots grouping the TA-proteins by subcellular 
localization and then highlighting the TA-proteins affected by the knockdown of 
WRB/TRC40. The following table lists the predicted human TA-proteins, predicted 
TMDs and the calculated hydrophobicity scores (Table 17). 
 
First, I plotted the TMD hydrophobicity scores for the transmembrane tendency scale 
(G. Zhao and London 2006) and clustered the TA-proteins according to the reported 
subcellular localization (Fig. 33A). The TMDs of the mitochondrial TA-proteins 
presented the lowest overall hydrophobicity scores. In contrast, those of ER, Golgi and 
nucleus showed a higher score according to this scale. This observation confirms the 
notion that the biggest divide with respect to transmembrane segment hydrophobicity 
exists between mitochondrial TA-proteins and those of the secretory pathway. Using 
this dot-plot as a template, I marked the proteins tested in this study regarding their 
sensitivity to a combined WRB/TRC40 knockdown (Fig. 33B). As a general trend, the 
TA-proteins sensitive to the knockdown had more hydrophobic TMDs. Moreover, the 
majority of the TA-proteins insensitive to the loss of WRB/TRC40 presented a  
113
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Table 17. Tail-anchored protein list. Modification and up to date list of TA-proteins based on (Kalbfleisch, Cambon, and Wattenberg 2007). Transmembrane tendency score accord-
ing to Zhao and London (G. Zhao and London 2006), Kyte and Doolittle scores (Kyte and Doolittle 1982) and apparent free-energy (ΔGapp) (Hessa et al. 2007) were calculated for all 
the TA-proteins of the list. The transmembrane domain region was predicted using the TMHMM algorithm (Krogh et al. 2001) or UniProt prediction if the TMHMM was missing. The 
list was cleared of proteins predicted to have more than one TMD and/or predicted to have a signal peptide.
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Figure 33. Transmembrane tendency of the TA-proteins used in this study. Dot-plots of the TMD 
hydrophobicity score according to the transmembrane tendency scale (G. Zhao and London 2006) for 
all the TA-proteins shown in Table 17. (A) The TA-proteins TMD were clustered by subcellular 
localization. The transmembrane domain region was predicted using the TMHMM algorithm (Krogh et 
al. 2001) or UniProt prediction if TMHMM prediction was missing. (B) TA-proteins affected due to the 
knockdown of TRC40 and WRB seen in Fig. 26-32 using as a base the dot-plot of (A). TA-proteins 
sensitive to the knockdown are highlighted in green and the ones not affected are colored in red. The 
dotted line in the dot-plot represents the Sec61β TMD hydrophobicity score, marking the approximate 
overlap between the EMC pathway and the TRC pathway as proposed in a recent paper (Guna et al. 
2018). Subsets of TA-proteins of the secretory pathway is highlighted. Solid line indicates that all belong 
to the secretory pathway, dashed line indicates that some of them belong to.  
0
10
20
30
40
TA-proteins
H
yd
ro
ph
ob
oc
ity
 (A
U
)
Transmembrane tendency
FDFT1
SEC61B
VAPA
GOSR2
STX5
STX6
VTI1A EMD
VTI1B
STX1B
STX1A
0
10
20
30
40
TA-proteins
H
yd
ro
ph
ob
oc
ity
 (A
U
)
Transmembrane tendency
Not reported localization
Golgi apparatus
Lysosomes
Plasma membrane
Nucleus
Endoplasmic reticulum
Mitochondria
Peroxisomes
Endosomes
Figure 33. Transmembrane tendency of the TA-proteins used in this study. Dot-plots of the 
TMD hydrophobicity score according to the transmembrane tendency scale (Zhao and London 
2006) for all the TA-proteins shown in Table 1. (A) The TA-proteins TMD were clustered by subce-
lullar localization. The transmembr e domain region was predicted using the T HMM algorithm 
(Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. (B) TA-proteins affect-
ed due to the knockdown of TRC40 and WRB seen in Fig. 26-32 using as a base the dot-plot of 
(A). TA-proteins sensitive to th  k ockdown are highlighted in green and the ones not affected are 
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pap r (Guna et al. 2017).
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moderately hydrophobic TMD. However, three TA-proteins (UBE2J1, VAPA and 
Stx1B) presented a TMD with similar hydrophobicity to those not affected, VAPB and 
Sec22b being very similar. After plotting the TMD hydrophobicity scores according to 
this scale there was no a clear distinction between TA-proteins affected by the 
combined knockdown and those that were unaffected. Broadly, the more hydrophobic 
the TMD was the more TRC-dependence was observed. 
 
Second, I plotted TMD hydrophobicity scores according to the Kyte and Doolittle scale 
(Kyte and Doolittle 1982) and clustered the TA-proteins according to their reported 
subcellular localization (Fig. 34A). The overall outcome was similar but, in this case, 
the TMD of ER TA-proteins had a more similar hydrophobicity to the mitochondrial 
ones. Regarding the TA-proteins affected, all but one (Sec22b) showed more 
hydrophobic TMDs than Sec61β. Besides, all but one (Vti1b) of the non-affected TA-
proteins had less hydrophobic TMDs than Sec61β (Fig. 34B). This scale showed a 
better separation between the two groups where the proteins whose TMD presented 
a similar hydrophobicity to the one of Sec61β were borderline between being affected 
or unaffected. 
 
Third, I used the so-called grand average of hydropathicity (GRAVY) that is based on 
the Kyte and Doolittle scores averaged by the length of the TMD giving a relative 
hydrophobicity score and clustered the TA-proteins according to subcellular 
localization (Fig. 35A). The dot-plot was very similar to the one shown for the 
transmembrane tendency (Fig. 33A) where the ER, Golgi and nucleus TA-proteins 
presented a more hydrophobic TMD whereas mitochondrial TA-proteins had a less 
hydrophobic one. The analysis of the TA-protein TMD hydrophobicity showed two 
distinct populations with the ones affected by a combined WRB/TRC40 knockdown 
showing more hydrophobic TMDs and the unaffected ones coming out with scores 
similar to the TMD of Sec61β and lower. However, there was no complete separation 
since Sec22b came out close to the TMD of TA-proteins that remained unchanged 
such as Sec61β, GOSR2 and Vti1b (Fig. 35B).  
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Figure 34. Transmembrane domain hydrophobicity of the TA-proteins used in this study. Dot-
plots of the TMD hydrophobicity score according to the hydrophobicity scale developed by (Kyte and 
Doolittle 1982) for all the TA-proteins shown in Table 17. (A) The TA-proteins TMD were clustered by 
subcellular localization. The transmembrane domain region was predicted using the TMHMM algorithm 
(Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. (B) TA-proteins affected 
due to the knockdown of TRC40 and WRB seen in Fig. 26-32 using as a base the dot-plot of (A). TA-
proteins sensitive to the knockdown are highlighted in green and the ones not affected are colored in 
red. The dotted line in the dot-plot represents the Sec61β TMD hydrophobicity score, marking the 
approximate overlap between the EMC pathway and the TRC pathway as proposed in a recent paper 
(Guna et al. 2018). Subsets of TA-proteins of the secretory pathway is highlighted. Solid line indicates 
that all belong to the secretory pathway, dashed line indicates that some of them belong to. 
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Figure 34. Transmembrane domain hydrophobicity of the TA-proteins used in this study. 
Dot-plots of the TMD hydrophobicity score according to the hydrophobicity scale developed by 
(Kyte and Doolittle 1982) for all the TA-proteins shown in Table 1. ( ) The TA-proteins TMD wer  
clustered by subcelullar localization. The transmembrane domain region was predicted using the 
TMHMM algorithm (Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. (B) 
TA-proteins affected due to th  knockdown of TRC40 and WRB seen in Fi . 26-32 using as a b s  
the dot-plot of (A). TA-proteins sensitive to the knockdown are highlighted in green and the ones 
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marking the approximate overlap between the EMC pathway and the TRC pathway as proposed in 
a recent paper (Guna et al. 2017).
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Figure 35. Transmembrane domain relative hydrophobicity of the TA-proteins used in this study. 
Dot-plots of the TMD hydrophobicity score according to the hydrophobicity scale developed by (Kyte 
and Doolittle 1982) divided by the length of the TMD, for obtaining the GRAVY score, for all the TA-
proteins shown in Table 17. (A) The TA-proteins TMD were clustered by subcellular localization. The 
transmembrane domain region was predicted using the TMHMM algorithm (Krogh et al. 2001) or UniProt 
prediction if TMHMM prediction was missing. (B) TA-proteins affected due to the knockdown of TRC40 
and WRB seen in Fig. 26-32 using as a base the dot-plot of (A). TA-proteins sensitive to the knockdown 
are highlighted in green and the ones not affected are colored in red. The dotted line in the dot-plot 
represents the Sec61β TMD hydrophobicity score, marking the approximate overlap between the EMC 
pathway and the TRC pathway as proposed in a recent paper (Guna et al. 2018). Subsets of TA-proteins 
of the secretory pathway is highlighted. Solid line indicates that all belong to the secretory pathway, 
dashed line indicates that some of them belong to. 
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Finally, I used another method for calculating the apparent free-energy (ΔGapp) of the 
TA-protein TMDs (Hessa et al. 2007). The lower the ΔGapp of a TMD is, the more it 
mirrors the physical properties of the membrane and vice versa. I plotted the results 
and grouped them by subcellular localization. The TMD of ER-, Golgi- and nucleus-
resident TA-proteins had a lower apparent free-energy whereas the mitochondrial and 
peroxisomal ones presented higher values (Fig. 36A). In general, the majority of the 
TA-proteins affected by combined WRB/TRC40 down-regulation showed very low 
ΔGapp values in contrast to higher values for those not affected. However, two of the 
unaffected TA-proteins had low ΔGapp values and appeared mixed with the affected 
ones (Fig. 36B). Even if a general tendency was present the two populations were not 
clearly separated. 
 
In summary, most of the TA-protein tested upon knockdown of TRC pathway 
components showed a strong reduction in response to WRB/TRC40 knockdown. In 
addition, some displayed an increase upon BAG6 knockdown. Interestingly, the TRC 
pathway components were destabilized in the absence of other proteins of the 
pathway. Using the GRAVY score of the TMDs of TA-proteins tested upon combined 
WRB/TRC40 knockdown, a clear separation between affected and unaffected TA-
proteins was observed. These findings shed light on some aspects of how the multiple 
targeting pathways cater to different TA-proteins. 
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Figure 36. Transmembrane domain apparent free-energy (ΔGapp) of the TA-proteins used in this 
study. Dot-plots of the apparent free-energy (Hessa et al. 2007) of the TMD from all the TA-proteins 
shown in Table 17 calculated via the ΔG prediction server (http://dgpred.cbr.su.se). (A) The TA-proteins 
TMD were clustered by subcellular localization. The transmembrane domain region was predicted using 
the TMHMM algorithm (Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. (B) 
TA-proteins affected due to the knockdown of TRC40 and WRB seen in Fig. 26-32 using as a base the 
dot-plot of (A). TA-proteins sensitive to the knockdown are highlighted in green and the ones not affected 
are colored in red. The dotted line in the dot-plot represents the Sec61β TMD hydrophobicity score, 
marking the approximate overlap between the EMC pathway and the TRC pathway as proposed in a 
recent paper (Guna et al. 2018). Subsets of TA-proteins of the secretory pathway is highlighted. Solid 
line indicates that all belong to the secretory pathway, dashed line indicates that some of them belong 
to. 
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3.3. The fate of BAG6 is tightly coupled to the 
TRC pathway 
 
BAG6 is the central component of the pre-targeting complex of the TRC 
pathway (Leznicki et al. 2010; Mariappan et al. 2010). It is the scaffolding protein in the 
heterotrimeric BAG6 complex (Mock et al. 2015; Mock et al. 2017), also including 
TRC35 and UBL4A, that facilitates the hand off of the TA-protein to TRC40.  
 
I previously showed the influence of the WRB/TRC40 knockdown on the steady-state 
levels of BAG6 in HeLa cells. Furthermore, I also showed that the stability of TRC-
pathway components depends on multiple components of the pathway: WRB or CAML 
knockdown mutually decreases the respective steady-state protein levels and TRC40 
knockdown also decreases the protein levels of the heterodimeric receptor, WRB and 
CAML. The relationship between TRC40 and BAG6 has not been extensively studied 
before. Thus, I set out to explore the effects of TRC40 on the key player of the pre-
targeting complex, BAG6. 
 
3.3.1. The absence of TRC40 affects the nuclear shuttling of 
BAG6 
 
It has been reported that BAG6 changes its subcellular localization when 
TRC35 or UBL4A, components of the heterotrimeric BAG6 complex, are absent (Q. 
Wang et al. 2011; Krenciute et al. 2013). Furthermore, BAG6 is involved in the quality 
control of mislocalized secretory and membrane proteins (MLPs) (Minami et al. 2010; 
Hessa et al. 2011; Leznicki and High 2012; Leznicki et al. 2013; Wunderley et al. 2014; 
Rodrigo-Brenni, Gutierrez, and Hegde 2014) and chaperoning translocated ERAD-
substrates (Q. Wang et al. 2011). TRC40 has also been related to different degradation 
processes since it has been reported to interact with BAG6 and ubiquitylated proteins 
(Baron et al. 2014). Moreover, the knockdown of either TRC40 or BAG6 leads to the 
accumulation of ubiquitinated proteins (Q. Wang et al. 2011; Akahane et al. 2013) and 
to defects in the assembly of the proteasome (Akahane et al. 2013; Sahara et al. 2014).  
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I tested for IF the specificity of custom-made BAG6 antibodies (Fig. 37A) as well as 
for Western blot (Fig. 37B) in cells transfected with a validated siRNA against BAG6. 
Then, I investigated the subcellular localization of BAG6 in the absence of TRC40. In 
order to monitor it, I used specific siRNA against TRC40 in HeLa cells. Following 
silencing, I performed an indirect immunofluorescence with an anti-BAG6 antibody to 
monitor the subcellular localization of BAG6. Strikingly, BAG6 changed its localization 
and showed a nuclear accumulation upon the loss of TRC40 (Fig. 38A). Quantification 
(Fig. 38B) allowed for an assessment of the statistical significance of this effect. 
Knockdown of TRC40 did not affect the steady-state levels of BAG6 (Fig. 38C) in 
agreement with what I found previously (Fig. 26A). Hence, absence of TRC40 alters 
the nucleo-cytoplasmic distribution of BAG6 without altering protein levels at the 
steady-state.  
 
 
Figure 37. Validation of the BAG6 antibodies for immunofluorescence and Western blot. (A) 
Validation of the BAG6 antibody used for immunofluorescence in HeLa cells (Fig. 38A, Fig. 38B) by 
siRNA-mediated down-regulation of BAG6. (B) Two different siRNAs for BAG6 were tested. Western 
blot was performed for the indicated proteins. Scale bars: 20 µm. 
 
3.3.2. The cytoplasmic localization of BAG6 can be rescued 
by TRC40 nucleotide-binding variants 
 
BAG6 localized to the nucleus in the absence of TRC40. I was interested in testing 
which domain of TRC40 was involved in keeping BAG6 cytoplasmic. For that purpose, 
I knocked-down TRC40 using siRNA in HeLa cells followed by transfection of 
siTRC40ins constructs carrying different mutations affecting the functional cycle of  
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Figure 38. Validation of the BAG6 antibodies for immunofluorescence and Western-blot. (A) 9DOLGD-
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Figure 38. Down-regulation of TRC40 affects the nuclear shuttling of BAG6 in HeLa cells. (A) 
Immunofluorescence detection of BAG6 upon silencing of TRC40 in HeLa cells. Images of BAG6 and 
Hsc70 stained by indirect immunofluorescence are shown. Cells were stimulated with 100 nM DEX, a 
glucocorticoid receptor agonist. (B) Scatter plot representing the nuclear-cytoplasmic ratio of BAG6 
upon silencing of TRC40. Each dot represents the fluorescence intensity of one cell. n= 78-104 cells 
are represented. The graphs show the mean and the error bars represent the standard deviation. * 
indicates a p-value < 0.05; ** a p-value < 0.05. Three biological replicates were analyzed. (C) Steady-
state levels of BAG6 upon knockdown of TRC40. Western blot was performed detecting the indicated 
proteins. Scale bars: 20 µm. 
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Figure 37. Down-regulation of TRC40 affects the nuclear shuttling of BAG6 in HeLa cells. (A) Immu-
nofluorescencent detection of BAG6 upon silencing of TRC40 in HeLa cells. Images of BAG6 and Hsc70 
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coid receptor agonist. (B) Scatter plot representing the nuclear-cytoplasmic ratio of BAG6 upon silencing of 
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graphs show the mean and the error bars represent the standard deviation. * indicates a p-value < 0.05; ** 
a p-value < 0.05. Three biological replicates were analysed. (C) Steady-state levels of BAG6 upon knock-
down of TRC40. Western blot was performed detecting the indicated proteins. Scale bars: 20 µm.
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TRC40. These constructs were insensitive to the TRC40 siRNA. Specifically, I 
transfected the following TRC40 constructs: TRC40wt, TRC40G46R that is a mutant in 
the Walker A motif that disrupts nucleotide binding (Shen et al. 2003; Baron et al. 
2014), TRC40D74E a mutant in the Switch I domain whose ATPase activity is strongly 
reduced, TRC40I193D that is a mutant that impairs TA-protein binding (Mateja et al. 
2009) and TRC40CC246,248SS that is mutant of the second CXC motif in TRC40 
conserved in yeast Get3. These cysteines are believed to be connected to the redox-
regulated chaperone activity of Get3 (Voth et al. 2014). 
 
TRC40wt rescued the BAG6 nucleo-cytoplasmic distribution (Fig. 39A). The presence 
of the TRC40wt shows BAG6 distributed more to the cytoplasm and less to the nucleus 
compared to the TRC40-knockdown cells. The rest of the TRC40 variants were able 
to restore the subcellular distribution of BAG6 with the exception of TRC40G46R (Fig. 
39A). Quantification of the results is shown in Fig. 39B. Therefore, nucleotide-binding 
of TRC40 appears to be relevant to the subcellular distribution of BAG6 whereas strong 
reductions in the ATPase activity or in TA-protein binding were compatible with keeping 
a proportion of BAG6 cytoplasmic.  
 
 
3.3.3. BAG6 steady-state levels are reduced in WRB 
knockout cardiomyocytes 
 
A mouse line with loxP sites integrated into the genome at positions flaking exon 
3 of the Wrb gene can be used to create tissue-specific WRB-knockout mouse models 
(Rivera-Monroy et al. 2016; Vogl et al. 2016). A cardiomyocyte-specific WRB knockout 
model enabled the characterization of the fate of a subset of TA-proteins and also the 
characterization of the steady-state levels of some of the proteins of the TRC pathway 
(Rivera-Monroy et al. 2016). Nevertheless, the characterization of BAG6 was still 
missing. I was able to show that the combined down-regulation of WRB/TRC40 in 
HeLa cells decreased the steady-state levels of BAG6 (Fig. 26A, Fig. 27C). Following 
up on this result, I tested whether BAG6 was affected in WRB-knockout isolated 
cardiomyocytes. Thus, I isolated cardiomyocytes from wt and knockout mice and 
checked the steady-state protein levels by Western blot. After analyzing the 
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corresponding blots, I found that BAG6 was strongly reduced at the steady-state level 
in WRB knockout isolated cardiomyocytes (Fig. 40A, Fig. 40B). The reduction was 
around 70% (Fig. 40B), which was a very similar decrease compared to the result 
upon WRB/TRC40 knockdown in HeLa cells (Fig. 27C). 
 
 
Figure 39. Most variants of TRC40 can rescue the subcellular localization of BAG6 upon down-
regulation of TRC40. (A) Immunofluorescence of BAG6 upon silencing of TRC40 and concomitant 
expression of different TRC40 variants in HeLa cells. Images of BAG6 and cmyc-TRC40 stained by 
indirect immunofluorescence are shown. (B) Quantification of immunofluorescent signal of BAG6 upon 
silencing of TRC40 and transfection of different TRC40 variants in HeLa cells. Images of BAG6 and 
cmyc-TRC40 stained by indirect immunofluorescence are shown. n= 22-60 cells. The graphs show the 
mean and the error bars represent the standard deviation. Two biological replicates were analyzed. 
Scale bars: 20 µm. 
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Figure 40. Protein steady-state levels of BAG6 are reduced in WRB-knockout cardiomyocytes. 
(A) BAG6 was analyzed by Western blot in WRB-knockout isolated cardiomyocytes. Cellular lysates 
were analyzed by Western blot detecting BAG6. (B) Quantification of BAG6 steady-state levels from 
blots in (A). Normalized against Na/K ATPase and then relative to the Cre- levels. Seven biological 
replicates were analyzed. The graphs show the mean and the error bars represent standard error of the 
mean. ** indicates a p-value < 0.05. 
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3.4. Investigation of a putative redox switch in 
TRC40 
 
Yeast Get3 functions, apart from TA-protein targeting, as a redox-regulated 
chaperone (Voth et al. 2014). Get3 shares features with Hsp33, a bacterial redox-
regulated chaperone (Jakob et al. 1999; Kumsta and Jakob 2009), such as a CXC-Xn-
CXXC motif that is the key of the redox switch of Hsp33 (Jakob et al. 1999; Voth et al. 
2014). Upon oxidation in vitro, Get3 undergoes structural rearrangements that bury the 
TA-binding groove, release the Zn2+ ion in the dimer interface and turn Get3 into an 
ATP-independent holdase. This conformational change is reversible once reducing 
conditions are restored and Zn2+ is present in the medium. Furthermore, the ATPase 
activity of Get3 is drastically reduced upon oxidation (Voth et al. 2014). Accordingly, 
Get3 in vivo colocalizes in foci with diverse chaperones under ATP-deprived 
conditions. Moreover, Get3 colocalizes with aggregates in glucose-deprived conditions 
(Powis et al. 2013). Almost nothing is known about the redox behavior of TRC40, which 
shares homology with yeast Get3. Another metazoan homolog plays a role in the 
sensitivity to oxidative agents like cisplatin and arsenite in C. elegans (Hemmingsson, 
Nöjd, et al. 2009; Hemmingsson et al. 2010). My aim was to further elucidate the redox 
behavior of TRC40 in vitro and explore the behavior of TRC40 under oxidative 
conditions in vivo in human cell lines. 
 
 
3.4.1. CXC and CXXC are conserved from Get3 to TRC40 
 
In order to investigate whether the CXC-Xn-CXXC motif present in yeast Get3 
was conserved in human TRC40, I aligned the two protein sequences. Get3 has seven 
cysteines in its sequence whereas TRC40 has eight. Five out of the seven are 
conserved from yeast Get3 to human TRC40 (in yellow). Four of these are present in 
the CXC-Xn-CXXC motif confirming the conservation of this motif (Fig. 41A). TRC40 
has an extra CXC motif (C53-X-C55) close to the N-terminus due to the appearance of 
a new cysteine (C53) not present in yeast Get3 (C36 from Get3 is aligned to C55 in 
TRC40). The presence of an extra CXC in TRC40 could increase cysteine reactivity. 
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C86 and C317 from yeast Get3 are not conserved in TRC40. Three non-conserved 
cysteines are present in TRC40 (in red): the aforementioned C53 plus C205 and C268 
(Fig. 41A). The conserved domains between yeast Get3 and TRC40 are highlighted 
in Fig. 6, Fig. 12A. 
 
 
Figure 41. Cysteine conservation after Get3 and TRC40 alignment. (A) Alignment of TRC40 and 
Get3 in different species indicating conserved (yellow) and non-conserved (red) cysteines. The 
sequences were aligned with Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/). The UniProt 
accession numbers have been provided in parentheses. 
 
 
3.4.2. Oxidation decreased TRC40 ATPase activity 
 
First, I purified recombinant TRC40 from E. coli. I purified a His-MBP-tagged 
version of TRC40 and cleaved the tag to obtain an untagged-TRC40 (Fig. 42A).  
 
To test the ATPase activity of purified TRC40 I applied a protocol to ensure control of 
the redox state. First, TRC40 was subjected to reduction and then to an oxidation step 
to fully oxidize TRC40. Next, I performed a NADH-coupled ATPase activity assay to 
elucidate the relative ATPase activity of the oxidized TRC40. Oxidation of TRC40 
resulted in a 50% reduction in ATPase activity compared to reduced TRC40 (Fig. 42B). 
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Figure 42. TRC40 shows similar in vitro redox behavior as yeast Get3. (A) Coomassie-stained 
SDS-PAGE gel coming from the purification of His-MBP-TRC40. (B) Effect of oxidation on the ATPase 
activity of TRC40. The reduced protein treated with 5 mM DTT (TRC40 reduced) was compared to the 
oxidized one treated with 2mM H2O2 and 50 µM Cu2+ (TRC40 oxidized) at 37°C. ATPase activity is 
normalized to the reduced state. (C) Redox state of TRC40 cysteines determining how many thiol groups 
are available before and after oxidation using the Ellman’s assay. At least three to four biological 
replicates were analyzed. The graphs show the mean and the error bars represent standard error of the 
mean. 
 
 
3.4.3. Recombinant TRC40 is not fully reduced after in vitro 
redox treatment 
 
To estimate the redox state of TRC40, I performed an Ellman’s assay to 
determine the free thiols (reduced cysteine thiols) in the recombinant reduced or 
oxidized TRC40. The reduced form of TRC40 contained four reduced cysteines 
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Figure 42. TRC40 shows similar in vitro redox behavior as yeast Get3. (A) Coomassie 
stained-SDS-PAGE gel coming from the purification of His-MBP-TRC40. (B) Effect of oxidation on the 
ATPase activity of TRC40. The reduced protein treated with 5 mM DTT (TRC40 reduced) was com-
pared to the oxidized one treated with 2mM H2O2 and 50 µM Cu
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activity is normalized to the reduced state. (C) Redox state of TRC40 cysteines determining how 
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four biological replicates were analysed. The graphs show the mean and the error bars represent 
standard error of the mean. 
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according to the Ellman’s assay, whereas the oxidized form of TRC40 contained one. 
Hence, three cysteines changed oxidation status between the two forms (Fig. 42C). 
The primary sequence of TRC40 contains eight cysteines (Fig. 41A), but only four of 
them could be detected in the reduced form after reduction of the protein (Fig. 42C) 
suggesting that this reduction treatment resulted in a partially oxidized instead of a fully 
reduced protein. 
 
 
Figure 43. TRC40 steady-state levels are not altered upon hypoxia. (A) TRC40 levels in conditions 
of normoxia, short and long hypoxia (94% N2, 5% CO2 and 1% O2). HIF-1 alpha was used as a positive 
marker for induced-hypoxia. Cellular lysates were analyzed for Western blot for TRC40. (B) 
Quantification of the TRC40 signal intensities for the different oxygen conditions from the blots 
performed in (A). (C) Quantification of the HIF-1 alpha signal intensities for the different oxygen 
conditions from the blots performed in (A). Four biological replicates were analyzed. The graphs show 
the mean and the error bars represent standard error of the mean. 
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3.4.4. TRC40 steady-state levels remained unaltered upon 
hypoxia 
 
I set out to assess whether TRC40 was oxidized by the high levels of oxygen 
under standard cell culture conditions. Therefore, I analyzed HeLa cells that underwent 
a hypoxic treatment (94% N2, 5% CO2 and 1% O2) for 6 h or 24 h. Western-blot analysis 
revealed no detectable changes of the TRC40 steady-state protein levels (Fig. 43A, 
Fig. 43B). 
 
 
3.5. Exploring the role of TRC40 in the steroid 
hormone-receptors chaperoning process 
 
Get3 was characterized as a redox-regulated chaperone (Voth et al. 2014) and 
it has been found to colocalize in foci with aggregates and chaperones (Powis et al. 
2013). Based on the high degree of conservation and the presence of the CXC-Xn-
CXXC motif I hypothesized that TRC40 may also act as a chaperone holdase upon 
oxidation. Yet, no physiological chaperone clients are known for TRC40. 
 
Recently, the cochaperone SGTA was proposed to be part of the cytosolic chaperoning 
of steroid-hormone receptors (SRs) (Paul et al. 2014). SGTA collaborates with the 
early maturation steps of the SRs and negatively regulates the activity of some of them, 
such as the glucocorticoid receptor (GR), androgen receptor and progesterone 
receptor (Paul et al. 2014). Moreover, the handover of a TA-protein from Sgt2, yeast 
homolog of SGTA, to Get3 seems to be isoenergetic, suggesting that the relative 
preference for hydrophobic substrates is very similar between Get3 and Sgt2 (Rao et 
al. 2016). Additionally, Sgt2 interacts with the same chaperones that Get3 was found 
to colocalize with (F. Wang et al. 2010; Powis et al. 2013). Based on these 
considerations, I hypothesized that the SRs could be potential TRC40 chaperone 
substrates. 
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Figure 44. β-galactosidase reporter assay for monitoring GR activity. The GR remains inactive in 
cytoplasm. In the presence of deoxycorticosterone (DOC, a GR agonist), the GR gets activated (1) and 
binds to the glucocorticoid response elements (GREs) present in the plasmid transformed into. This 
binding to the GREs upregulates the expression of the beta-galactosidase gene (lacZ) (2). β-
galactosidase hydrolyzes the provided non-fluorescent galactose analog Fluorescein-di-β-D-
galactopyranoside (FDG) which consists of two galactose monomers and a fluorescein. The reaction 
will be sequential: first hydrolyzing a galactose monomer to obtain Fluorescein-mono-β-D-
galactopyranoside (FMG) and again hydrolyzes a second galactose for releasing fluorescein whose 
fluorescence (ex: 485 nm, em: 530 nm) can be monitored in a plate reader (3). For that matter cells are 
semipermeabilized with Triton-X100 before measuring. Glucocorticoid receptor signaling scheme 
adapted from (Cato et al. 2014). 
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3.5.1. The GR activity increased in the absence of Get3 
 
SGTA acts as a chaperone for the SRs and modulates their activity (Paul et al. 
2014). In order to test the activity of the SRs, I used an engineered reporter assay in 
yeast (Fig. 44). I started testing one SR: the GR. Despite the fact that yeast has no 
steroid receptors, all chaperones involved in chaperoning the GR in mammals are 
present. The reporter assay relies on the fluorescence of fluorescein, a non-fluorescent 
fluorescein-derivate, Fluorescein di-β-D-galactopyranoside (FDG) (Hofmann and 
Sernetz 1983), is added to the media. Upon the stimulation of the GR with a 
glucocorticoid agonist, a GR-regulated lacZ (b-galactosidase gene) is expressed. This 
enzyme cleaves the FDG and releases fluorescein that is measured in a plate reader 
at the pertinent excitation and emission wavelengths. 
 
Deoxycorticosterone (DOC) is a glucocorticoid agonist of the GR. This agonist binds 
to the LBD and activates the GR enabling its translocation into the nucleus (Goodman 
2009). The relative reporter expression is a ratio obtained by dividing the fluorescence 
signal from DOC-stimulated cells by the fluorescence signal of non-stimulated cells. It 
is an indirect reading of how many fold the receptor is activated over the background 
level. 
 
To test whether the absence of Get3 affects the activity of the GR, I chose a wt and a 
Dget3 strains with three different genetic backgrounds (BY4741, BY4742 and K700a). 
The genetic background is relevant to the experiment because some auxotrophic 
marker genes used in yeast laboratory strains, i.e. the MET15 gene, affect the redox 
state of the cells, which may in turn cause different levels of activation of the redox-
sensitive Get3 chaperone. I also analyzed a Dsgt2 strain in the BY4741 background to 
be able to compare it directly to the Dget3 and a Dget1/2 strain in this background. This 
experiment was intended to assess whether the GET receptor plays a role in GR 
activity, potentially because the receptor may have a role in the switch between the 
TA-protein targeting and chaperone form of Get3. I transformed these strains with the 
plasmids for the rat GR and the lacZ reporter gene under the control of a GR-
responsive promoter, glucocorticoid responsive elements (GREs), and performed the 
reporter measurements using yeast grown to log phase. The lack of Get3 increased 
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the GR activity in the BY4741 background (Fig. 45A). In contrast, loss of Get3 had no 
effect over the activity of the GR in the other two genetic backgrounds (Fig. 45B, Fig. 
45C). Indeed, as reported (Paul et al. 2014), the activity of the GR was higher in the 
Dsgt2 strain, whereas no effect was observed in the Dget1/2 strain (Fig. 45A). Lack of 
Get3 had a stronger effect on GR activity than lack of Sgt2.  
 
 
Figure 45. The absence of yeast Get3, in the BY4741 background, increases the activity of the 
glucocorticoid receptor. (A) Fluorescein-reporter assay measuring the activity of the glucocorticoid 
receptor (GR). BY4741 wt, get3, sgt2, get1/get2 were used, they were transformed with the GR and 
treated with 100 nM deoxycorticosterone (DOC), a glucocorticoid receptor agonist. The ratio of the signal 
obtained from DOC-treated cells and mock-treated cells is shown in the graph. (B) Fluorescein-reporter 
assay for measuring the activity of the GR. BY4742 wt and get3 were used, they were transformed with 
the GR and treated with 100 nM DOC, and the data was analyzed as in (A). (C) Fluorescein-reporter 
assay measuring the activity of the GR. K700α wt and the isogenic get3 deletion strain were used, they 
were transformed with the GR, and treated with 100 nM DOC. Data was analyzed as in (A). Four to five 
cultures independently inoculated from different transformations were analyzed. The graphs show the 
mean and the error bars represent standard error of the mean. 
A
C
Figure 47. The absenc  of yeast Get3, in the 4741 background, increases the activity of the 
glucocorticoid receptor. (A) Fluorescein reporter assay measuring the activity of the glucocorticoid 
receptor (GR). BY4741 wt, get3, sgt2, get1/get2 were used, they were transformed with the GR and 
treated with 100 nM doxycorticosterone (DOC), a glucocorticoid receptor agonist. The ratio of the 
signal obtained from DOC-treated cells and mock-treated cells is shown in the graph. (B) Fluorescein 
reporter assay for measuring the activity of the GR. BY4742 wt and get3 were used, they were trans-
formed with the GR and treated with 100 nM DOC, and the data was analysed as in (A). (C) Fluores-
FHLQUHSRUWHUDVVD\PHDVXULQJWKHDFWLYLW\RIWKH*5.αZWDQGWKHLVRJHQLFget3 deletion strain 
were used, they were transformed with the GR, and treated with 100 nM DOC. Data was analysed as 
in (A). Four to five cultures independently inoculated from ifferent transformations were analysed. 
The graphs show the mean and the error bars represent standard error of the mean.
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3.5.2. Get3 was unable to rescue the basal activity of the GR 
 
Get3 has an effect on the GR activity but it was unclear whether this result does 
indeed reflect the chaperone activity of Get3. To address this question, I focused on 
the BY4741 genetic background and performed another reporter assay using a set of 
cysteine-mutants of Get3 plus an ATPase-impaired mutant (Get3D57E) and a TA-
binding deficient mutant (Get3I193D) in the Dget3 strain. Get3 mutants unable to restore 
the wt activity of the GR were expected to inform on the required function of Get3. 
When analyzing the results, none of the Get3 variants were able to restore the GR 
activity of the Dget3 strain to BY4741 wt levels (Fig. 46B). However, they did have a 
clear impact on the absolute GR activity as shown in Fig. 46A. The potential 
explanation may be that the absolute GR activity in non-stimulated cells and the GR 
activity in stimulated cells were affected to the same extent (Fig. 46A), which canceled 
out any change in the ratio (Fig. 46B). 
 
 
Figure 46. Get3 variants cannot restore the reduced GR activity of the wt, although these variants 
result in significantly different absolute activity levels. (A) Fluorescein-reporter assay measuring 
GR activity. Absolute luminescence in BY4741 wt and get3 transformed with the GR and Get3 variants 
upon treatment with 100 nM DOC, a glucocorticoid receptor agonist. * indicates a p-value < 0.05; ** a 
p-value < 0.05; *** a p-value < 0.001. (B) GR activity upon DOC stimulation in a selected set of mutants. 
Ratio between DOC-treated cells and mock-treated cells from the experiment performed in (A). Six to 
nine cultures independently inoculated from different transformations were analyzed. The graphs show 
the mean and the error bars represent standard error of the mean. 
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Figure 48. Get3 variants cannot restore the reduced GR activity of the wt, although these vari-
ants result in significantly different absolute activity levels. (A) Fluorescein-reporter assay meas-
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variants upon treatment with 100 nM DOC, a glucocorticoid receptor agonist. * indicates a p-value < 
0.05; ** a p-value < 0.05; *** a p-value < 0.001. (B) GR activity upon DOC stimulation. Ratio between 
DOC-treated cells and mock-treated cells from the experiment performed in (A). Six to nine cultures 
independently inoculated from different transformations were analysed. The graphs show the mean 
and the error bars represent standard error of the mean.
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3.5.3. Get3 modulated the stability of the GR 
 
To complement the reporter assay (Fig. 46), I determined Get3 and the GR 
steady-state protein levels by Western blot. Interestingly, the GR levels were 
decreased upon Get3 transformation. That suggests that Get3 modulates the steady-
state protein levels of the GR (Fig. 47A). In general, they were inversely correlated, 
with higher Get3 levels (Fig. 47B) correlating with lower GR levels (Fig. 47C). 
 
 
3.5.4. Get3 and GR levels correlated inversely 
 
In the constructs used, Get3 mutants were expressed from a MET25 promoter. 
This promoter can be repressed by methionine. To further corroborate whether the 
Get3 levels modulated those of the GR, I titrated down the steady-state protein levels 
of Get3 by culturing the cells in the presence of increasing amounts of methionine 
followed by Western blot analysis. For this experiment I included Dget3, Dget3+Get3wt, 
Get3D57E and Get3C240,242,285,288T. 
 
On the one hand in the case of the Dget3, the steady-state levels of the GR remained 
unaffected regardless of the methionine concentration (Fig. 48A, Fig. 48B). On the 
other hand, in the presence of Get3wt the steady-state levels of the GR increased with 
decreasing levels of Get3wt at higher methionine concentrations (Fig. 48A, Fig. 48C). 
 
Both Get3 mutants investigated, Get3D57E and Get3C240,242,285,288T, showed the same 
behavior as Get3wt. The more Get3 was down-regulated, the higher the GR levels were 
observed (Fig. 49). These experiments support the conclusion that Get3 modulates 
the steady-state levels of the GR in yeast. 
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Figure 47. Get3 variants levels affect the stability of the GR. (A) BY4741 wt and BY4741 get3 
transformed with the glucocorticoid receptor and different Get3 mutants were analyzed for Western blot 
detecting the indicated proteins. (B) Get3 steady-state levels. Quantification of the signal intensities 
from the blots performed in (A). (C) Glucocorticoid receptor steady-state levels. Quantification of the 
signal intensities from the blots performed in (A). Three cultures independently inoculated from different 
transformations were analyzed. The graphs show the mean and the error bars represent standard error 
of the mean. 
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Figure 48. Titration of wt Get3 expression levels confirms that these affect the stability of the 
GR. (A) Methionine titration of Get3 expression levels in BY4741 Δget3 cells transformed with a plasmid 
of Get3wt under the MET25 promoter. Western blot was performed detecting the indicated proteins. (B) 
Quantification of GR steady-state levels based on the blots performed in (A). (C) Quantification of Get3 
steady-state levels from the blots performed in (A). Three cultures independently inoculated from 
different transformations were analyzed. The graphs show the mean and the error bars represent 
standard error of the mean. 
 
B
Figure 50. Titration of wt Get3 expression levels confirms that these affect the stability of the 
GR. (A)0HWKLRQLQHWLWUDWLRQRI*HWH[SUHVVLRQOHYHOVLQ%<ǻget3 cells transformed with a plas-
mid of Get3 under the Met25 promoter. Western blot was performed detecting the indicated proteins. 
(B) Quantification of GR steady-state levels based on the blots performed in (A). (C) Quantification of 
Get3 steady-state levels from the blots performed in (A). Three cultures independently inoculated from 
different transformations were analysed. The graphs show the mean and the error bars represent 
standard error of the mean.
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Figure 49. Titration of the steady-state levels of mutant Get3D57E and a mutant lacking the 
conserved cysteines confirms that these variants also affect the stability of the GR. (A) 
Methionine titration of Get3 expression levels in BY4741 Δget3 cells transformed with a plasmid of Get3 
variants under the MET25 promoter. Western blot was performed and the indicated proteins were 
detected. (B) Quantification of GR steady-state levels based on the blots performed in (A) in the 
presence of the indicated Get3 variants. (C) Quantification of Get3 steady-state levels from the blots 
performed in (A). Three cultures independently inoculated from different transformations were analyzed. 
The graphs show the mean and the error bars represent standard error of the mean. 
B
Figure 51. Titration of the steady-stated levels of mutant Get3 D57E and a mutant lacking the 
conserved cysteines confirms that these variants also affect the stability of the GR. (A) Methio-
QLQHWLWUDWLRQRI*HWH[SUHVVLRQOHYHOVLQ%<ǻget3 cells transformed with a plasmid of Get3 
variants under the Met25 promoter. Western blot was performed and the indicated proteins were 
detected. (B) Quantification of GR steady-stat  levels based on the blots performed i  (A) in the pr s-
ence of the indicated Get3 variants. (C) Quantification of Get3 steady-state levels from the blots 
performed in (A). Three cultures independently inoculated from different transformations were ana-
lysed. The graphs show the mean and the error bars represent standard error of the mean.
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3.5.5. The GR subcellular localization was unaffected by the 
absence of TRC40 in HeLa cells 
 
One relevant step of GR signaling is the translocation into the nucleus 
(Guiochon-Mantel et al. 1991; Haché et al. 1999). This must take place for this receptor 
to exert its control on the expression of glucocorticoid target genes. This has been well-
established in human cell lines. HeLa P4 cells express GR endogenously and there is 
no need to transiently express it under a strong promoter. Hence, I decided to avoid 
the heterologous system and move to HeLa cells to perform the next experiments. To 
test whether TRC40 alters the shuttling of the GR into the nucleus, TRC40 was 
silenced using siRNA and the cells were stimulated with dexamethasone (DEX). 
Dexamethasone is a synthetic corticoid agonist of the GR (Bunim et al. 1958). Then I 
performed an indirect immunofluorescence with an antibody against the GR to monitor 
the GR subcellular localization and the shuttling into the nucleus upon DEX stimulation. 
 
After analyzing the images, the knockdown of TRC40 had no effect on the subcellular 
localization of the GR, neither in non-stimulated cells nor DEX-stimulated cells (Fig. 
50A, Fig. 50B). 
 
 
3.5.6. The GR stability was unaltered in TRC40-knockdown 
HeLa cells 
 
In yeast, Get3 was shown to modulate the steady-state protein levels of the GR 
(Fig. 47, Fig. 48, Fig. 49). Here I show that the subcellular localization of the GR was 
not affected by down-regulation of TRC40 in HeLa cells (Fig. 50). Yet, the GR steady-
state levels might be modulated by TRC40. To test this, I silenced TRC40 with siRNA 
in HeLa cells and performed Western blot analysis. From the blots I can conclude that 
the GR steady-state levels were not modulated by the absence of TRC40 (Fig. 51A, 
Fig. 51B). 
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Figure 50. Down-regulation of TRC40 does not alter the nuclear shuttling of the GR in HeLa cells. 
(A) Immunofluorescence of the GR upon silencing of TRC40 in HeLa cells. Images of the GR and 
TRC40 stained by indirect immunofluorescence are shown. Cells were stimulated with 100 nM 
dexamethasone (DEX), a glucocorticoid receptor agonist. (B) Scatter plot representing the nuclear-
cytoplasmic ratio of the GR upon silencing of TRC40. Each dot represents the fluorescence intensity of 
one cell. n= 85-116 cells are represented. The graphs show the mean and the error bars represent the 
standard deviation. (C) Steady-state levels of GR and selected heat shock proteins (Hsps) upon 
silencing of TRC40. Western blot was performed detecting the indicated proteins. Three biological 
replicates were analyzed. Scale bars: 20 µm. 
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Figure 52. Down-regulation of TRC40 
does not alter the nuclear shuttling of 
the GR in HeLa cells. (A) Immunofluores-
cence of the GR upon silencing of TRC40 
in HeLa cells. Images of the GR and 
TRC40 stained by indirect immunofluores-
cence are shown. Cells were stimulated 
with 100 nM dexamethasone (DEX), a 
glucocorticoid receptor agonist. (B) Scatter 
plot representing the nuclear-cytoplasmic 
ratio of the GR upon silencing of TRC40. 
Each dot represents the fluorescence 
intensity of one cell. n= 85-116 cells are 
represented. The graphs show the mean 
and the error bars represent the standard 
deviation. (C) Steady-state levels of GR 
and selected heat shock proteins (Hsps) 
upon silencing of TRC40. Western blot was 
performed detecting the indicated proteins. 
Three biological replicates were analysed. 
Scale bars: 20 µm.
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Figure 52. Down-regulation of TRC40 
does not alter the nuclear shuttling of 
the GR in HeLa cells. (A) Immunofluores-
cence of the GR upon silencing of TRC40 
in HeLa cells. Images of the GR and 
TRC40 stained by indirect immunofluores-
cence are shown. Cells were stimulated 
with 100 nM dexamethasone (DEX), a 
glucocorticoid receptor agonist. (B) Scatter 
plot representing the nuclear-cytoplasmic 
ratio of the GR upon silencing of TRC40. 
Each dot represents the fluorescence 
intensity of one cell. n= 85-116 cells are 
represented. The graphs show the mean 
and the error bars represent the standard 
deviation. (C) Steady-state levels of GR 
and selected heat shock proteins (Hsps) 
upon silencing of TRC40. Western blot was 
performed detecting the indicated proteins. 
Three biological replicates were analysed. 
Scale bars: 20 µm.
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3.5.7. TRC40 and the GR were not found to interact 
 
The absence of TRC40 does not affect the nuclear shuttling of the GR (Fig. 50) 
and TRC40 does not modulate the steady-state protein levels of the GR in HeLa cells 
(Fig. 51). There is still the possibility that they interact and TRC40 regulates the GR in 
a different way. To test the potential interaction between TRC40 and the GR, I 
transfected HeLa cells with a Venus-TRC40wt construct and I affinity-purified the 
Venus-tagged TRC40 using a nanobody matrix directed against GFP. The GFP 
nanobody can detect the Venus tag (Nagai et al. 2002). After affinity-purification of 
Venus-TRC40wt no interaction with the GR was detected (Fig. 52). I also tested the 
inverse affinity-purification targeting Venus-GR after transfection with the 
corresponding construct, and no interaction with TRC40 was detected (Appendix Fig. 
2B). Additionally, I performed an immunoprecipitation using antibodies against the GR 
and TRC40 and no obvious interaction was detected (Appendix Fig. 2A). Taking 
together all these results, I conclude that there is no evidence that shows that GR and 
TRC40 do interact. 
 
 
Figure 51. GR steady-state levels do not change upon TRC40 or BAG6 knockdown. (A) Knock-
down of TRC40, WRB/TRC40 or BAG6 performed in HeLa P4 cells. Cytosolic fractions were analyzed 
for Western blot for TRC-pathway components and the glucocorticoid receptor. (B) Quantification of the 
GR signal intensities from the blots performed in (A). Four biological replicates were analyzed. The 
graphs show the mean and the error bars represent standard error of the mean. 
A
Figure 53. GR steady-state levels do not change upon TRC40 or BAG6 knockdown. (A) 
Knock-down of TRC40, WRB/TRC40 or BAG6 performed in HeLa P4 cells. Cytosolic fractions 
were analysed for Western-Blot for TRC40-pathway components and the glucocorticoid receptor.  
(B) Quantification of the GR signal intensities from the blots performed in (A). Four biological repli-
cates were analysed. The graphs show the mean and the error bars represent standard error of the 
mean. 
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Figure 52. The GR is not influenced by the manipulation of TRC40 in HeLa cells. (A) GFP pull-
down from HeLa cells transfected with Venus-TRC40. Cells transfected with a Venus construct served 
as a control. Western blot was performed for the indicated proteins. Venus proteins subjected to SDS-
PAGE after TCA-precipitation migrate at the expected size (72 kDa Venus-TRC40, 27 kDa Venus) 
whereas the samples applied in sample buffer without previous TCA precipitation samples migrate faster 
(around 60 kDa Venus-TRC40, 22 kDa Venus). Two biological replicates were analyzed. 
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4. Discussion 
4.1. TRC40D74E is a trapping mutant suitable for 
the study of TA-protein biogenesis in vivo 
 
The TRC40D74E mutant altered the native subcellular localization of a certain 
subset of TA-proteins, which show cytoplasmic localization by indirect 
immunofluorescence. However, TRC40D74E had no effect over another set of TA-
proteins. The manipulation of the TA-binding groove in combination with this mutant 
showed the following results: when combined with one single mutation, 
TRC40D74E/I193D, was not sufficient to revert the phenotype. However, combined with 
two mutations, TRC40D74E/L190D/I193D, was enough to abrogate the D74E effect over 
Stx8 and EMD (Fig. 13A, Fig. 14A, Fig. 15A, Fig.19B, Appendix Fig. 6). In contrast, 
Stx5 subcellular localization was still mildly affected (Fig. 13A, Fig. 19B) which would 
suggest that either these two mutations were not able to abolish the interaction of Stx5 
and TRC40 or that there might potentially be an additional binding region of TRC40 
that interacts with Stx5. Nevertheless, some of the TA-proteins tested in this study 
remained unchanged in the presence of TRC40D74E suggesting that not all the TA-
proteins are susceptible to be affected by this ATPase-impaired mutant (Fig. 16A, Fig. 
17A, Fig. 18A, Fig. 19A). Stx5 and EMD could be washed out in digitonin 
semipermeabilized cells (Fig. 20B, Fig. 21B), however a population of EMD remained 
at the ER membrane, unlike Stx5. The inhibition of DUBs did not prevent the 
cytoplasmic accumulation of Stx5 in the TRC40D74E-transfected cells (Fig. 22A). 
Moreover, cytosolic Stx5 steady-state levels were higher in the TRC40D74E-transfected 
cells compared to the EV (Fig. 23B) and the majority of this Stx5 population in cytosol 
was unglycosylated (Fig. 24A). Finally, the co-immunoprecipitation of Stx5 and TRC40 
showed that both proteins interact in cytosol and that other chaperones like BAG6 
might be also recruited to the complex (Fig. 25A). Taken together, these would indicate 
that TRC40D74E might prevent the insertion of newly synthesized Stx5 and instead 
captures it in cytoplasm acting as a trapping mutant. 
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The ATPase-impaired mutant, D57x, of yeast Get3 has been reported in literature 
(Mateja et al. 2009; F. Wang et al. 2011; Stefer et al. 2011; Powis et al. 2013; Chio et 
al. 2017). The aspartate residue sits in the very well-conserved Switch I region that is 
shared with other SIMIBI ATPases (Koonin 1993; Bange and Sinning 2013). It was 
originally mutated in the archaeal homolog ArsA (Tongqing Zhou and Rosen 1999) 
and eventually translated to Get3 (Mateja et al. 2009). ArsAD45E was reported to 
possess 20-fold less ATPase activity compared to ArsAwt whereas ArsAD45N showed 
no measurable ATPase-activity (Tongqing Zhou and Rosen 1999). In the case of yeast 
Get3, Get3D57N was reported to have a 100-fold slower ATPase activity compared to 
Get3wt (Chio et al. 2017). Similarly, Get3D57E ATPase activity was also decreased 
compared to the wt (Powis et al. 2013). Furthermore, TRC40D74N could not restore the 
Golgi integrity and Stx5 and Stx6 expression in mouse explants coming from the 
pancreatic epithelium TRC40-knockout cells (Norlin, Parekh, and Edlund 2018). The 
TA-protein targeting function of Get3 is coupled to the ATPase activity and the 
conformational changes derived from ATP hydrolysis (Chio, Cho, and Shan 2017). 
Along the same lines, Get3D57N showed an 85% reduction compared to Get3wt in 
relative insertion efficiency of Sec61b into membranes in an in vitro experiment 
(Mariappan et al. 2011). Moreover, Get3 is unable to efficiently insert TA-proteins in 
the presence of adenosine 5′-O-(3-thiotriphosphate) (ATP-g-S), a slowly hydrolyzable 
ATP-analog (Stefer et al. 2011). Interestingly, Get3D57N has recently been proposed as 
a mutant that cannot undergo the conformational changes required to dissociate from 
Get4/Get5 and therefore cannot interact with the GET receptor (Chio et al. 2017). 
Hence, it is thought to remain bound to the TA-protein and probably to the pre-targeting 
complex (Chio et al. 2017).  
 
As a part of the SIMIBI ATPase class (Leipe et al. 2002; Bange and Sinning 2013; 
Shan 2016), Get3, YlxH, ArsA and ParA, share a high homology in the ATPase Switch 
I and the aspartate residue is conserved in each of them (Koonin 1993; Bange and 
Sinning 2013). ParA, or Soj, is a bacterial ATPase involved in the regulation of the 
DNA replication initiation that has been studied in Bacillus subtilis. ParA forms dimers 
and also relies on nucleotide-dependent conformational changes. As mentioned, the 
aspartate residue within the Switch I is conserved in ParA (D44) (Bange and Sinning 
2013) and it has been described that mutations in this residue locks ParA into a fixed 
conformation in an ATP-bound state (Quisel, Lin, and Grossman 1999; Scholefield et 
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al. 2011). Moreover, the aspartate residue is conserved in the bacterial ATPase MinD 
(D40) (Hayashi, Oyama, and Morikawa 2001), a protein involved in bacterial cell 
division, that undergoes into nucleotide-dependent conformational changes 
(Lutkenhaus and Sundaramoorthy 2003). Mutations in this residue locks the protein in 
an ATP-bound conformation that fails to dissociate from its substrate (W. Wu et al. 
2011).  
 
The TRC40 Switch I region has been conserved in its entirety during evolution 
(Appendix Fig. 3A) and it is shared with the ATPases of the SIMIBI class (Bange and 
Sinning 2013; Shan 2016). Similar to other SIMIBI ATPases, the mutation of the 
aspartic residue could lock TRC40. This would support the hypothesis that when 
TRC40 is strongly impaired in ATP-hydrolysis, it results in its being locked in a 
conformation that makes it a trapping mutant. Due to the high degree of homology 
between human TRC40 and yeast Get3, it is possible to draw parallels between the 
well-characterized yeast Get3 ATPase cycle (Fig. 53). The present study provides 
evidence that a subset of TA-proteins is localized in the cytoplasm upon mutation of 
TRC40 to its ATPase-impaired form. Furthermore, this effect is dependent on the 
integrity of the TA-binding groove. Additionally, Stx5 present in cytosol was 
unglycosylated suggesting that it was not inserted into the membrane but instead kept 
in cytoplasm. In a similar fashion as described for Get3 (Chio et al. 2017), it is possible 
to speculate that TRC40D74E is able to interact with the pre-targeting complex and can 
be loaded with newly synthesized TA-protein. Nevertheless, the impairment in the ATP 
processing makes it unable to interact with the TRC receptor and subsequently hand 
off the TA-protein leading to an accumulation of TRC40 loaded with the TA-protein in 
the cytoplasm (Fig. 53, step 3). This essentially makes TRC40D74E a good tool for the 
study of tail-anchored protein biogenesis in vivo. Combined with the use of 
TRC40D74E/L190D/I193D as a negative control, the experiments can shed light on the 
biogenesis of TA-proteins substrates of the TRC pathway. 
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Figure 53. The TRC40D74E ATPase-deficient cycle model. Based on the ATPase cycle described in 
Fig. 5. (1) and (2) are exactly as described. (3) The TA-protein (PDB ID: 2LPF) is thus loaded into Get3 
(PDB ID: 4XTR) from Sgt2. This interaction with the TA-protein should make Get3 lose its affinity for 
Get4/Get5 (PDB ID: 4PWX), dissociate and process the ATP. But instead, Get3 remains loaded with 
the TA-protein and ATP. It is believed that Get4/Get5 remains bound to the ATPase-impaired Get3. 
Get3 subunits are depicted in orange and deep purple.  
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Figure 52. The Get3 ATPase-deficient cycle hypothesis. (1) Get3 is in an apo-Get3 conforma-
tion (P B ID: 3H84). This is an open Get3 conformation with no nucleotides bound. The binding of 
ATP triggers a conformational change towards a so called close state (PDB ID: 2WOJ). (2) The 
pretargeting complex, through Get4, has a higher affinity for this close state preferentially (PDB ID: 
4PWX). The binding of Get4/Get5 (additionally Sgt2, not shown in the figure) inhibits the ATPase 
activity of Get3. (3) The TA-protein (PDB ID: 2LPF) is thus loaded into Get3 (PDB ID: 4XTR) from 
Sgt2. This interaction makes Get3 lose its affinity for Get4/Get5 and they dissociate. Get3 is loaded 
with the TA-prot and ATP. Get2  (PDB ID: 3ZS9), Get1 (PDB ID: 3SJB). Get3 subunits are depicted 
in orange and deep purple. CD stands for cytosolic domain.
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4.2. TA-protein dependence of the TRC pathway 
in vivo 
 
4.2.1. Studying TA-biogenesis in vitro versus in vivo 
 
In order to understand TA-protein biogenesis, several in vitro experiments were 
reported in literature, especially insertion assays into ER-derived membranes. These 
experiments were based on either affinity purified complexes (Get3/TRC40 and a TA-
protein) or in vitro synthesized protein in rabbit reticulocyte lysate (RRL) plus rough 
microsomes (RMs) under varying conditions such as: ATP-depletion, immunodepletion 
of components and peptide-based competition assays. Most of these in vitro 
experiments used Sec61b as a model TA-protein (Stefanovic and Hegde 2007; 
Favaloro et al. 2008; Favaloro et al. 2010; Leznicki et al. 2010; Leznicki, Warwicker, 
and High 2011; Mariappan et al. 2011; Johnson et al. 2012). In these experiments, 
Sec61b was shown to be a clear substrate of the TRC pathway. The TRC pathway 
and yeast GET pathway have been the reference pathways regarding TA-protein 
biogenesis (Mandon and Gilmore 2007; Mateja et al. 2009; Mariappan et al. 2010), 
although some authors considered that the chaperones Hsp40/Hsc70 furnished an 
alternative insertion pathway (Rabu et al. 2008; Rabu et al. 2009). However, in recent 
years many in vivo studies have been performed and other pathways related to TA-
protein biogenesis have been described. The in vivo studies were based on 
knockdowns or knockouts of human cell lines or in mouse knockout models. 
Surprisingly, in these studies the TRC-dependence of Sec61b was not evident at 
steady-state. Sec61b steady-state levels were not significantly altered in either primary 
cardiomyocytes or primary hepatocytes depleted of WRB (Rivera-Monroy et al. 2016). 
Likewise, Sec61b steady-state levels were not significantly altered in TRC40-
knockdown, WRB-knockdown and TRC40-knockout HeLa M cells (Casson et al. 2017) 
as well as in this study (Fig. 26B, Fig. 32C). Additionally, Sec61b did not suffer any 
apparent change in the subcellular localization in TRC40-knockout HeLa M cells 
(Casson et al. 2017), in TRC40-knockout pancreatic b-cells (Norlin et al. 2016) and in 
this study upon the over-expression of TRC40D74E in HeLa P4 cells (Fig. 16A). 
However, a couple of studies showed Sec61b altered upon the TRC pathway 
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manipulation: in WRB-knockdown HeLa cells Sec61b is decreased at the steady-state 
level after ER-fraction normalization (Haßdenteufel et al. 2017) and there is a reduction 
in opsin-tagged Sec61b-glycosylation at steady-state level in WRB-knockdown HeLa 
M cells upon the transient over-expression of Sec61b (Casson et al. 2017).  
 
The in vitro TRC-dependence for insertion is not necessarily correlated with the TRC-
dependence of the steady-state levels in vivo. Hence, more in vivo studies are required 
for further investigating TA-protein biogenesis due to the following arguments: 
 
o The presence of other pathways for TA-biogenesis. The integration of these 
pathways such as the EMC pathway (Guna et al. 2018), ubiquilins (Itakura et 
al. 2016), Hsp40/Hsc70 (Rabu et al. 2008; Rabu et al. 2009), the SND pathway 
(Aviram et al. 2016; Haßdenteufel et al. 2017) or the PEX pathway (Jones, 
Morrell, and Gould 2004; Fujiki et al. 2014; Buentzel et al. 2015) makes it more 
difficult to discriminate the contribution of these pathways to TA-protein 
biogenesis. A role of the SRP in TA-protein biogenesis has also been implied 
(Johnson, Powis, and High 2013; Casson et al. 2017). The overlapping of 
substrates and shared contribution between the pathways emerge as a general 
concept (van der Zand, Braakman, and Tabak 2010; Buentzel et al. 2015; 
Itakura et al. 2016; Casson et al. 2017; Guna et al. 2018). 
o Another important factor to take into account is the tissue-specific fate of the 
TA-proteins. Stx5 is affected regardless of the tissue-type when the TRC 
pathway is impaired (Rivera-Monroy et al. 2016; Norlin et al. 2016; Casson et 
al. 2017) (as well as this study, Fig. 13A, Fig. 19B, Fig. 26B, Fig. 28A). Yet 
there are other TA-proteins whose dependence on the TRC pathway varies 
from tissue to tissue. For instance, Stx6 was decreased at the steady-state level 
in WRB-knockout mouse hepatocytes (Rivera-Monroy et al. 2016), also in this 
study (Fig. 26B, Fig. 28B), and Stx6 had altered expression and subcellular 
distribution in two TRC40-knockout mouse models: pancreatic b-cells and 
pancreatic epithelial cells (Norlin et al. 2016; Norlin, Parekh, and Edlund 2018). 
In contrast, Stx6 was not affected at steady-state level in WRB-knockout mouse 
cardiomyocytes (Rivera-Monroy et al. 2016). Furthermore, EMD was decreased 
at the steady-state level in WRB-knockout mouse cardiomyocytes, also in this 
study (Fig. 26B, Fig. 29B), whereas no change at the steady-state level was 
4.Discussion 
 
 
 
152 
observed in WRB-knockout mouse hepatocytes (Rivera-Monroy et al. 2016). 
Moreover, it has been reported that otoferlin, a tissue-specific TA-protein of the 
inner-hair cells, is impaired in WRB-knockout mice, which present hearing 
problems (Vogl et al. 2016). Finally, the variability in the mRNA expression and 
protein at steady-state levels of the TRC components in several tissues 
(Appendix Fig. 4A, Appendix Fig. 5A) may differentially play a role in TA-
protein biogenesis upon impairment of the TRC pathway. 
 
 
4.2.2. TRC pathway-dependence of the TA-proteins in vivo 
 
The fate of endogenous TA-proteins in vivo when the TRC pathway is impaired 
has remained unexplored until recently. The overlapping of the different pathways 
over-seeing the insertion of TA-proteins also poses the question of how relevant the 
TRC pathway is in the biogenesis of a specific TA-protein. From the 17 TA-proteins 
tested in this study, 11 were found to be decreased at steady-state level in 
WRB/TRC40 down-regulated cells: Stx5, Stx6, Stx1, Stx8, UBE2J1, USE1, EMD, 
VAPB, Vti1a, Sec22b and VAPA (Fig. 26B). In contrast, another 6 did not show any 
change at steady-state level in spite of the loss of WRB and TRC40: Stx18, GOSR2, 
PTP1B, Vti1b, Sec61b and SQS (Fig. 26B). Furthermore, 3 out of the 11 TA-proteins 
affected upon WRB/TRC40 knockdown were also affected upon the loss of TRC40: 
Stx5, UBE2J1 and VAPB (Fig. 26B). Based on these results, I will discuss how these 
findings relate to the information of individual TA-proteins in the literature.  
 
Stx1a was classified as a TRC pathway substrate whose insertion had to be facilitated 
by a molecular chaperone (Rabu et al. 2008). Besides, Stx1 showed a typical 
subcellular localization in TRC40-knockout pancreatic b-cells in mouse (Norlin et al. 
2016). Along the same lines, Stx1 showed a reduction at steady-state level upon the 
knockdown of WRB and TRC40 (Fig. 28C). Taken together with my results, at least a 
proportion of Stx1 may be targeted by the TRC pathway in vivo. Unfortunately, the 
Stx1 detecting antibody did not work for IF, preventing the more direct test of trapping 
Stx1 with TRC40D74E and instead will require the transient expression of tagged Stx1. 
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Syn8, the yeast homolog of Stx8, was unaffected in its subcellular distribution in Dget3, 
Dget1/Dget2, Dget1/Dget2/Dget3 strains (Rivera-Monroy et al. 2016). In the same 
study, Stx8 protein levels at the steady-state did not change in either WRB-knockout 
cardiomyocytes or WRB-knockout hepatocytes but they were decreased upon TRC40-
knockdown in HeLa cells (Rivera-Monroy et al. 2016). Moreover, Stx8 requires TRC40 
to get inserted into RMs in vitro (Rivera-Monroy et al. 2016). Accordingly, Stx8 showed 
a cytoplasmic staining by IF in TRC40D74E-transfected HeLa cells (Fig. 15A). However, 
Stx8 showed no reduction in TRC40-downregulated cells whereas Stx8 was found to 
be decreased to 62% at steady-state level upon combined WRB/TRC40 knockdown 
compared to the control cells in this study (Fig. 28D). The above results may indicate 
that TRC40 is important for targeting a population of Stx8 to the membrane. But in the 
absence of TRC40 or WRB, the results may indicate the existence of a redundant 
pathway that takes over the role of targeting Stx8 to the membrane. However, the 
combined loss of WRB/TRC40 affects the protein steady-state level of Stx8. This may 
indicate the relevance of WRB and TRC40 for the proper targeting of the potential 
redundant pathway. 
 
In one study, strongly over-expressed Ubc6, yeast homolog of UBE2J1, was 
mislocalized to mitochondria in a Dget1/Dget2 strain (Schuldiner et al. 2008) but in 
another study where no effect on its subcellular distribution was found in Dget3, 
Dget1/Dget2, Dget1/Dget2/Dget3 strains (Rivera-Monroy et al. 2016). In mammals, for 
UBE2J1 it was suggested that its insertion had to be facilitated by a molecular 
chaperone (Rabu et al. 2008) but did not to require energy-dependent cytoplasmic 
chaperones for the insertion into ER-membranes (Haßdenteufel et al. 2011). It was 
later reported that UBE2J1 was a TRC40-substrate (Claessen et al. 2010). In this 
study, UBE2J1 showed a reduction by 60% at the steady-state level in TRC40-silenced 
cells whereas UBE2J1 revealed a decrease of 64% at the steady-state level in the 
combined silencing of WRB and TRC40 (Fig. 29C). Taken together with my results, a 
major proportion of UBE2J1 might be targeted by the TRC pathway in vivo. Owing to 
the unavailability of an antibody detecting UBE2J1, a tagged-version of UBE2J1 should 
be used for testing whether TRC40D74E would trap it. 
 
EMD insertion was TRC pathway dependent and upon TRC40-knockdown showed 
reduced fluorescence intensity by IF (Pfaff et al. 2016). Additionally, EMD presented 
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altered subcellular localization in WRB-knockout mouse cardiomyocytes (Rivera-
Monroy et al. 2016). At steady-state, EMD was reduced in WRB-knockout mouse 
cardiomyocytes, but no further change at the steady-state level was observed in WRB-
knockout mouse hepatocytes (Rivera-Monroy et al. 2016). Along the same lines, 
following the over-expression of TRC40D74E EMD presented a cytoplasmic staining in 
this study (Fig. 14A). Furthermore, EMD steady-state levels were reduced in the 
combined WRB/TRC40-knockdown cells compared to the siLuc control cells (Fig. 
29B). In summary, these results may indicate that EMD targeting relies on the TRC 
pathway in vivo. EMD targeting may be more sensitive to the loss of WRB, since EMD 
showed no effect, at the steady-state, in TRC40-downregulated cells (Fig. 29B), yet 
TRC40D74E is able to trap it in the cytoplasm. 
 
Stx5-dependence on the TRC pathway has been discussed in a detailed manner in 
the previous sections. Briefly, Stx5 is affected in different tissues when the TRC 
pathway is impaired (Rivera-Monroy et al. 2016; Norlin et al. 2016; Casson et al. 2017). 
Moreover, yeast Stx5 (Sed5) is reported to have an altered subcellular distribution 
when the GET pathway is impaired (Schuldiner et al. 2008; Jonikas et al. 2009; Battle 
et al. 2010; Kohl et al. 2011; Powis et al. 2013; Vilardi et al. 2014; Voth et al. 2014; 
Rivera-Monroy et al. 2016). Likewise, Stx5 steady-state levels were reduced in TRC40-
knockdown and in combined WRB/TRC40-knockdown cells in this study (Fig. 28A). 
Furthermore, Stx5 demonstrated a cytoplasmic staining in the TRC40D74E-transfected 
cells (Fig. 13A). Taken together with my findings, Stx5 showed a strong dependence 
on the TRC pathway in vivo for targeting, interestingly not on BAG6.  
 
Stx6 was reported to have altered expression and subcellular distribution in two 
TRC40-knockout mouse models: pancreatic b-cells and pancreatic epithelial cells 
(Norlin et al. 2016; Norlin, Parekh, and Edlund 2018). Likewise, Stx6 subcellular 
distribution was altered in WRB-knockout mouse cardiomyocytes (Rivera-Monroy et 
al. 2016). In contrast, Stx6 remained unaffected at steady-state in WRB-knockout 
mouse cardiomyocytes but was decreased at the steady-state in WRB-knockout 
mouse hepatocytes (Rivera-Monroy et al. 2016). Stx6 was also found to be reduced at 
steady-state upon combined WRB/TRC40 knockdown compared to the control cells in 
this study (Fig. 28B). Furthermore, preliminary results indicate that Stx6 is localized in 
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the cytoplasm in TRC40D74E-transfected cells (data not shown). Taken together, these 
results indicate that Stx6 targeting may depend on the TRC pathway in vivo. 
 
There are studies on the biogenesis of VAPA and VAPB in yeast but not in mammals. 
Upon strong over-expression Scs2p, the yeast homolog of VAPA and VAPB, was 
mislocalized in a Dget1/Dget2 strain (Schuldiner et al. 2008). However, another study 
reported no change on its subcellular distribution in Dget3, Dget1/Dget2, 
Dget1/Dget2/Dget3 strains (Rivera-Monroy et al. 2016). VAPB was reported to interact 
with TRC40 (Baron et al. 2014). In this study, VAPB subcellular localization was not 
affected by the presence of TRC40D74E (Fig. 18A). However, the steady-state levels of 
VAPB were found to be decreased in combined WRB/TRC40 silenced cells (Fig. 29D). 
The same was true for VAPA (Fig. 30B). In addition, steady-state levels of VAPB were 
also reduced in TRC40-knockdown cells (Fig. 29D). Taken together my results indicate 
that VAPA and VAPB may be targeted by the TRC pathway in vivo. In contrast to 
VAPA, VAPB steady-state levels were affected in TRC40-knockdown cells. Therefore, 
VAPB might require TRC40 for its biogenesis in vivo but it might be a downstream 
effect since TRC40D74E had no effect on the subcellular localization of VAPB. Indeed, 
the reported interaction of TRC40 with VAPB was independent of the transmembrane 
segment (Baron et al. 2014) indicating that the effect at steady-state level in this study 
may not be due to targeting. 
 
Sec22p, the yeast homolog of Sec22b, could not be inserted in yeast microsomes 
lacking the Get1/Get2 receptor, highlighting its GET-pathway dependence (Schuldiner 
et al. 2008; Stefer et al. 2011). Sec22p was unable to be inserted into wt or Dget1/Dget2 
microsomes when incubated with Dget5 cytosolic extracts (Jonikas et al. 2009). In 
contrast, its subcellular distribution remained unaltered in Dget3, Dget1/Dget2, 
Dget1/Dget2/Dget3 strains (Rivera-Monroy et al. 2016). In mammalian studies, a typical 
subcellular localization of Sec22b was observed in TRC40-knockout pancreatic b-cells 
in mouse (Norlin et al. 2016). Conversely, in this study where Sec22b showed a 
reduction at the steady-state level in WRB/TRC40-knockdown cells (Fig. 30C). In 
combination with my results, Sec22b seems to rely on the TRC pathway for targeting 
in vivo. Nevertheless, the effect of the TRC40D74E mutant on Sec22b subcellular 
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localization could not be evaluated because the antibody against Sec22b did not work 
for IF. A tagged Sec22b will be required to test this hypothesis.  
 
There are no studies linking Vti1a and USE1 with the TRC pathway. In this study, Vti1a 
levels showed a reduction at the steady-state upon combined WRB/TRC40 knockdown 
compared to the control cells (Fig. 30A). USE1 showed a reduction at steady-state 
level in combined WRB/TRC40-silenced cells (Fig. 29A). A proportion of USE1 and 
Vti1a might be targeted by the TRC pathway in vivo, especially in the case of USE1. 
This calls for further analysis in order to dissect the reliance of these TA-proteins on 
the TRC pathway. Due to the unavailability of an antibody that detects endogenous 
Vti1a and USE1, a tagged-variant of these proteins in combination with the TRC40D74E 
trapping mutant may shed some light on any putative dependence on the TRC 
pathway. 
 
However, from the TA-proteins tested some remained unaffected at steady-state level 
by the combined down-regulation of WRB and TCR40: 
 
PTP1B was found to be inserted in an unassisted-manner into protein-free lipid 
bilayers (Brambillasca et al. 2006). Moreover, it showed increased membrane insertion 
in the presence of Hsp40/Hsc70 and it was therefore suggested not to be a TRC 
pathway substrate (Rabu et al. 2008). Similarly, PTP1B was proposed to not need 
cytoplasmic chaperones that require energy for the insertion into ER-membranes 
(Haßdenteufel et al. 2011). Likewise, as shown in this study, PTP1B levels remained 
unchanged at the steady-state upon WRB/TRC40 knockdown (Fig. 32A) and its 
subcellular localization did not change in the presence of TRC40D74E (Fig. 17A, Fig. 
19A). Therefore, there is no evidence that PTP1B targeting relies on the TRC pathway 
in vivo. 
 
Sec61b localization remained unaltered upon WRB/TRC40 or TRC40 knockdowns in 
this study (Fig. 32C). Sec61b was broadly discussed previously with respect to the 
discrepancies of studying it in vitro and in vivo. In addition to those studies mentioned, 
others have also tried to shed light on Sec61b biogenesis. Sec61b was considered 
substrate of the TRC pathway substrate whose insertion had to be facilitated by a 
molecular chaperone (Rabu et al. 2008). Similarly, Sec61b was found to require 
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energy-dependent cytoplasmic chaperones for its insertion into the ER-membrane 
(Haßdenteufel et al. 2011). Sbh1/2, homologs of Sec61b in yeast, were mislocalized 
in a Dget1/Dget2 strain when strongly over-expressed (Schuldiner et al. 2008). 
However, another study reported no alteration in its subcellular localization in Dget3, 
Dget1/Dget2, Dget1/Dget2/Dget3 strains when expressed at moderate levels (Rivera-
Monroy et al. 2016). Sec61β levels at steady-state demonstrated no observable effect 
in HEK293T following the down-regulation of BAG6 (Q. Wang et al. 2011). Besides, a 
normal subcellular distribution of Sec61b was observed in TRC40-knockout pancreatic 
b-cells in mouse (Norlin et al. 2016). Finally, Sec61b was believed to fall at the 
boundary where the TRC pathway and the EMC pathway overlap in their substrate 
specificity. Sec61b can be inserted in vitro into RMs in a TRC40-dependent way. 
However, Sec61b-insertion is affected by the knockdown of EMC5 in HEK293T cells, 
demonstrating an overlapping dependence on both pathways (Guna et al. 2018). 
Taken together with my results, Sec61b can be inserted by TRC40 in vitro but it may 
not be targeted by the TRC pathway in vivo. Alternatively, the TRC- and EMC- 
pathways are possibly redundant in vivo offering Sec61b varied means of membrane 
targeting and insertion. 
 
There are no studies in the literature regarding Stx18 and GOSR2 with the TRC 
pathway. Neither Stx18 nor GOSR2 were not affected at the steady-state level upon 
TRC40 or the combined WRB/TRC40 silenced cells in this study (Fig. 31A, Fig. 31B). 
Taken together, there is no evidence that either Stx18 or GOSR2 targeting relies on 
the TRC pathway in vivo. Because the antibodies against Stx18 and GOSR2 did not 
work for IF, the more direct test of trapping both proteins with TRC40D74E will have to 
rely on tagged-versions of Stx18 and GOSR2. 
 
In the case of Vti1b, it was found cross-linked with TRC40 and its in vitro insertion into 
RMs was disturbed by the addition of WRBcc (a peptide containing the coil-coiled 
region of WRB that competes for binding to TRC40 thereby preventing the delivery of 
the TA-protein to the membrane) and was therefore considered to be a TRC pathway-
dependent substrate. In contrast, Vti1b showed no effect on insertion upon the 
knockdown of EMC5 in HEK293T cells (Guna et al. 2018). However, Vti1b levels were 
not affected at the steady-state upon the combined WRB/TRC40 or TRC40 down-
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regulated cells in this study (Fig. 32B). Taken together with my results, Vti1b targeting 
may not rely on the TRC pathway in vivo due to the potential existence of redundant 
pathways that help with the targeting of Vti1b when the TRC pathway was impaired. It 
was reported that the EMC pathway was not the redundant pathway facilitating Vti1b 
insertion (Guna et al. 2018).  
 
Finally, SQS levels remained unaltered at the steady-state upon the combined 
WRB/TRC40 or TRC40 knockdown cells in this study (Fig. 32D). Likewise, SQS is not 
reported to interact with TRC40 and its in vitro insertion into RMs was not TRC40-
dependent. Instead, its insertion in vivo was reported to be dependent on the EMC 
pathway and its subcellular distribution was altered upon the knockdown of EMC5 in 
HEK293T cells (Guna et al. 2018). Therefore, there is no evidence that SQS targeting 
relies on the TRC pathway in vivo. 
 
There have been many discrepancies in the literature about the biogenesis of the 
aforementioned TA-proteins. Based on the findings of this study combined with others 
findings in the literature, many TA-proteins may depend on the TRC pathway for their 
targeting in vivo. Stx5 and Stx6 seem to be the most dependent on the TRC pathway, 
based on their steady-state levels when the TRC pathway is impaired and their altered 
subcellular localization upon TRC40D74E. Curiously, some TA-proteins of which little 
was known, yielded interesting results: a proportion of USE1 and UBE2J1 may present 
a strong TRC-dependence. In contrast, other TA-proteins showed no change in their 
steady-state levels what may indicate that they present little or no TRC-dependency in 
vivo. It would be helpful to use TRC40D74E as a tool to further characterize the 
interaction of the TA-proteins with the TRC pathway. This can be complemented by in 
vivo experiments knocking-down TRC pathway components for studying steady-state 
levels and the subcellular localization of the TA-proteins. 
 
 
4.2.3. Exploring the causes for the TRC-dependence of a TA-
protein in vivo 
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There have been many factors taken into consideration: transmembrane 
segment length (Isenmann et al. 1998; Pedrazzini et al. 2000; Bulbarelli et al. 2002; 
Borgese, Brambillasca, and Colombo 2007), C-terminal tail length and charge 
(Elgersma et al. 1997; Kuroda et al. 1998; Mullen and Trelease 2000; Horie et al. 2002; 
Borgese, Brambillasca, and Colombo 2007; Yagita, Hiromasa, and Fujiki 2013; 
Costello, Castro, Camões, et al. 2017), membrane composition (Borgese, 
Brambillasca, and Colombo 2007), the cytoplasmic domain (Linstedt et al. 1995; 
Misumi et al. 2001; Joglekar et al. 2003) and hydrophobicity of the TMD (Borgese, 
Colombo, and Pedrazzini 2003; Borgese, Brambillasca, and Colombo 2007). Actually, 
hydrophobicity has always been regarded as an important factor for organelle-targeting 
of the TA-proteins. Other in vitro and in vivo studies have also studied this 
physicochemical property (Rao et al. 2016; Guna et al. 2018; F. Wang et al. 2010; 
Costello, Castro, Camões, et al. 2017). This study tries to shed some light on some of 
the potential causes that determine the in vivo TRC-pathway dependence of a TA-
protein.  
 
 
4.2.3.1. Hydrophobicity is a major contributor for the TRC-
dependence in vivo 
 
TMD hydrophobicity has always been considered as a relevant factor in TA-protein 
biogenesis. It has been proposed that moderately hydrophobic TMDs were substrates 
of the TRC pathway (F. Wang et al. 2010; Rao et al. 2016; Costello, Castro, Camões, 
et al. 2017; Guna et al. 2018; Borgese, Colombo, and Pedrazzini 2003; Borgese, 
Brambillasca, and Colombo 2007). From the different TMD-hydrophobicity analyses 
carried out (Fig. 33-36), it is clear that hydrophobicity is indeed a determinant factor in 
the fate of the endogenous TA-proteins in vivo. The majority of the TA-protein affected 
by WRB/TRC40 knockdown presented moderate-to-high hydrophobic TMDs whereas 
the majority of the unaffected TA-proteins had low hydrophobic TMDs. Using the 
GRAVY scoring (based on the Kyte and Doolittle scale) the group of affected and 
unaffected TA-proteins could be separated (Fig. 35A). However, for the other 
hydrophobicity scales, some TA-proteins remained in an intermediary region, similar 
to the Sec61b-TMD hydrophobicity score, with no clear separation between affected 
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and unaffected groups. This result was independent of the scale used: the TMD 
tendency scale (Fig. 33A), the Kyte and Doolittle scale (Fig. 34A) and for the apparent 
free-energy (Fig. 36A). The answer to why proteins that have TMDs with very similar 
hydrophobicity yielded different behaviors may lie in the amino acid composition of the 
TMDs. Helical wheels projections, generated from the predicted TMD sequences, 
showed little evidence of which residues could be crucial for the TRC-pathway 
dependence (Fig. 54, Fig. 55). However, a deeper analysis of the TMD sequences 
from those TA-proteins sensitive to the WRB/TRC40 knockdown yielded an interesting 
result. The sequence logo showed the relevance of aromatic amino acids at the 
beginning of the TMD and the presence of isoleucines, phenylalanines, leucines or 
valines (Fig. 56A). The algorithm chosen for the logo representation highlights amino 
acid enrichment and emphasizes the relevant parts (Thomsen and Nielsen 2012). It is 
not a consensus sequence and cannot be treated as such, since neither the 
experimental approach nor the sample size is large enough for making that claim. 
Other than that, it is an analysis that showed that the presence of an aromatic amino 
acid was relevant at either the beginning or the end of the TMD. Moreover, the central 
part of the TMD also appeared to be important since the relative weight of certain 
hydrophobic amino acids (almost exclusively isoleucines, phenylalanines, leucines) 
was higher. In contrast, the sequence logo for the TMD of the unaffected TA-proteins 
showed an enrichment in aromatic amino acids in the last third of the TMD (Fig. 56B). 
The enrichment in hydrophobic amino acids is lower than in the case of the affected 
TA-protein TMDs.  
 
Taken together, hydrophobicity is an important factor in TA-targeting as seen in the 
TMD-hydrophobicity dot-plots, especially using the GRAVY score. However, 
hydrophobicity on its own cannot explain the in vivo dependence on the TRC pathway 
for every TA-protein, especially those with moderately hydrophobic TMD close to the 
hydrophobicity of Sec61b. The zone of hydrophobicity close to Sec61b could be a 
region where other pathways overlap in vivo, as pointed out for certain TA-proteins in 
a previous study (Guna et al. 2018).  
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Figure 54. Helical wheel projections of TMDs of the TA-proteins affected by the WRB/TRC40 knockdown. TA-proteins were ordered according to the 
affectation in steady-state level in the knockdown cells, descendent order. Numbers indicate the TMD hydrophobicity score according to the hydrophobicity scale 
developed by (Kyte and Doolittle 1982) divided by the length of the TMD (in aa), for obtaining the GRAVY score. Those TA-proteins affected by the presence of 
TRC40D74E are highlighted in green or in red if they remain unchanged. The helical wheel analysis was done using the application wheel.pl v1.4 (Zidovetzki et al. 
2003). Available here: http://rzlab.ucr.edu/scripts/wheel/wheel.cgi 
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Figure 55. Helical wheel projections of TMDs of the TA-proteins that remained unaffected upon the WRB/TRC40 knockdown. TA-proteins whose steady-
state levels were not altered upon the WRB/TRC40 knockdown were displayed in a random order. Numbers indicate the TMD hydrophobicity score according to 
the hydrophobicity scale developed by (Kyte and Doolittle 1982) divided by the length of the TMD (in aa), for obtaining the GRAVY score. Those TA-proteins 
affected by the presence of TRC40D74E are highlighted in green or in red if they remain unchanged. The helical wheel analysis was done using the application 
wheel.pl v1.4 (Zidovetzki et al. 2003). Available here: http://rzlab.ucr.edu/scripts/wheel/wheel.cgi
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Figure xx. Helical wheel projections of TMDs of the TA-proteins that remained unaffected upon the WRB/TRC40 knockdown. TA-proteins whose 
steady-s ate levels were not altered upon the WRB/TRC40 knockdown were displayed in a ran om order. Numbers indicate the TMD hydrophobicity 
score according to the hydrophobicity scale developed by (Kyte and Doolittle 1982) divided by the length of the TMD, for obtaining the GRAVY score. The 
helical wheel analysis was done using the application wheel.pl v1.4 (Zidovetzki et l. 2003). Available here: http://rzlab.ucr.edu/scripts/wheel/wheel.cgi 
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Figure 56. Sequence logo of the TMDs of TA-proteins tested upon the WRB/TRC40 knockdown. 
(A) Sequence logo of the twelve 19 aa TMDs of the affected TA-proteins. (B) Sequence logo of the six 
21 aa TMDs of the unaffected TA-proteins. The probability weighted Kullback-Leibler logo. The height 
of the amino acids represents the probability times their log-odds score. The code of color used is similar 
to the one used in the helical wheel projections (Fig. 54, Fig. 55). The sequence logo was generated 
using the web-based generator Seq2Logo 2.0(Thomsen and Nielsen 2012). Available here: 
http://www.cbs.dtu.dk/biotools/Seq2Logo/. Parameters used for the analysis are available in section 
7.5.3 within Appendix. 
Figure 56. Sequence logo of the TMDs of TA-proteins aftected upon the WRB/TRC40 knock-
down. Sequence logo of the twelve TMDs using the probability weighted Kullback-Leibler. The height 
of the amino acids represents the probability times their log-odds score. The sequence logo was 
generated using the web-based generator Seq2Logo 2.0 (Thomsen and Nielsen 2012). Available 
here: http://www.cbs.dtu.dk/biotools/Seq2Logo/
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4.2.3.2. The silent role of the cytoplasmic domain in the subcellular 
localization of TA-proteins 
 
Hydrophobicity cannot entirely explain the results regarding the dependence of 
TA-proteins on the TRC pathway. There must be additional factors. TA-protein 
biogenesis has always been connected to the lack of a signal sequence and the post-
translational insertion into membranes, features that placed the focus on the TMD. 
However, the role of the cytoplasmic domain in TA-protein biogenesis remains unclear. 
In a study preceding the discovery of TA-insertion pathways, it was reported that GFP 
fused to the TMD of rat Bet1 was not localized properly (Joglekar et al. 2003). Shortly 
after the TRC40 characterization, TRC40 was found to be cross-linked with the N-
terminal domain of Sec61b (Favaloro et al. 2008) as apposed to the findings of another 
study in which no cross-linking was observed in the absence of the Sec61b-TMD 
(Stefanovic and Hegde 2007). In a similar fashion, Get3 was reported to interact with 
Sec22p lacking its TMD (Yamagata et al. 2010) but another study showed that there 
was no evidence of interaction with Get3 in the absence of the TMD of Sec22p (F. 
Wang et al. 2010). VAPB was reported to interact with TRC40 but TRC40 was unable 
to interact with a VAPB FFAT-binding defective mutant (K87D/M89D) and a VAPB 
DMSP construct (even though the TMD of VAPB was present) (Baron et al. 2014). 
Some SNARE proteins were observed to be typically localized despite the deletion of 
their TMD (L. Chen, Lau, and Banfield 2016). The expression of yeast Sed5 in COS-7 
cells showed it localized to the Golgi. The swap of the Sed5 TMD by those of the yeast 
TA-proteins Pep12, Sso1 or Bos1 did not yield any change in the Golgi localization of 
yeast Sed5 (Banfield et al. 1994). In this study the ATPase-impaired TRC40 mutant 
which carried two mutations in the hydrophobic TA-binding groove 
(TRC40D74E/L190D/I193D) was still able to alter the subcellular localization of Stx5 (Fig. 
13A). This would suggest that either TRC40 binds Stx5 via a different binding region, 
compared to other TA-proteins, or that Stx5 cytoplasmic domain has additional contact 
sites, apart from the ones of the TMD, that were not disrupted by the mutations. The 
Stx5 cytoplasmic domain presented thermal instability and unfolding propensity in an 
in vitro aggregation assay (Rivera-Monroy et al. 2016). This thermal instability can be 
prevented by the presence of TRC40 (Rivera-Monroy, unpublished). Likewise, the 
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cytoplasmic domain of Stx5 was reported to be important for the Golgi localization of 
the short isoform of Stx5 (Misumi et al. 2001). Stx5 did not required the presence of 
the TMD, but requires the last one hundred amino acids (which contains the t-SNARE 
coiled-coil domain) for being Golgi-localized (Misumi et al. 2001). Surprisingly, a 
construct lacking these last one hundred amino acids of Stx5 was localized in the 
cytoplasm (Misumi et al. 2001). In the same study two more TA-proteins were 
analyzed: Giantin and Golgin-84. Golgin-84 and Giantin Golgi-localization were 
unaffected by the lack of their respective TMDs (Misumi et al. 2001). Golgi-84 had a 
cytoplasmic localization upon the deletion of the last 160 amino acids (Misumi et al. 
2001). The swap of the TMDs of Stx5, Giantin or Golgin-84 with the one of Stx2 (a TA-
protein localizing in plasma membrane) did not alter the Golgi subcellular localization 
of those proteins. Along the same lines, another study showed that just the last 51 
amino acids were necessary for the Golgi localization of Golgin-84 (Bascom, 
Srinivasan, and Nussbaum 1999). These 51 amino acids included the C-tail, the TMD 
and 20 amino acids upstream of the TMD where no coiled-coil domain was present. In 
contrast, Stx1 was localized in the cytoplasm and not in membranes upon the 
truncation of the TMD (Vogel, Cabaniols, and Roche 2000). Finally, a very interesting 
study focused on the role of the cytoplasmic domain in SNARE proteins (K Kasai and 
Akagawa 2001). In this publication, the authors studied five TA-proteins: Stx1, Stx5, 
Stx6, Stx7 and Stx8. They tested all of them in rat cell lines for their subcellular 
localization in all combinations of each cytoplasmic domain with each TMD. The swap 
of the original TMDs with the Stx1 TMD (Stx5-TMD1, Stx6-TMD1, Stx7-TMD1, Stx8-
TMD1) did not alter the reported localization of the syntaxin proteins suggesting that 
the cytoplasmic domain was the one determining the final localization. The 
combination of these syntaxins with the TMD of Stx5 (Stx1-TMD5, Stx6-TMD5, Stx7-
TMD5, Stx8-TMD5) resulted in cis-Golgi localization, indicating that the Stx5 TMD 
abolishes the transport out of the Golgi. Chimaeras of the cytoplasmic domain of Stx1 
with the TMDs of Stx6, Stx7 and Stx8 (Stx1-TMD6, Stx1-TMD7, Stx1-TMD8) were 
observed at the plasma membrane, where Stx1 is localized. This would indicate that 
the Stx1 cytoplasmic domain dictates the subcellular localization of those constructs. 
To sum up, the cytoplasmic domain of this subset of SNAREs was responsible for the 
final subcellular localization of the chimeric constructs (when carrying the TMDs of 
Stx1, Stx6, Stx7, Stx8) unless they had the TMD of Stx5 in which case the localization 
was the one of Stx5, at the Golgi (K Kasai and Akagawa 2001). These results indicate 
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that Get3/TRC40 could potentially interact with the cytoplasmic domains of certain TA-
proteins and that the cytoplasmic domain might play a very important role in the 
biogenesis of some TA-proteins. 
 
 
4.2.3.3. Potential downstream consequences may contribute to the 
readout 
 
In spite of the role that TMD hydrophobicity and the cytoplasmic domain of the 
TA-proteins play, it is important to consider the impact of downstream factors present. 
In vivo knockdown studies of endogenous proteins may lead to downstream effects 
such as the destabilization of a protein complex due to the perturbation of an interactor 
partner. Some of the TA-proteins studied may have had their steady-state levels 
reduced due to the destabilization of a binding partner that was affected by the 
knockdown. In this case it would be an indirect effect of the loss of the downregulated 
protein that characterizes the phenotype of the knockdown. Hence the mechanistic 
discussion proposed in this section would not apply. 
 
 
4.2.4. Physiological effects of the TRC-pathway impairment 
 
In recent times, several studies have reported some physiological 
consequences of the impairment of the TRC pathway. In one of these studies, a mouse 
model carrying WRB-deficient inner hair cells presented synaptic hearing impairment 
(Vogl et al. 2016). In addition, the same phenotype was reported in zebrafish (Vogl et 
al. 2016; Lin et al. 2016). Reduced levels of otoferlin, a tissue-specific TA-protein in 
inner-ear hair cells, were observed in WRB-deficient mice (Vogl et al. 2016). 
Dysfunction of otoferlin is connected with deafness and auditory neuropathies (Varga 
et al. 2006). In another study, the authors generated a Wrb-knockout zebrafish model 
that suffered an impairment of the synaptic transmission in photoreceptors (Daniele et 
al. 2016). In the same study, the TRC40-knockdown mirrored the phenotype shown in 
the Wrb-knockout (Daniele et al. 2016). A TRC40-knockout specific to the pancreatic 
b-cells in mice led to defects in retrograde transport and ER-stress. These mice 
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developed hypoinsulinemia and defects in the insulin secretion that led to diabetes 
(Norlin et al. 2016). TRC40 loss in mouse pancreatic progenitor cells provoked 
redistribution of Stx5 and Stx6 and the fragmentation of the Golgi. TRC40 was found 
to be required for pancreatic cell survival (Norlin, Parekh, and Edlund 2018). 
Interestingly, GET pathway impairment in Arabidopsis thaliana results in reduced 
SNARE levels (Xing et al. 2017). Likewise, SYP72, a plant SNARE ER-resident 
protein, is found accumulated in cytosol in get3-1, get1 and get4 knockouts in A. 
thaliana (Srivastava et al. 2017). 
 
In this study, eleven TA-proteins were decreased at the steady-state in WRB/TRC40-
knockdown cells (Fig. 26B). Seven out of these affected TA-proteins are SNARE 
proteins involved in membrane-trafficking. Stx5 and Stx6 were among them. The levels 
of these two SNAREs were found to be reduced at steady-state or redistributed in the 
cell when TRC40 or WRB were missing (Rivera-Monroy et al. 2016; Norlin et al. 2016; 
Norlin, Parekh, and Edlund 2018). As recently mentioned, the knockout of TRC40 in 
b-cells resulted in plasma membrane-to-TGN and ER-to-Golgi retrograde transport 
defects (Norlin et al. 2016). Hence, alterations of SNARE-proteins membrane-targeting 
by the TRC pathway are linked thus an impairment of this pathway could lead to 
membrane-trafficking defects. The decrease in the steady-state levels of these 
important SNAREs, in WRB/TRC40 down-regulated cells, could potentially affect 
several transport pathways (Fig. 56A). The steady-state levels of other SNAREs such 
GOSR2, Vti1b and Stx18 remained unchanged upon the WRB/TRC40 knockdown. 
Other SNARE proteins were not tested in this study. From the SNARE complexes 
shown in Fig. 57A all are TA-proteins but Ykt6, SNAP23, SNAP25, SNAP29. The 
remaining SNARE TA-proteins present high TMD-hydrophobicity (Fig. 57B) which, 
according to what was previously discussed, seems to be lead to a reliance on the 
TRC-pathway. However, the role of the cytoplasmic domain in TA-protein targeting 
was also discussed, especially with regard to SNARE proteins. Therefore, among the 
physiological effects derived from the impairment of the TRC pathway, the most 
prominent one is the disruption or malfunctioning of membrane-trafficking due to the 
perturbation of SNARE-protein homeostasis. Further investigation is required in this 
regard to determine the scope of the TRC pathway impairment in membrane-
trafficking. 
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Figure 59. The SNARE complexes in membrane-trafficking pathways in WRB/TRC40 knock-
down cells. (A) QR-SNARE classification of the different SNAREs and the membrane trafficking 
pathways they are involved. The empty spots represent the TA-proteins affected by the WR-
B/TRC40 knockdown. Adapted from: Jahn and Scheller 2006; T. Wang, Li, and Hong 2017. (B) 
Dot-plots of the TMD hydrophobicity score according to the hydrophobicity scale developed by 
(Kyte and Doolittle 1982) divided by the length of the TMD, for obtaining the GRAVY score, for all 
the TA-proteins shown in Table 1. The transmembrane domain region was predicted using the 
TMHMM algorithm (Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. 
SNARE proteins not tested in this study are colored in orange. The dotted line represents the 
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and the TRC pathway as proposed in a recent paper (Guna et al. 2017).
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Figure 57. The SNARE complexes in membrane-trafficking pathways in WRB/TRC40 knockdown 
cells. (A) QR-SNARE classification of the different SNAREs and the membrane trafficking pathways 
they are involved in (Bock et al. 2001; Hong 2005). The non-colored slots with the red-labelled protein 
represent the TA-proteins affected by the WRB/TRC40 knockdown. Adapted from: (Jahn and Scheller 
2006; T. Wang, Li, and Hong 2017). (B) TA-proteins tested in this study and SNAREs not tested dot-
plots. Dot-plots of the TMD hydrophobicity score according to the hydrophobicity scale developed by 
(Kyte and Doolittle 1982) divided by the length of the TMD (in aa), for obtaining the GRAVY score, for 
all the TA-proteins shown in Table 17. The transmembrane domain region was predicted using the 
TMHMM algorithm (Krogh et al. 2001) or UniProt prediction if TMHMM prediction was missing. TA-
proteins affected by the WRB/TRC40 knockdown are depicted in green, unaffected in red and not tested 
SNAREs in dark blue. The dotted line represents the Sec61β TMD hydrophobicity score, marking the 
approximate overlap between the EMC pathway and the TRC pathway as proposed in a recent paper 
(Guna et al. 2018). 
 
 
4.3. The enigmatic role of BAG6 in TA-protein 
biogenesis 
 
The TRC pathway in mammals and the GET pathway in yeast are conserved. 
The proteins constituting this pathway are conserved (Get2 and CAML are functional 
homologs) except mammalian BAG6, which is not present in yeast (Leznicki et al. 
2010; Mariappan et al. 2010). According to the literature there is another major 
difference between these two pathways beside the presence of BAG6; namely the 
interactions within the pre-targeting complex. One of the main reasons for this 
difference resides in the fact that TRC35 and UBL4A cannot directly interact, in 
contrast to yeast where they do directly interact (Mock et al. 2015) (Fig. 58A). The b-
loop involved in the Get4-Get5 interaction interface is missing in TRC35 (Chartron et 
al. 2010) whereas UBL4A lacks the N-terminal domain present in Get5 that mediates 
the interaction between Get4 and Get5 (Chartron et al. 2010; Mock et al. 2015). 
Instead, TRC35 and UBL4A interact with BAG6, which serves as a scaffolding protein. 
TRC35 docks on the NLS of BAG6 thereby masking it and UBL4A is tethered to the 
BAG domain of BAG6 (Mock et al. 2015; Kuwabara et al. 2015; Mock et al. 2017). This 
heterotrimeric BAG6 complex is believed to be responsible for collecting the nascent 
substrates after their release from the ribosome (Mariappan et al. 2010). Subsequently, 
SGTA is recruited, via the UBL domain, to either BAG6 or preferentially UBL4A (Xu et 
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al. 2012; Leznicki et al. 2013; Darby et al. 2014) (Fig. 58B). Therefore, BAG6 is the 
pre-targeting-complex cornerstone protein. In fact, a truncated version of BAG6 
containing just the C-terminal domain (which comprises the NLS and the BAG domain) 
was sufficient to facilitate the handoff of a TA-protein to TRC40 in vitro (Mock et al. 
2015; Shao et al. 2017).  
 
Surprisingly, none of the seventeen TA-proteins tested showed a reduction of protein 
at the steady-state levels in BAG6 down-regulated cells (Fig. 28-32). In contrast, three 
out of seventeen TA-proteins presented an increase at the steady-state level: UBE2J1 
(Fig. 29C), Stx18 (Fig. 31A), GOSR2 (Fig. 31B). It is known from this study that the 
down-regulation of BAG6 does not affect the steady-state levels of downstream 
components of the pathway such as WRB (Fig. 27B), CAML (Fig. 27D) or TRC40 (Fig. 
27A). However, it has been reported that upon the knockdown of BAG6, the steady-
state levels of TRC35 and UBL4A are severely affected (Krenciute et al. 2013).  
 
According to the model proposed in the literature, the described interactions within the 
pre-targeting complex are necessary for the TA-protein transfer to TRC40. Thus, the 
lack of any protein forming part of the heterotrimeric BAG6 complex would abrogate 
the handoff of the TA-protein to TRC40 in vitro (Shao et al. 2017). Likewise, the 
immunodepletion of BAG6 in RRL inhibited the insertion of Sec61b into the membrane 
(Leznicki et al. 2010). In addition, mutations in either SGTA or UBL4A disrupting their 
interaction interface, led to a strong loss of TA-protein handoff to TRC40 (Mock et al. 
2015). It is reported that TRC40 is a bad competitor for free TA-proteins compared to 
other chaperones (Shao et al. 2017). Interestingly, Get3 has substrate preferences 
very close to those of Sgt2 (Rao et al. 2016). Moreover, TRC40 alone does not induce 
the release of the TA-protein loaded in SGTA, indicating that the potential SGTA-
TRC40 interaction is not enough for the TA-protein handoff (Shao et al. 2017). 
Although there is some contradiction in this point since TRC40 itself is able to receive 
some TA-substrates from SGTA (Mock et al. 2015). Taking into consideration the 
elucidated hierarchy of TA-protein handoff within TRC-pathway components, this 
raises the question as to why the steady-state levels of the TA-proteins in the 
membrane fractions were not reduced in BAG6-knockdown cells when compared with 
the control cells. 
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Figure 58. Differences in the pre-targeting complex between the yeast GET pathway and the 
mammalian TRC pathway. (A) Get4-Get5 interaction gets in close proximity Get3 and Sgt2 loaded 
with the TA-protein. (B) BAG6 heterotrimeric complex serves as a scaffolding protein that gets in close 
proximity TRC40 and SGTA loaded with the TA-protein. The PDB IDs are the following: Get3 (4XTR), 
Get4-Get5 (4PWX), Sgt2 (3ZDM, 5LYP), TA-protein (2LPF), SGTA (4CPG, 5LYP), TRC35 (6AU8), 
UBL4A (4X86). TRC40 is represented with the Get3 protein structure and BAG6 is depicted as a 
silhouette due to the lack of structure for both. 
 
BAG6 knockdown was highly efficient (Fig. 27C). The BAG6 siRNA used (siBAG6 #1) 
had been successfully used in previous studies (Minami et al. 2010; Suzuki and 
Kawahara 2016; K. Yamamoto et al. 2017) and it was validated with our custom-made 
antibodies by IF and WB (Fig. 37A, Fig. 37B). BAG6 has several isoforms due to 
splicing (Kämper et al. 2012). The siBAG6#1 target sequence is present in all the 
isoforms reported in UniProt and in the literature (Kämper et al. 2012) ruling out the 
possibility of a siRNA-insensitive BAG6 isoform that was taking over the TA-protein 
TRC35
SGTA
BAG6
UBL4A
SGTA
TA-protein
TA-protein
TRC40
Get4/Get5/Sgt2
TA-protein
Get3
B
A
4.Discussion 
 
 
 
172 
targeting. BAG6 and SGTA play a role in the quality control of MLPs (Hessa et al. 
2011; Leznicki et al. 2013; Rodrigo-Brenni, Gutierrez, and Hegde 2014; Wunderley et 
al. 2014). Via its UBL domain, BAG6 can recruit the E3 ubiquitin ligase RNF126 
(Rodrigo-Brenni, Gutierrez, and Hegde 2014; Krysztofinska et al. 2016) which 
ubiquitylates proteins and targets them for proteasomal degradation. For instance, it 
has been reported that the ERAD substrate TCRa accumulates upon BAG6 down-
regulation (Q. Wang et al. 2011). Hence, the increased steady-state levels of Stx18, 
GOSR2 and UBE2J1 in the absence of BAG6 may be explained by the fact that BAG6 
is implicated in their degradation.  
 
BAG6 is not essential for a subset of TA-proteins since their steady-state levels 
remained unchanged in membranes in this study. Interestingly, it was proposed that 
the BAG6 complex does not have a big role for TA-protein biogenesis since Sec61b 
and UBE2J1 steady-state levels remained unaffected in BAG6-knockdown cells and 
in UBL4A-knockdown cells (Q. Wang et al. 2011). In contrast to the BAG6-knockdown 
cells, many TA-proteins showed decreased steady-state levels in WRB/TRC40-
knockdown cells. Since the heterotrimeric BAG6 complex is reported to be severely 
affected upon the down-regulation of BAG6, SGTA or other unknown chaperones may 
insulate the nascent TA-protein. SGTA-to-TRC40 TA-handoff has been reported to be 
slow and poor (Mock et al. 2015) or nonexistent (Shao et al. 2017). Regardless of the 
upstream chaperone that delivers the TA-protein to TRC40, the steady-state levels of 
the TA-proteins are unaffected suggesting that redundancies may exist in this 
upstream system. This also suggests that an alternative pathway might exist where 
another cytoplasmic effector handles the TA-protein in the absence of TRC40 (not so 
relevant in the cases of Stx5, VAPB, UBE2J1 that were affected by the knockdown of 
TRC40). CaM and ubiquilins have been reported to chaperone low-hydrophobic TMDs 
of TA-proteins (Itakura et al. 2016; Suzuki and Kawahara 2016; Guna et al. 2018), as 
well as Hsp40/Hsc70 (Rabu et al. 2008). Nevertheless, the substrates covered by the 
TRC pathway have moderate-to-high hydrophobic TMDs (Borgese, Brambillasca, and 
Colombo 2007; Costello, Castro, Camões, et al. 2017; Guna et al. 2018). Therefore, 
the role and the relevance of BAG6 within the TRC pathway regarding the TA-protein 
biogenesis have to be redefined in the light of the results obtained in vivo in this study. 
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4.4. The fragile internal balance of the TRC 
pathway 
 
Besides the aforementioned changes in the steady-state levels of TA-proteins, 
it was remarkable that the steady-state levels of the TRC pathway components were 
also altered upon the loss of other proteins of the pathway. The steady-state levels of 
the heterodimeric receptor of the TRC pathway, WRB and CAML, were decreased 
upon the down-regulation of TRC40 (Fig. 26B, Fig. 27B, Fig. 27D). Additionally, CAML 
was severely affected when knocking-down WRB (Fig. 26B, Fig. 27D), as previously 
described in literature (Rivera-Monroy et al. 2016; Sara Francesca Colombo et al. 
2016; Haßdenteufel et al. 2017). The interdependence of the GET receptor (Get1, 
Get2) stability was already described (Schuldiner et al. 2008). Moreover, it was also 
reported for the TRC receptor (Vilardi et al. 2014). In WRB-knockout cardiomyocytes, 
TRC40 was severely decreased at steady-state level (Rivera-Monroy et al. 2016) as 
well as in WRB-knockdown HeLa cells (Rivera-Monroy et al. 2016). Besides, TRC40 
was reported to be slightly decreased upon CAML knockdown (Sara Francesca 
Colombo et al. 2016). Interestingly, the TRC40 steady-state levels in WRB-knockdown 
HeLa cells can be rescued with chloroquine (Rivera-Monroy et al. 2016), a drug that 
prevents the acidification of lysosomes by inhibiting lysosomal proteases (Mizushima, 
Yoshimori, and Levine 2010). 
 
Regarding the proteins at the pre-targeting complex, BAG6 steady-state levels upon 
the loss of WRB and TRC40 were severely decreased (Fig. 26A, Fig. 27C). In addition, 
BAG6 steady-state levels remained unaffected upon the silencing of TRC40 (Fig. 26A, 
Fig. 38C), in line with what was shown in previous studies in vivo (Baron et al. 2014) 
and TRC40-immunodepleted RRL (Mariappan et al. 2010). Similar to the results in 
HeLa cells, BAG6 steady-state levels were decreased in WRB-KO cardiomyocytes 
(Fig. 40B). It is also known from the literature that the loss of SGTA does not have an 
impact on BAG6 protein level at the steady-state (Xu et al. 2012). In contrast, the 
knockdown of BAG6 affects the levels of TRC35 and UBL4A, both being decreased. 
Likewise, the BAG6-immunodepletion of RRL has the same consequence (Mariappan 
et al. 2010). Reciprocally, the simultaneous loss of TRC35 and UBL4A also decreases 
the levels of BAG6 (Krenciute et al. 2013) whereas individual knockdowns of TRC35 
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or UBL4A does not have an effect on BAG6 levels at the steady-state (Xu et al. 2012; 
Krenciute et al. 2013). In contrast, the immunodepletion of UBL4A in RRL results in 
undetectable protein levels of BAG6 and TRC35 (Mariappan et al. 2010). 
 
Interestingly, the mRNA levels of TRC35 and UBL4A remained unchanged upon the 
knockdown of BAG6 (Krenciute et al. 2013). The same is true for CAML mRNA in the 
case of the WRB knockdown, which remains unaffected suggesting that the instability 
was at protein level (Rivera-Monroy et al. 2016; Sara Francesca Colombo et al. 2016). 
However, a recent publication reported that the loss of CAML destabilizes WRB mRNA 
rather than the protein itself, resulting in reduced WRB protein at the steady-state level, 
as mentioned previously (Sara Francesca Colombo et al. 2016). This complex interplay 
has been summarized in the following figure (Fig. 59A).  
 
Considering the available data reflected in the figure, a first glance shows two clusters 
in terms of interdependence: one grouping the heterotrimeric BAG6 complex proteins 
and another one downstream of the pathway grouping TRC40 and TRC receptor, WRB 
and CAML (Fig. 59A, Fig. 59B). The loss of BAG6 has direct effect on TRC35 and 
UBL4A stability at protein level. It is known that BAG6 prevents the degradation of 
TRC35 by ubiquitylation via RNF126 (Mock et al. 2017). Individual knockdowns of 
TRC35 and UBL4A do not alter the steady-state levels of BAG6 but the double 
knockdown of TRC35/UBL4A decreases the steady-state levels of BAG6. This 
indicates that BAG6 on the one hand and TRC35/UBL4A on the other hand are 
hierarchically at the same level (Fig. 59B). However, TRC35 knockdown leads to 
decreased UBL4A at steady-state levels indicating that TRC35 plays a role in UBL4A 
stability but UBL4A knockdown does not have a role in TRC35 steady-state levels (Fig. 
59B). Regarding the other cluster, the loss of TRC40 decreases the steady-state levels 
of both WRB and CAML and the down-regulation of WRB affects the steady-state 
levels of TRC40 and CAML. The knockdown of CAML affects the steady-state levels 
of WRB but only slightly affects the steady-state levels of TRC40 (Fig. 59A). The 
knockdown of TRC40 has no impact on the steady-state levels of BAG6 but the double 
knockdown of WRB/TRC40 decreases the steady-state levels of BAG6. In addition, 
BAG6 levels were decreased in WRB KO cardiomyocytes (Fig. 59A). These 
relationships would place the TRC receptor and TRC40 at the same level of 
hierarchical level but the steady-state levels of TRC40 are more affected when WRB 
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is not present than the other way around. Furthermore, WRB loss affects BAG6 but 
not vice versa. There is a mild increase of WRB steady-state levels upon BAG6 
knockdown. Taken together, this would indicate that the loss of WRB affects the 
stability of most proteins in the TRC pathway. Moreover, the stability of other proteins 
of the TRC pathway is dependent on the presence of other interacting components 
within pathway. Besides, it has to be taken into account that TCR35 and TRC40 
regulate the subcellular localization of BAG6. In conclusion, due to this tight regulation 
of the proteins of the TRC pathway, changes in the steady-state levels of most of these 
TRC proteins will provoke further consequences within the TRC pathway that may 
subsequently affect the biogenesis of a subset of TA-protein.  
 
4.5. TRC40 showed some evidence of its 
potential role as a redox-regulated chaperone  
 
Yeast Get3 has been reported to be a redox-regulated chaperone (Voth et al. 
2014). The structural rearrangement Get3 undergoes upon oxidation happens via a 
CXC-Xn-CXXC motif present in the protein, in a similar fashion as was reported for the 
bacterial chaperone Hsp33 (Jakob et al. 1999). The CXC-Xn-CXXC motif is conserved 
in TRC40 (Fig. 41A). Besides, the ATPase activity is decreased upon oxidation (Fig. 
42B) as was reported for yeast Get3 (Voth et al. 2014). However, recombinant TRC40 
presented a lesser number of reduced cysteines than expected in reducing conditions. 
This might indicate that TRC40 has a more complex redox behavior than Get3.  
 
Experiments in conditions that stimulate the production of reactive oxygen species 
(ROS), such as hypoxia (Chandel et al. 1998; Chandel et al. 2000; Clanton 2007; 
Tafani et al. 2016), did not show any change of TRC40 at the steady-state level or any 
change in the electrophoretic mobility of TRC40 in non-reducing SDS-PAGE (as is 
observed for Get3) (Fig. 43A). 
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Figure 59. TRC pathway knockdown impacts the stability of other components of the pathway. 
(A) The knockdown of the components of the TRC pathway alters the protein steady-state levels. (1) 
This study, (2) Rivera-Monroy et al. 2016, (3) Colombo et al. 2016, (4) Haßdenteufel et al. 2017, (5) 
Baron et al. 2014, (6) Xu et al. 2012, (7) Krenciute et al. 2013, (8) Vilardi et al. 2014. (B) Hierarchical 
protein network based on protein stability at steady-state level. Arrows indicate which knockdown affects 
the stability of a protein. 
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Based on the studies reporting SGTA as a collaborator in the early maturation steps 
of the SRs, such as the glucocorticoid receptor (GR) (Paul et al. 2014), I hypothesized 
that the GR could be a potential substrate of TRC40 as redox-regulated chaperone. 
Additionally, SGTA negatively regulates the activity of some SRs (Paul et al. 2014). 
Furthermore, Sgt2 interacts with the same chaperones that Get3 was found to 
colocalize in foci (F. Wang et al. 2010; Powis et al. 2013). In a yeast-based reporter 
assay, in a similar fashion as described in (Paul et al. 2014), the absence of yeast Get3 
affected the GR activity in a stronger manner than the absence of Sgt2 in this study 
(Fig. 45A). The relative GR activity could not be rescued by the Get3 mutants (Fig. 
46B) but they had an effect over the absolute GR activity (Fig. 46A). However, complex 
modulation of the GR steady-state levels (Fig. 47B) by the steady-state levels Get3 
(Fig. 47C) made GR activity results difficult to interpret. In contrast, there was no 
modulation of the GR steady-state levels by TRC40 in HeLa cells (Fig. 51B) and the 
absence of TRC40 did not change the cellular distribution of the GR in stimulated and 
unstimulated cells in HeLa cells (Fig. 50B). In their study, from the yeast-based 
reporter assay results, Paul et al., came to the conclusion that Sgt2 was regulating the 
activity of the GR. In this study, I showed that Get3 and GR levels correlated inversely 
(Fig. 47B, Fig. 47C). However, Paul et al. never showed any evidence of quantification 
of the steady-state levels of the GR or the SGTA over-expression in the rescue 
experiments. Given the fact that the GR steady-state levels can influence its activity it 
is important to know how stable they are in the different conditions tested. SGTA over-
expression may also affect the steady-state levels of the GR, and therefore its activity, 
in a similar fashion to Get3. Get3 has an effect over the activity of the GR, based on 
the yeast-reporter assay, but the fact that Get3 levels modulate those of the GR makes 
the results particularly difficult to interpret.  
 
Taken together, there is no experimental evidence currently that shows the GR might 
represent an in vivo chaperone substrate of TRC40. Nevertheless, further in vitro 
experiments regarding the redox state of the TRC40 cysteines, the role of these 
cysteines in a putative conformational change, the potential formation of TRC40 
tetramers or high-order oligomers must be carried out systematically in order to 
characterize the potential role of TRC40 as a redox-regulated protein. 
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5. Conclusion and perspectives 
5.1. Conclusions 
 
In this study, I demonstrated that TRC40D74E, an ATPase-impaired mutant of 
TRC40, can trap TA-protein substrates (e.g. Stx5, Stx8, EMD), in cytoplasm. 
Therefore, this trapping mutant can be used as a tool for determining the in vivo 
interactome of TRC40. 
 
Furthermore, I could determine the in vivo TRC-dependence of eleven TA-proteins by 
knocking-down TRC-pathway components such as WRB and TRC40. In contrast, 
another six TA-proteins did not show any evidence of in vivo TRC-dependence in this 
study, either affected by down-regulation of TRC components or by the presence of 
TRC40D74E. Many of the TA-proteins (e.g. USE1, UBE2J1, Vti1a) tested in this study 
were not reported to be TRC-dependent in the literature. These experiments led me to 
explore the potential causes behind the TRC-dependence of the TA-proteins in vivo. 
TMD-hydrophobicity showed a good correlation and it may be a major contributor in 
the TRC-dependence of the TA-proteins. BAG6 has been reported essential for the 
targeting of the TA-proteins according to the model in the literature. Strikingly, TA-
proteins remained unaffected at steady-state level upon BAG6 knockdown suggesting 
that BAG6 is not essential for TA-protein targeting in vivo. 
 
Taken together, the literature and the results in this study suggest that the TRC-
pathway is kept in balance by a mechanism that tightly regulates the steady-state 
levels of its components. Upon the loss of some of the components others get severely 
reduced in their steady-state levels. This TRC-pathway balance is not symmetrical and 
shows a hierarchical organization within the pathway. 
 
There was no experimental evidence that showed the glucocorticoid receptor might 
represent an in vivo chaperone substrate of TRC40. Nevertheless, further in vitro 
experiments regarding the redox state of the TRC40 cysteines, role of those cysteines 
in a potential conformational change, the potential formation of TRC40 tetramers or 
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high-order oligomers must be carried out in order to characterize the potential role of 
TRC40 as a redox-regulated chaperone. 
 
 
5.2. Perspectives 
 
TRC40D74E has been shown in this study to be an efficient tool for determining 
TRC40 substrates. A wider analysis of the interactome of TRC40D74E should be 
performed. For that purpose, I would propose the following: 
 
o Mass spectrometry (MS) for determining TRC40D74E interactome. 
Samples for MS will be obtained by co-immunoprecipitation of 
TRC40D74E from cells over-expressing this mutant. TRC40D74E/L190D/I193D 
will be used as negative control of TA-protein targeting. 
o Validation of the hits by IF. Preferentially using antibodies against 
endogenous proteins, in case that it is not possible tagged-
proteins will be used for validation. 
o Biochemical validation of the hits via co-immunoprecipitation of 
TRC40D74E from cells over-expressing this mutant. 
o Analysis of the causes of the TRC-dependence of a TA-protein 
based on the hits obtained in the interactome analysis of 
TRC40D74E. 
o Determination of the in vivo TRC-pathway dependence of the 
validated TA-protein hits by knocking-down TRC components in 
HeLa cells. 
 
o BAG6 knockdown did not yield any major effect at the steady-state level 
for the TA-proteins tested in this study. However, the effect of the SGTA 
knockdown over the TA-protein steady-state levels remains unknown. 
SGTA is the other relevant chaperone in the pre-targeting complex, 
upstream of TRC40. One would expect a major effect at the steady-state 
of the TA-proteins according to the models present in the literature. 
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Therefore, I would downregulate SGTA in HeLa cells and determine the 
state-levels of the TA-proteins tested in this study. 
 
o The cytoplasmic domain of the SNARE proteins has been shown to play 
an important role in targeting and trafficking. Get3/TRC40 have been 
reported to interact with these cytoplasmic domains, as discussed 
previously. Thus, it is important to determine whether the role that TRC40 
plays in the SNARE homeostasis is due to the chaperone or the targeting 
function of TRC40. 
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7. Appendix 
7.1. Abbreviations 
 
A ampere 
aa amino acids 
Ab antibody 
ADP adenosine di-phosphate 
Amp ampicillin 
ArsA arsenical pump-driving ATPase 
ATP adenosine tri-phosphate 
ATP-g-S adenosine 5′-O-(3-thiotriphosphate) 
AU arbitrary units 
BAG bcl-2-associated athanogene 
BAG6 large proline-rich protein BAG6 
BAT3 HLA-B-associated transcript 3 
BSA bovine serum albumin 
°C degree Celsius 
CaM calmodulin 
CAML calcium signal-modulating cyclophilin ligand 
CD cytosolic domain 
CMV cytomegalovirus 
Cre cre recombinase 
CT C-terminus 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride 
DBD DNA-binding domain 
DDR DNA damage response 
DEX dexamethasone 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
DOC deoxycorticosterone or 21-hydroxyprogesterone 
DTT dithiothreitol 
DUB deubiquitinase 
EDTA disodium ethylenediaminetetraacetate 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
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em emission 
EMC ER-membrane protein complex 
EMD emerin 
ER endoplasmic reticulum 
ERAD endoplasmic reticulum-associated degradation 
EV empty vector 
ex excitation 
F farad 
FBS fetal bovine serum 
FDG fluorescein di(β-D-galactopyranoside) 
FDFT1 squalene synthase 
fl/fl sequence flanked by loxP sites 
FMD fluorescein mono-D-galactopyranoside 
FRT Flp recombination target 
g gram(s) 
g times gravity 
GET guided entry of tail-anchored proteins 
Get guided entry of tail-anchored protein 
GFP green fluorescent protein 
GPI glycosylphosphatidylinositol 
GR glucocorticoid receptor 
GRAVY grand average of hydropathicity 
GRE glucocorticoid response element 
h hour(s) 
HIF-1a hypoxia-induced factor 1 alpha 
His 6x His tag 
Hsp(s) heat-shock protein(s) 
IB immunoblot 
IF indirect immunofluorescence 
IgG immunoglobulin G 
IMP integral membrane protein 
INM inner-nuclear membrane 
IP immunoprecipitation 
IPTG isopropyl β-D-1-thiogalactopyranoside 
Kan kanamycin 
kb kilo-base pair 
kcal kilo-calorie 
KD knockdown 
kDa kilo-Dalton 
KO knock-out 
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L liter 
lacZ E.coli b-galactosidase gene 
LB Luria-Bertani 
LBD ligand-binding domain 
LDH lactate dehydrogenase 
M molar 
MBP maltose binding protein 
Mer ligand binding domain mutant estrogen-receptor 
Met methionine 
µ micro 
min minute(s) 
MLP mislocalized secretory and membrane protein 
mM milimolar 
MOM mitochondrial outer membrane 
mRNA messenger RNA 
MS mass spectrometry 
MW molecular weight 
NAD+ β-nicotinamide adenine dinucleotide, oxidized 
NADH β-nicotinamide adenine dinucleotide, reduced 
NLS nuclear localization sequence 
nM nanomolar 
nm nanometer 
NTD N-terminal domain 
O/N overnight 
OD optical density or absorbance 
op opsin tag 
P phosphorylated 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PDB ID Protein Data Bank unique accession 
PEG polyethylene glycol 
PEP phosphoenol pyruvate 
PEX peroxin 
PFA paraformaldehyde 
Pi inorganic phosphate 
PK pyruvate kinase 
PLN cardiac phospholamban 
PMP peroxisomal membrane protein 
PMSF phenylmethanesulfonyl fluoride 
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PNGase peptide-N-glycosidase 
PTS peroxisomal targeting sequence 
RMs rough microsomes 
RNA ribonucleic acid 
RNC ribosome nascent chain complex 
ROS reactive oxygen species 
RPKM reads per kilo base per million mapped reads 
rpm revolution per minute 
RRL rabbit reticulocyte lysate 
RT room temperature 
sec second(s) 
SDS sodium dodecyl sulfate 
SGTA small glutamine-rich tetratricopeptide repeat-containing protein alpha 
siBAG6 siRNA against BAG6 
siLuc siRNA against Luciferase (control siRNA) 
siNT non-targeting siRNA 
siRNA small interference RNA 
siTRC40 siRNA against TRC40 
siTRC40ins siRNA-insensitive TRC40 
siWRB siRNA against WRB 
SNARE SNAP (soluble NSF attachment protein) receptor 
SND SRP-independent targeting 
SQS squalene synthase 
SRs steroid hormone receptors 
SRP signal recognition particle 
SRa SRP receptor alpha 
SRb SRP receptor beta 
SS signal sequence 
Stx1A syntaxin-1A 
Stx1B syntaxin-1B 
Stx5 syntaxin-5 
Stx5-G syntaxin-5 glycosylated 
Stx6 syntaxin-6 
Stx8 syntaxin-8 
Stx18 syntaxin-18 
TA tail-anchored 
TCA trichloroacetic acid 
Tet tetracycline 
TEV tobacco etch virus protease 
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TGN trans-Golgi network 
TMD transmembrane domain 
TPR tetratricopeptide repeat 
TRC35 transmembrane recognition complex subunit of 35 kDa 
TRC40 transmembrane recognition complex subunit of 40 kDa 
U unit 
UBL ubiquitin-like 
UBL4A ubiquitin-like protein 4A 
UBQLN ubiquilin 
UV ultra violet 
V volt 
v/v volume per volume 
W watt 
w/v weight per volume 
WB Western blot 
WRB tryptophan-rich basic protein 
wt wild-type 
W ohm 
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7.2. Appendix figures 
 
 
 
Appendix figure 1. Stx5 subcellular localization is affected upon the presence of certain TRC40 
variants. (A) Stx5 immunofluorescence in cells silenced for TRC40 upon over-expression of different 
siRNA-insensitive TRC40 variants in HeLa cells. Images of Stx5 and cmyc-TRC40 stained by indirect 
immunofluorescence are shown. Two biological replicates were analyzed. Scale bars: 20 µm. 
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Appendix figure 2. Co-immunoprecipitation does not indicate a complex containing TRC40 and 
GR in HeLa cells. (A) Immunoprecipitation using mouse anti-GR and rabbit anti-TRC40 antibodies in 
HeLa cells. Western blot was performed and detecting the indicated proteins. Mouse IgG (mIgG) and 
rabbit IgG (rIgG) were used as controls of the immunoprecipitation. (B) GFP pull-down from lysed HeLa 
cells over-expressing Venus-GR. Cells transfected with Venus alone were used as controls. Western 
blot was performed detecting the indicated proteins. One replicate was analyzed. 
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Appendix figure 2. Co-immunoprecipitation does not indicate a complex containing 
TRC40 and GR in HeLa cells. (A),PPXQRSUHFLSLWDWLRQXVLQJDPRXVHDQWL*5DQGDUDEELW
DQWL75&LQ+H/DFHOOV:HVWHUQEORWZDVSHUIRUPHGDQGGHWHFWLQJWKHLQGLFDWHGSURWHLQV
0RXVH,J*P,J*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U,J*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Appendix figure 3. Phylogenetic analysis of the N-terminus of TRC40. (A) Sequence alignment of 
the N-terminus of TRC40 (around 100 aa) with homologs from other species. The upper scheme 
indicates in red the nucleotide-related regions of bacterial ArsA. The lower scheme of the protein 
corresponds to human TRC40 and the numbers indicate the initial and the last residue of the highlighted 
domains that were obtained from UniProt. (B) Phylogenetic tree of the species shown in (A). The 
phylogenetic tree was generated in the website iTOL v4.2 (http://itol.embl.de) (Letunic and Bork 2016). 
The respective NCBI/UniProt accession numbers can be found in order of appearance: P08690, 
A8B3G9, A0BZ55, C4LY44, Q949M9, Q12154, Q9P7F8, I1FYB1, A7RQM5, A0A075A5S8, G4V6J4, 
A0A0L8I9S4, T1FNV7, Q7JWD3, P30632, W4Y937, XP_006825619.1, H2ZIV5, V9KYT3, Q6IQE5, 
Q6GNQ1, O43681, XP_005310692.1, JAG47418.1, KYO32296.1. 
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Appendix figure 4. mRNAs encoding TRC components show differential expression levels 
across different human organs. (A) mRNA expression of TRC40 and the TRC receptor components, 
WRB and CAML, across different human tissues. (B) mRNA expression levels of TRC40, WRB and 
CAML in a selected group of human tissues where the TRC40 mRNA is more abundant compared to 
those encoding receptor subunits WRB and CAML. (C) mRNA expression ratios of TRC40 against 
WRB, TRC40 against CAML and WRB against CAML in the same group of human tissues shown in (B). 
Analyzed data from the Genotype-Tissue Expression project (GTEx V6p; https://www.gtexportal.org) 
(GTEx Consortium 2015; Melé et al. 2015; Rivas et al. 2015). 
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Figure 44. mRNAs encoding TRC components show differential expression levels across 
different human organs. (A) mRNA expression of TRC40 and the TRC receptor components, WRB 
and CAML, across different human ti . (B) mRNA expression level of TRC40, WRB and CAML 
in a selected group of human tissues where the TRC40 mRNA is more abundant compared to those 
encoding receptor subunits WRB and CAML. (C) mRNA expression ratios of TRC40 against WRB, 
TRC40 ag inst CAML and WRB against CAML in the same group f human tissues hown in (B). 
Analyzed data from the Genotype Tissue Expression project (GTEx V6p; https://www.gtexportal.org) 
(GTEx Consortium 2015; Melé et al. 2015; Rivas et al. 2015).
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Appendix figure 5. Steady-state protein levels of TRC components and their relative abundance 
differ in mouse organs. (A) Steady-state levels of TRC40 and the subunits of the TRC receptor in 
different mouse organs. Total tissue lysates were analyzed by Western blot for the indicated proteins. 
(B) Quantification of the signal intensities for the different mouse organs from the blots performed in (A) 
in arbitrary units. (C) Ratios of the signals shown in (B) relating TRC40 to the receptor subunits and 
relating the two receptor subunits to each other. Five biological replicates were analyzed. The graphs 
show the mean and the error bars represent standard error of the mean. 
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Figure 45. Steady-state protein levels of TRC components and their relative abundance differ 
in mouse organs. (A)6WHDG\VWDWHOHYHOVRI75&DQGWKHVXEXQLWVRIWKH75&UHFHSWRULQGLIIHUHQW
PRXVHRUJDQV7RWDOWLVVXHO\VDWHVZHUHDQDO\VHGE\:HVWHUQEORWIRUWKHLQGLFDWHGSURWHLQV(B)
4XDQWLILFDWLRQRIWKHVLJQDOLQWHQVLWLHVIRUWKHGLIIHUHQWPRXVHRUJDQVIURPWKHEORWVSHUIRUPHGLQ$
LQDUELWUDU\XQLWV(C)5DWLRVRIWKHVLJQDOVVKRZQLQ%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VKRZWKHPHDQDQGWKHHUURUEDUVUHSUHVHQWVWDQGDUGHUURURIWKHPHDQ
Ad
ren
al 
gla
nd
Br
ain
He
ar
t
Liv
er
Sp
lee
n
0
50
100
150
Tissue
Si
gn
al
 in
te
ns
iti
es
 (A
U
)
TRC pathway components
75&4
:5B
&$0/
Ad
ren
al 
gla
nd
Br
ain
He
art
Liv
er
Sp
lee
n
0
20
40
60
Tissue
Si
gn
al
 in
te
ns
iti
es
 ra
tio
s 
(A
U
)
TRC pathway components ratios
75&:5B
75&/&$0/
:5B/&$0/
7.Appendix 
 
 
 
234 
 
 
Appendix figure 6. Quantification of the subcellular localization phenotype of the TA-proteins in 
the presence of different TRC40 mutants. (A) Quantification of the subcellular localization phenotype 
of EMD in the presence of TRC40 mutants tested in Fig. 14. n= 40-203 cells are represented. (B) 
Quantification of the subcellular localization phenotype of Stx8 in the presence of TRC40 mutants tested 
in Fig. 15. n= 17-62 cells are represented. Three to six biological replicates were analyzed. 
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7.5.2.CellProfiler pipeline. Quantification transfected cells
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7.5.3. Seq2logo parameters 
 
These parameters were used for the sequence logo in Fig. 56A and Fig. 56B. 
 
Table 18. Seq2logo parameters. 
Background frequencies: bgfreq.txt 
Blosum substitution matrix: blosum.txt 
Chosen segment: None 
Colors: 
{'FF9900': 'VAST', '991AE6': 'RKH', 'E60000': 
'NPQ',  
'0000FF': 'DE', 'FFFF1D': 'MICG', '00D900': 
'WFYL'} 
Hobohm identity threshold: 0.63 
Lines per page/picture: 3 
Logo type: Probability Weighted Kullback-Leibler 
Minimum stack width fraction: 0.5 
Position number of first stack: 1 
Requested formats: PNG 
Resolution: 640x480 
Sequence weighting type: Hobohm algorithm 1 
Show Ends: FALSE 
Show X-axis: TRUE 
Show Y-axis: TRUE 
Show Y-axis label: TRUE 
Show fineprint: TRUE 
Stacks per line: 40 
Tic interval of the x-axis: 0 
Title:   
Unit type: Bits 
Vertical x-axis numbers: FALSE 
Weight on Prior: 200.0 
Y-axis range: [0.0, 0.0] 
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